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Abstract
Traditionally, epigenome-wide association studies have focused on the relationship between epigenetic marks
and specific traits by relating the methylation intensity of CpG sites with a phenotype. Rather than inter-
preting these values and relate them to the expression of a gene, our research investigates the correlation
in DNA methylation intensity between CpG sites on the same chromosome within the human genome. We
postulate that a strong correlation in methylation intensity (as we have defined) can be indicative of an un-
derlying epigenetic trend; an analysis of correlation only requires DNA methylation data, so we can attempt
to identify underlying these epigenetic associations in the absence of gene expression information (such as
that obtained through RNA sequencing or recording or phenotypes).
We make use of existing DNA methylation array data to answer our research questions:
• What constitutes a meaningful strong correlation in methylation intensity?
• Does array normalisation have an effect on the strong correlations we can detect?
• Is correlation strength influenced by the distance between a pair of CpG sites?
• Does co-location of two CpG sites within a functional group such as a gene or pathway tend to produce
a stronger correlation in methylation intensity?
• Are we able to identify new biological pathways (or support existing ones) by looking at correlations
in methylation intensity?
Our research identified that the strongest 10% positive and negative Spearman correlation coefficients were
a suitable subset for our analyses. Array normalisation was shown to have a profound effect on methylation
intensity, and there was some impact on correlation as well. Correlation strength did not follow a linear
relationship with distance between the correlating pair, though we did see that CpG sites within the same
gene tended to correlate more strongly. Our research suggested that it may be possible to use correlation
analysis to identify pathways in some circumstances, though future research is needed to develop a robust
approach for this. An important incidental finding was that CpG islands tend to contain much stronger
correlations in methylation intensity than the average for a chromosome - a fact which may be exploitable
for future delineation of CpG islands.
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Epigenetics is the study of the stable and heritable alterations of gene expression that occur during cellular
development and proliferation. Unlike conventional genetics, which is more concerned with the implications
of an organism’s genome sequence, epigenetics looks at non-sequence changes that are associated with vari-
ability in gene expression.
There are a number of known epigenetic regulation mechanisms, including histone modification (Bannis-
ter and Kouzarides, 2011), RNA interference (Hannon, 2002) and DNA methylation (Moore et al. 2013).
This study will focus on cytosine-based DNA methylation - the process by which methyl groups are attached
to cytosine residues in DNA, forming 5-methylcytosine. The presence of these methyl groups can regulate
gene expression by modulating the interaction between DNA and proteins involved in transcription (Jaenisch
and Bird, 2003). More specifically, it has been shown that the methylation level of the first intron of a gene
inversely correlates with gene expression in mammals (Anastasiadi et al. 2018).
A family of enzymes known as DNA methyltransferases (DNMTs) catalyse the DNA methylation reac-
tion (Moore et al. 2013), which is reversible via enzymes such as those from the ten-eleven translocation
(TET) family (Kohli and Zhang, 2013). The ability for DNA to be reversibly methylated allows an organism
to better-respond to the environment by changing gene expression, though it can also occur stochastically
as an organism ages (Jaenisch and Bird, 2003). Epigenetic alterations are known to be heritable, both in
the context of cellular proliferation and at the whole-organism reproductive level (Trerotola et al. 2015).
Epigenetic alterations are known to occur in response to external or environmental factors and have been
shown to play a role in a number of major developmental events (Jaenisch and Bird, 2003; Kiefer, 2007).
The environmental response provides a mechanism wherein gene expression levels can be propagated from
one generation of cells to the next, boosting an organism’s ability to survive stress conditions in the mid-
to long- term. The reversibility of epigenetic alterations provides the advantage of being able to adapt to
a changing environment without relying on mutation or other genomic sequence alterations (Jaenisch and
Bird, 2003). In terms of organism development, DNA methylation is known to silence gene expression in the
long-term as appropriate for each cell type – epigenetic expression has been described as the ‘software’ of the
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genome that directs embryogenesis and development, as opposed to the ‘hardware’ comprised of the genome
itself (Kanherkar et al. 2014). DNA methylation is passed between whole-organism generations via methods
such as genomic imprinting (Reik et al. 2001) and the epigenetic consequences of stressors such as major
famine have been shown to be trans-generational (Veenendaal et al. 2013). Section 1.2 reviews a number of
important considerations related to DNA methylation which provide justification for the hypotheses of this
study, which are described in section 1.6.
1.2 Overview of DNA methylation
The conversion of cytosine to 5-methylcytosine (5mC), as well as the reverse reaction, comprise the most
well-studied mechanism of methylation-based epigenetic regulation. Though the existence of 5mC in the
mammalian genome was known as early as the 1940s (Hotchkiss, 1948), its role in mammalian gene regu-
lation was not shown experimentally until the 1980s. Compere and Palmiter (1981) showed that synthesis
of a specific mRNA in a mammalian cell line correlated with hypomethylation of its associated gene, and
that this change in expression was passed between cells as an epigenetic change, i.e. the expression change
was retained in daughter cells despite no apparent alteration of genetic sequence. More generally, DNA
methylation alters gene expression by directly inhibiting binding of transcription factors (Brenet et al. 2011)
or by recruiting proteins with other epigenetic effects, such as methyl-CpG-binding domain (MBD) proteins
which are involved in histone modification (Roloff et al. 2003). As gene expression is inextricably linked to
phenotype, DNA methylation is known to have a significant role in cell development (Smith and Meissner,
2013) and disease etiology (Robertson and Wolffe, 2000).
In mammals, DNA methylation occurs primarily at CpG sites, which are regions of DNA where a cyto-
sine nucleotide is followed by a guanine nucleotide in its 5’ to 3’ direction. Assuming that the distribution
of bases in DNA is uniform (i.e. they all appear at roughly the same rate) then the probability that any two
consecutive bases are a C and G would be about 1 in 16, or 6.25%, equating to about 194 million CpG sites
throughout the human genome. However, there are only about 29.3 million CpG sites observed in recent
assemblies of the human genome (Luo et al. 2014), or just under 1% - drastically lower than what one would
assume from a probabilistic standpoint. In unmethylated DNA, spontaneous deamination of cytosine results
in the creation of uracil, which is typically repaired via the uracil-DNA glycosylase pathway. The methylated
form, 5-methylcytosine, deaminates into thymine and remains as a permanent mutation until repaired by
the BER pathway (Duncan and Miller, 1980; Krokan and Bjør̊as, 2013). Consequently, CpG sites are fewer
in number than one would expect. Despite the relatively low abundance of CpG dinucleotides in the human
genome, there are regions that show a dramatic increase in CpG frequency, referred to as CpG islands (Larsen
et al. 1992). These regions are often associated with gene promoters (Saxonov et al. 2006; Illingworth et
al. 2010), and their methylation is considered to be play a major role in gene silencing (Illingworth and
Bird, 2009). About half of all identified CpG islands contain transcription start sites, with the other half
being referred to as ’orphan’ CpG islands owing to the uncertainty of their purpose (Deaton and Bird, 2011).
The procedure of ‘writing’ DNA methylation is carried out by a family of enzymes known as DNA methyl-
transferases, or DNMTs, of which there are many different types (Lyko, 2018). The specifics of each DNMT
are beyond the scope of this thesis, but DNMTs can generally be assigned to one of two categories (Moore
et al. 2013):
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• de novo methyltransferases, which in concert with cofactors, catalyse the methylation of cytosines.
DNMT3A is one such methyltransferase and is associated with genomic imprinting (Kaneda et al.
2004)
• maintenance methyltransferases, which maintain existing patterns of DNA methylation. DNMT1, for
example, is associated with the epigenetic maintenance of haematopoietic stem cells (Trowbridge et al.
2009)
‘Erasing’ DNA methylation can occur passively or actively. Maintenance errors or inhibition during cell
division can result in lowered levels of DNA methylation (Moore et al. 2013), and as described previously in
this section, 5mC can be spontaneously deaminated and repaired into thymine which causes a G/T mismatch
- repair via the BER pathway would not re-implement the methyl group. Active DNA methylation, such as
that which occurs during epigenetic reprogramming (see section 1.2.4) occurs due to enzymes such as the
ten-eleven translocation (TET) methylcytosine dioxygenases and their associated pathways (Wu and Zhang,
2017).
Recent studies have shown that bases other than cytosine can also be methylated in mammals in both
DNA and RNA. Methylation of adenine to form N6-methyladenine (6mA) is a common DNA modification
in prokaryotes, but was largely ignored in eukaryotes up until recently (reviewed by Heyn and Esteller,
2015). A number of studies have suggested that 6mA plays a significant role in human epigenetic regulation
- some examples of this include work by Wu et al. (2016) suggesting adenine methylation plays a role in
embryonic development; and a paper by Xiao et al. (2018) suggesting that levels of 6mA influence human
tumorigenesis. Conversely, an article by Douvlataniotis et al. in March 2020 asserts that current approaches
to assessing 6mA in mammals are flawed and publications they reviewed (including those by Wu et al. and
Xiao et al.) provide insufficient evidence to support the action of 6mA as significant epigenetic mechanism
in mammals. This thesis focuses on cytosine methylation data, but many of the concepts and hypotheses
may still apply and could be a potential avenue for future research.
1.2.1 Environmental influences
The conditions that an individual exposes themselves to on a regular basis are often referred to as ‘lifestyle
factors’ and can have a significant impact on DNA methylation. Diet and nutrition are also known to greatly
influence DNA methylation in specific tissue types (Ulrey et al. 2005; Kadayifci et al. 2018) - a recent study
proposed that changes in DNA methylation may play a role in the effectiveness of the ketogenic diet in the
treatment of epilepsy (Chen et al. 2019). Exercise is associated with altered regulation of a number of genes
typically associated with good health (Sailani et al. 2019; Ferrari et al. 2019). It has also been shown that a
particularly sedentary lifestyle has effects on DNA methylation (van Roekel et al. 2020). Sleep deprivation,
a condition affecting millions of people across the world, has significant impact on the epigenome as a whole
(Gaine et al. 2018) and DNA methylation specifically is implicated in the glucose-managed maintenance of
the circadian rhythm (Peng et al. 2019).
Environment in the more-literal sense also has an impact on the epigenome. Temperature and humidity
have been shown to have an effect on DNA methylation (Bind et al. 2014), as has sun exposure (Grönniger
et al. 2010). Environmental exposure to pollutants has been shown to alter DNA methylation, especially at
younger ages; cellular toxicity due to the presence of arsenic has been shown to impact the methylome in
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multiple different age groups (Bandyopadhyay et al, 2016; Hossain et al. 2017; Lambrou et al. 2012) as well
as in utero (Kile et al. 2012). Tobacco smoke has similarly been shown to change DNA methylation across
all age ranges, particularly in utero (Joubert et al. 2012; Peluso et al. 2014) and the effects remain over the
long-term (Shenker et al. 2013). Martin and Fry (2018) review a number of studies related to the effects of
environmental pollutants on the human epigenome.
1.2.2 Age influences
The association between an individual’s chronological age and their DNA methylation patterns has been
studied in depth for some time (Boks et. al 2009; Teschendorff et. al 2010; Rakyan et. al 2010). A surge
of academic interest in the epigenetics of aging during the early 21st century quickly lead to researchers
considering the prospect of using DNA methylation as a predictor of age and age-related diseases. A seminal
paper by Horvath et. al in 2011 was followed shortly thereafter by a number of estimators for chronological
or biological age which use methylation status of particular CpG sites within a given tissue type (Horvath,
2013; Hannum et. al, 2013; Weidner et. al, 2014; Giuliani et. al, 2016). The difference between an indi-
vidual’s chronological age and their age as predicted by one of these ‘clocks’ is referred to as epigenetic age
acceleration (Horvath and Raj, 2018). This acceleration can result in someone being epigenetically younger
or older than their chronological ages, which comes with its associated age-associated morbidities (Horvath
et al. 2015, Marioni et al. 2015). Individuals with Werner syndrome, a disease characterised by the appear-
ance of premature aging, may be subjected to faster epigenetic aging as per a study which compared the
chronological age of individuals with their DNA methylation-based clock age (Maierhofer et al. 2017).
Two key observations can be made with regards to the effects of aging on the methylome: genome-wide
hypomethylation, and promoter-specific hypermethylation (Bollati et al. 2009; Johnson et al. 2012). The
rate of passive change of DNA methylation, referred to as part of a broader ‘epigenetic drift’, is stochastic
in nature resulting in compounding of DNA methylation maintenance errors over time (Issa, 2014). Conse-
quently, these effects can vary greatly between even genetically-identical individuals. Multiple twin studies
have found that while monozygotic twins are epigenetically very similar when they are young, older twins can
differ significantly in their DNA methylation (Fraga et al. 2005; Talens et al. 2012). It has been suggested
that epigenetic mosaicism occurring in-part as a result of DNA methylation drift is one of the key factors
that lead to phenotypes associated with aging (Issa, 2014).
1.2.3 Genetic influences
Epigenetics, literally ‘on top’ of genetics is ultimately subject to an individual’s genomic sequence. Genetic
variation will result in epigenetic variation to some degree. For example, single nucleotide polymorphisms at
a CpG site may remove the site completely, preventing cytosine methylation. There has been a number of
studies researching the effects of SNPs on DNA methylation of nearby CpG sites (Soto-Ramı́rez et al. 2013;
Veenstra et al. 2018). The effects of genetic variation on the methylation status of CpG sites of interest
throughout the genome have also been studied (Gaunt et al. 2016) - this study presented a catalogue of
genetic influences on DNA methylation in human blood at a number of different life stages, suggesting that
the genetic component of methylation may have a causal role in complex traits.
Possibly the most striking genetic influence on the mammalian epigenome is caused by the presence of
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multiple X chromosomes, as is typically the case in females. The phenomenon of X-inactivation and its
role in mammalian development was first described by Mary Lyon (1972). Essentially, one of the two X
chromosomes is ‘inactivated’ at random to prevent excessive expression of genes located on this chromosome
(Brockdorff and Turner, 2015). This is associated with a number of epigenetic effects - most relevant to this
thesis is the impact on DNA methylation, which can be a tendency to increase or decrease in a site-dependent
manner (Sharp et al. 2011).
1.2.4 Inherited influences
One of the key attributes of epigenetic modifications is that they are heritable to some extent. Within a
few hours of fertilisation, DNA methylation patterns in the newly-formed zygote are largely erased or ‘reset’
as part of a process referred to as ‘epigenetic reprogramming’ (Fraser and Lin, 2016) though some marks
present in the parental methylomes are retained (Wang et al. 2014). The expression of certain genes changes
depending on whether that gene was inherited from the mother or father, owing to a process referred to
as ‘imprinting’ (Reik and Walter, 2001; Ferguson-Smith, 2011). DNA methylation plays a significant role
in mammalian genomic imprinting, and the epigenetic marks on many imprinted genes are retained after
epigenetic reprogramming (Bartolomei 2009; Bartolomei and Ferguson-Smith, 2011).
Additionally, stresses on the either parent prior to fertilisation, or during pregnancy in the case of the
mother, can manifest as an epigenetic influence. A well-studied example of epigenetic inheritance from the
father is the 1944-45 Dutch famine which has been the subject of a number of trans-generational studies. It
has been shown that not only the direct descendants who were prenatally exposed to this famine via their
parents had a famine-influenced DNA methylation pattern (Heijmans et al. 2008) but children of prenatally
under-nourished fathers (but not mothers) were comparatively heavier and more obese than children whose
fathers were not under-nourished (Veenendaal et al. 2013). As an example of maternal epigenetic inheri-
tance, a study found that prenatal maternal hardship due to the 1998 North American ice storm correlated
with a deviation of methylation levels of a large number of genes associated with immune function in their
children (Cao-Lei et al. 2014).
1.2.5 Tissue type
The study of epigenetics has answered many of the questions relating genotype to phenotype and provides a
justification for how a single genome can produce many different cell types. Studies have shown that patterns
of DNA methylation (and changes thereof) are dependent on the local tissue type (Thompson et al. 2010;
Horvath 2013), and a number of initiatives exist to capture this information, such as the NIH Roadmap
Epigenomics Mapping Consortium (Bernstein et al. 2010).
The study of correlations in samples derived from tissues other than whole blood is beyond the scope
of this thesis, though this presents a promising area of future research.
1.2.6 Dysregulation of DNA methylation
As with other epigenetic phenomena, DNA methylation is ultimately a mechanism which controls cellular
development and metabolism via regulation of genes relevant to these processes. As described in section
1.2, DNA methylation alters gene expression by directly inhibiting binding of transcription factors or by
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recruiting proteins with other epigenetic effects. Dysregulation of this process results in sub-optimal gene
expression and can often lead to disease phenotypes.
Several genetic disorders that impact DNA methylation have been characterised. ICF syndrome, named
for its presentation of immunodeficiency, centromeric instability and facial anomalies, is an extremely rare
genetic disorder (Brown et al. 1995). An epigenetic characteristic of ICF syndrome is a genome-wide loss
of DNA methylation owing to a mutation in DNMT3b, one of the DNA methyltransferases thought to be
involved in de novo methylation (Heyn et al . 2012). Earlier research suggested that immunodeficiency
occurring as a result of ICF syndrome may be a result of non-specific hypomethylation in regions critical
to B cell development (Hansen et al. 1999). Rett syndrome is a genetic disorder characterised mainly by
neurological disorders (in particular, seizures and apraxia) and reduced physical growth, primarily of the
head (Smeets et al. 2012). The syndrome is caused by mutations in the MECP2 gene (Amir et al. 1999). As
the inheritance pattern is X-linked, this mutation is lethal to the vast majority of genetic males who inherit
it; consequently, Rett syndrome is predominantly associated with females (Chahil et al. 2018). MECP2, or
methyl CpG binding protein 2 is an abundant nuclear protein which binds to methylated CpG sites in the
genome and recruits transcriptional repressors such as mSin3A and histone deacetylases (Nan et al. 1998).
A more recent study has shown that it can also activate transcription, rather an suppress it, and postulates
that aberrant MECP2-facilitated regulation of genes in the hypothalamus may be the main driver behind
Rett syndrome (Chahrour et al. 2008). Fragile X syndrome is another X-linked dominant genetic disorder
characterised by intellectual disability (Bagni et al. 2012), though it is significantly less lethal; one study
suggested that the average age of death was only about 12 years lower than the general population but admits
that this may have been biased (Partington et al. 1992). Fragile X syndrome occurs as a result of a mutation
of the FMR1 gene which causes an increase in CGG trinucleotide repeats in the 5’ untranslated region - this
leads to hypermethylation (and deacetylation) of the gene which suppresses transcription (Crawford et al.
2001).
In terms of cancers, DNA methylation has been proposed as an early diagnostic biomarker for several
types (Dong et al. 2014) and the etiology of many different cancers involves aberrant regulation of tumour
suppressor genes (Dong et al. 2014; Paska et al. 2015; Tse et al. 2017; Saghafinia et al. 2018; Sun et
al. 2018; Wang et al. 2020). Dysregulation of genes required for normal development, such as the HOX
genes, is also associated with oncogenesis despite these genes having no apparent onco-suppressive ability;
rather, these proto-oncogenes only result in disease phenotypes if their epigenetically-driven expression is
incorrect (Bhatlekar et al. 2014). Some studies suggest that aberrant DNA methylation is the cause of
cancer and could be a potential target for medical intervention (Esteller, 2005; Mossman and Scott, 2006)
- researchers have proposed the ‘correction of a diseased epigenome’ as a potential treatment or cure for
cancer (Takeshima et al. 2019). Indeed, some clinical trials of epigenetic treatments for cancer have been
conducted or are currently underway (Cheng et al. 2019).
An individual’s age is by far the strongest indicator of mortality risk - the older one gets, the more likely
they are to succumb to any number of diseases (Rae et al. 2010). In terms of DNA methylation, the trend
with age is that hypomethylation tends to occur in heterochromatic regions of the genome, particularly in
repetitive elements (Bollati et al. 2009; Heyn et al. 2012), though age-associated hypermethylation has also
been shown to occur (Madrigano et al. 2012). As discussed in section 1.2.2, researchers such as Horvath
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and Hannum have developed epigenetic clocks that can predict one’s age based on specific CpG sites within
their methylome to a high degree of accuracy. Some researchers have suggested that aging is the result
of the accumulation of epigenetic modifications over time (Kane and Sinclair, 2019). As a consequence,
researchers have invested some effort into reversing these epigenetic modifications in an attempt to find a
therapeutic treatment for the consequences of aging. An experiment in an animal model showed that its
possible to restore a ‘youthful’ epigenetic state which improves tissue function in aged mice (Lu et al. 2020).
The idea of a youthful versus an elderly epigenetic state ties into the earlier discussion regarding cancer.
Cancer rates increase exponentially with age (Cancer Research UK, 2020) and is also thought to be driven in
part by DNA methylation. Multiple studies have proposed that cancer and aging are inextricably linked to
the accumulation of aberrant patterns of DNA methylation, or ‘epigenetic legions’, over the course of one’s
lifespan (Esteller, 2000; Liu et al. 2003; Daniel et al. 2015; Unnikrishnan et al. 2018). Research in the field
is progressing at a rapid pace, and the concept of an epigenetic treatment for both aging and age-associated
diseases such as cancer may prove itself to be a reality in years to come.
1.3 Correlations and their applicability to DNA methylation
Correlation between a pair of variables suggests that there may be an underlying association between the
variables. In general terms, a correlation is only a statistical association within data and does not mean that
a causal relationship exists within that data.
In the context of DNA methylation, we calculate correlation between the degree of methylation present
at individual CpG sites. We use beta values for this calculation as they are a linear representation of methy-
lation intensity, bound between 0.0 (predominantly unmethylated) and 1.0 (predominantly methylated). A
correlation in this case suggests that as one particular CpG site increases in methylation intensity, another
specific CpG site will also tend to increase in methylation intensity (or decrease in the case of a negative
correlation).
While our ability to accurately measure DNA methylation has increased dramatically over the past few
decades, it is still an imperfect science and we would expect some noise and technical bias regardless of
sequencing platform. We can attempt to reduce this using statistical approaches such as using sufficiently-
large datasets and making informed choices when it comes to array normalisation. Assuming these were
sufficiently accounted for, and taking only sufficiently-strong and statistically-significant correlations for our
analysis, we would have a set of CpG pairs for which one of the following would be true:
1. Both CpGs are influenced by a common underlying epigenetic mechanism
2. Methylation of one CpG directly influences methylation of the other
These are discussed in more detail in section 1.3.3.
Other EWAS tend to focus on methylation intensity values directly, rather than focusing on associations.
The use of different sequencing platforms and processing methods adds a layer of difficulty when comparing
studies, but we would expect biologically-grounded, strong correlations to remain in place regardless. It
follows that we may be able to use a correlation-based approach to identify biological pathways that are
regulated (at least in part) by DNA methylation.
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1.3.1 Limitations of correlations
1.3.1.1 Representation and minimum sample size
Statistically-speaking, a cohort will tend to have characteristics that are an approximation of the overall
population. These approximations get closer to the overall population characteristics as the sample size
grows larger, but unless the entire population is represented within that sample, there is generally going to
be some divergence in any particular sample. In the context of what we are doing here, the statistical prop-
erties of any given cohort, such as the distribution of methylation intensities at any given CpG site, are only
going to approximate the human population at large. An excellent p-value (or other metric) for a correlation
coefficient means significantly less if the underlying distribution of the data is not a good representation of
the population. We are a long way off being able to accurately assess the methylome of every human on the
planet and the relative youth of the field of epigenetics (and in particular, population epigenetics) means
that we do not have enough data to say for sure if any particular cohort is an accurate representation of our
species as a whole.
To my understanding, no serious work on genome-wide methylation correlation has been published be-
fore. This is unfortunate, given the scientific potential of such a study, and compounds the issue mentioned
above as we do not have any basis on which to identify a ‘good’ cohort for any correlation study. We do not
know the minimum sample size required for decent and stable correlation computation. A past study has
suggested that stable estimates of correlation occur as the sample size approaches 250 (Schönbrodt and Pe-
rugini, 2013) but it is not known how well this research applies to correlations in DNA methylation intensity,
or even if it applies to all correlation methods - the authors did not explicitly mention which method they
used, and their simulated dataset used randomly-generated values from a bi-variate Gaussian distribution,
which may not be an accurate representation of the underlying distribution of the data we are using in this
thesis.
1.3.1.2 Spurious correlation of ratios
A mathematical quirk often overlooked in the biological sciences is referred to as ‘spurious correlation of
ratios’. This was first described by Karl Pearson in 1897. The basic idea is that given three random uncor-
related variables x, y and z, a correlation between xz and
y
z will be found. This is because the pairs with a
relatively large value of z will tend to be larger than those with a smaller one, and a significant correlation
may occur between the two ratio variables as a result.
This study primarily uses beta values to represent methylation intensity. At a technical level, the beta
value is a ratio representing the proportion of methylated reads at a given CpG site. This is an estimation
of the probability that a CpG site is methylated, as opposed to a genuine ratio, so the principle of spurious
correlation of ratios does not apply here. However, care must be taken to ensure other correlations between
ratios are not misinterpreted in other studies.
1.3.1.3 Correlations due to randomness
Similar to the spurious correlation of ratios, we can occasionally see correlations in random uncorrelated
data. Randomly-distributed pairs would have a correlation coefficient that tends towards zero for a suffi-
ciently large sample size. For smaller datasets, we would expect these stochastic factors to manifest as a bell
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curve in the overall distribution of correlations.
Deconvoluting ‘legitimate’ correlations from random ones is beyond the scope of this thesis. We can, how-
ever, make efforts to minimise the number of random-chance correlations by using only correlations above a
certain threshold. Legitimate strong correlations will tend to be distributed closer to the extremes of 1.0 and
-1.0 - the ratio of legitimate to random correlations (and therefore the likelihood that a given correlation is
legitimate) increases for values closer to these extremes, so by setting a high threshold for a correlation to be
considered ‘strong’, we also decrease the number of random-chance correlations in our set of identified strong
correlations. There will always be some present with this method, but we will still be able to reduce the
number (albeit at the cost of potentially losing some information regarding legitimately strong correlations).
1.3.2 Options for evaluating correlation
We can consider three common measures of correlation for the purposes of our studies:
• Pearson’s Correlation
• Spearman’s Rank Correlation
• Kendall’s Rank Correlation
All three of these are compared in a brief study documented in chapter 5, and this section contains an
overview.
An important assumption we make for the purposes of our research is that any statistical relationship
between two CpG sites is monotonic but not necessarily linear, i.e. as one increases, the other will tend to
increase or decrease, but not necessarily in proportion.
1.3.2.1 Pearson’s Correlation Coefficient
The simplest canonical method of calculating correlation is by taking the Pearson correlation coefficient.
This is the standard measure of correlation between two variables, and generally what most people think of
when they think of correlation. Given a cohort of size n and paired data xi and yi with respective sample
means of x̄ and ȳ, the sample Pearson correlation coefficient r can be calculated with the following equation:
r =
∑n
i=1(xi − x)(yi − y)√∑n
i=1(xi − x)2(yi − y)2
(1.1)
The Pearson correlation coefficient assumes a linear monotonic relationship between two variables. While
we assume that the relationship between two associated CpG sites is monotonic, we don’t assume that this
relationship is necessarily linear; therefore, Pearson’s method may be unsuitable for our research.
1.3.2.2 Spearman’s Rank Correlation Coefficient
Spearman’s rank correlation is a measure of how well a relationship between two variables can be described
using an arbitrary monotonic function - in other words, whether or not a relationship exists between two
variables that can be described as either:
1. As the value of one variable increases, the other variable will also tend to increase (positive correlation)
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2. As the value of one variable increases, the other variable will tend to decrease (negative correlation)
Given the pairwise distances of the ranks of the variables d and a number of samples n, the Spearman
correlation coefficient ρ can be calculated with the following equation:





The Spearman rank correlation coefficient is usually larger in magnitude than the alternative Kendall coef-
ficient. As a consequence, this may increase variance within our correlation data, as a tendency for larger
magnitudes will cause the distribution of correlation coefficients to ‘spread out’. This would make it easier to
identify a threshold for selecting strong correlations as the frequency of correlations for a given range would
be lower, as the statistical distribution would generally be less dense.
1.3.2.3 Kendall’s Rank Correlation Coefficient
Kendall’s rank correlation is similar to Spearman’s in the sense that it is also a measure of how well a
relationship between two variables can be described using an arbitrary monotonic function. The key difference
is that it is based on concordant and discordant pairs; given a set of observations (x1, y1), ..., (xn, yn), any
pair of observations (xi, yi) and (xj , yj) are concordant if both xi < xj and yi < yj , otherwise they are
discordant. Given nc concordant pairs and nd discordant pairs, for a total of n pairs overall, the Kendall





Kendall’s approach is the preferred method for calculating rank correlation for a small sample size as it
provides better estimates than the Spearman method. Additionally, Kendall’s rank correlation coefficient is
easier to interpret, as it is directly linked to the probabilities of observing the concordant and discordant
pairs.
1.3.2.4 Selection of method for preliminary studies
Given the assumption of a monotonic and possibly non-linear relationship, a rank correlation coefficient would
likely be a better choice. A 2010 study by Croux and Dehon suggested that both Spearman and Kendall
correlation are statistically ‘robust’ and ‘efficient’ measures, with the Kendall method being preferable due to
its superior performance under the conditions of their study. An informal test (similar to the one discussed
in section 5.2) found that computation of the Spearman correlation matrix was orders of magnitude faster
than that of the Kendall method, using the Python packages available for our research. Given the need for
evaluation of a number of large correlation matrices, and limitations on time available for computing, the
Spearman measure will be used for preliminary studies.
1.3.3 Biological interpretation of correlations
As per section 1.3, we have identified two possible explanations for a significant correlation in DNA methy-
lation intensity between two CpG sites.
The first explanation is that both CpGs are influenced by a common underlying epigenetic mechanism.
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This is known in statistics as a spurious relationship - one wherein two variables are not causally related,
but may be associated due to the presence of confounding factors. A positive correlation in this case could
suggest that two distinct CpG sites both experience DNA methylation in response to the same environmental
stimulus. A possible example of this could arise in genes associated with diet, where multiple correlating
CpG sites are methylated or demethylated based on consumption of specific foods, as has been seen in fruit
and fruit juice (Nicodemus-Johnson and Sinnott, 2017).
The second explanation is that methylation of one CpG site directly influences methylation of the other.
In this case, a positive correlation could suggest that the presence of one gene product activates a pathway
which results in the demethylation of CpG sites on another gene. A similar mechanism could exist in the
reverse direction, wherein the absence of one gene product activates a pathway which results in the methy-
lation of CpG sites on another gene. In the instance of a negative correlation, a negative feedback loop
could exist, where an increase in one gene product activates a pathway which methylates another CpG site
(perhaps to reduce its associated gene product), and vice versa.
The lack of studies so far into patterns of correlation in DNA methylation means that these two explanations
are simply conjecture at this point. Nonetheless, they provide the basis for hypotheses and a justification
for continuing with this research.
1.3.4 How correlations are used in this study
For array-derived data, the beta values for each CpG site are calculated individually for each individual
(or distinct sample) in the cohort. The number of beta values for each CpG site is equal to the number of
individuals (or distinct samples; both correspond to n) in the cohort. Any two CpG sites will have n data
points consisting of two beta values, allowing a correlation coefficient to be calculated between the CpG sites
for the cohort in general.
Due to the absence of past correlation studies in this area, it is difficult to define a ‘strong’ correlation
in the context of DNA methylation intensity. One could select a threshold based on personal preference
and go with that - for example, 0.7 - and any correlation with a magnitude greater than or equal to this is
considered a strong correlation. Perhaps the better thing to do would be to take a certain percentage of the
strongest positive and negative correlations and look for trends in this subset, rather than arbitrarily setting
a threshold. Section 2.2.5 discusses our options for identifying strong correlations.
1.3.4.1 Correlation networks
We can define a correlation network as a set of pairs of CpG sites that are associated by means of at least
one shared strong correlation in methylation intensity. In other words, a correlation network is an undirected
graph with CpG sites as the vertices, with edges comprised by strong correlations between beta values of
these CpG sites. The smallest possible correlation network is one consisting of two CpG sites that only
strongly correlate with each other, i.e. they do not strongly correlate with any other site. Larger correlation
networks, consisting of CpG sites that correlate with multiple other CpG sites (each of which correlate with
other CpG sites, and so on) are of particular interest as they provide a means by which we can evaluate
hypothesis 1 (as described in section 1.6).
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The primary application of correlation networks in our research is the identification of pathways which
are connected by strong correlations in DNA methylation. Chapter 7 contains our work regarding this
topic.
1.4 Cohorts
A cohort is typically described as a group of subjects with some common factor that allows them to be
grouped together in some meaningful way. For example, a cohort that we might use in an EWAS could be
based on age or ethnicity. Appendix B details the cohorts used for original research described in this thesis.
Unless otherwise stated, they have the following characteristics:
• Same sequencing/data acquisition platform (e.g. WGBS sequencing, Illumina EPIC array)
• A defined age range
• A sufficient number of subjects such that meaningful insights can be derived from the data
In practical terms, cohorts used for studies in this thesis will generally be a collection of samples of the same
tissue type from different individuals. For example, the CHDS cohort described in Appendix B consists of
EPIC array data for 120 different blood samples. Cohorts can be broken down into sub-cohorts relevant to
a specific purpose, such as only taking samples from individuals of a particular age.
1.5 Study Rationale
Though there are established links between DNA methylation and gene expression (e.g. Anastasiadi et al.
2018), and a vast number of biochemical pathways have been identified, the study of correlation between
DNA methylation intensities at different CpG sites appears to have been largely ignored. Conventionally,
epigenome-wide association studies (EWAS) look at the methylation intensities directly (as a derived beta
or M value) as opposed to the correlations between them (examples: Wang et al. 2015, Sala et al. 2020).
Correlation in the mathematical sense occurs when there is an association between two variables; correlation
of DNA methylation between two different CpG sites would suggest the existence of an association that may
be grounded in other biological processes. The biological interpretation of these correlations is discussed in
section 1.3.3.
Studies in this thesis will ultimately attempt to find epigenetic trends by looking at DNA methylation
derived from microarray analysis of whole blood samples from living humans. Whole blood DNA methyla-
tion data has been used in the past for a multitude of EWAS (e.g. Osborne et al. 2020; Gerring et al. 2018).
The heterogeneous nature of blood can lead to some difficulties due to the cell composition effects on DNA
methylation, but epigenetic regulation of processes that are not cell-mediated are typically interpretable in
blood DNA methylation data (Houseman, 2015). It follows that the underlying associations of processes that
are cell-mediated would still be present, if obscured by ‘noise’; the effect of this noise on correlations in our
data are currently unknown. If it can be shown that genes within the same pathway tend to have correlating
methylation at their CpG sites, then this may lead to the discovery of new pathways as unforeseen corre-
lations could indicate that a pair of genes comprise part of an unknown network. As such, the study may
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shed some light on undiscovered regulatory pathways while also verifying pathways identified in other studies.
A number of the studies presented in this thesis are undertaken with the intention of supporting accurate
evaluation of correlations in other studies. This includes data-based experiments for the following:
• Comparing the effects of microarray normalisation on correlations
• Identifying the ideal measure of correlation
This will help produce a protocol which will promote the identification of correlations which are grounded
in underlying biological phenomena. Such a protocol will facilitate a more robust investigation into the hy-
potheses presented in this thesis and may be useful for future researchers who intend to compare correlations
in DNA methylation intensity, rather than comparing the data directly as is usually the case in EWAS. Some
recommendations for future work can be found in section 8.5.
1.6 Research Aims
Hypothesis 1: CpG sites on different genes which are part of the same pathway
will strongly correlate in methylation intensity
The downregulation of a metabolic pathway may manifest due to an increase in DNA methylation of CpG
sites on genes within that pathway, and vice versa. We can validate this hypothesis by finding stronger-
than-average correlations in methylation intensity at these sites.
Hypothesis 2: CpG sites that are located closer together will tend to correlate
more strongly
A topologically-associating domain (TAD) is a region in which DNA sequences physically interact with each
other more frequently than with sequences outside this domain (Pombo and Dillon, 2015). It is hypothesised
that CpGs on TADs, which would tend to be closer together, are more likely to have a similar methylation
intensity. We can validate this hypothesis by comparing methylation intensity with CpG distance within
each chromosome.
Hypothesis 3: Strong correlations in microarray-derived methylation intensities
will tend to be consistent regardless of which normalisation method was used
DNA methylation microarray normalisation, discussed in sections 2.1.2 and 4.1, is a step which can improve
the calculation of methylation intensities. While selection of normalisation method will certainly impact
the calculated methylation intensities, it is hypothesised that strong correlations will be consistent as the
underlying trends will still be present. This can be validated by comparing the strong correlations identified






There are multiple ways of determining the methylation trends of a particular CpG site within a genome.
Two of the most-used modern methods of profiling DNA methylation, based on search results for NCBI GEO
(Edgar et al. 2002) are high-throughput sequencing techniques such as whole-genome bisulfite sequencing
(WGBS), and the use of microarrays such as Illumina’s MethylationEpic BeadChip (which will be referred
to as the EPIC array in this thesis), with high-throughput techniques being used in roughly three times as
many studies as arrays as of late 2020.
Sequencing techniques such as WGBS (Frommer et al. 1992) are capable of producing a full methylome
of 28 million CpG sites in the case of the human genome. DNA methylation arrays provide a quick and
relatively simple means of assessing the methylation of a vast number of CpG sites within a genome, though
the current state-of-the-art EPIC array only looks at about 850,000 CpG sites at single-nucleotide resolution,
or roughly 3% of the total number of CpG sites in the human genome (Pidsley et al. 2016). EPIC arrays
are reasonably new and more data is available for the earlier Illumina Infinium HumanMethylation450 ar-
ray, which has about 450,000 CpG sites (Dedeurwaerder et al. 2014). Previous studies have compared the
two arrays and shown that there is significant correlation in the overlapping sites for whole blood samples,
suggesting that both can be used in the same study (Solomon et al. 2018), and other studies have compared
array data with WGBS data and found that derived results are also highly correlating (Pidsley et al. 2016).
State-of-the-art nanopore sequencing technology has recently been used for identification of DNA methyla-
tion state, correlating greatly with results from bisulfite sequencing (Ni et al. 2019) though datasets such as
this are few in number compared to datasets produced via other methods, and the relative infancy of this
approach means that few software tools exist to work with nanopore-derived methylation data.
2.1.2 An overview of DNA methylation microarrays
Microarray technology has been used to assess DNA methylation for some time (Deatherage et al. 2009).
The general concept of a microarray (referred to as simply ‘array’ throughout the majority of this thesis) is
that oligonucleotides are fixed to a chip (forming ‘probes’), and this chip is subjected to a DNA sample, from
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which complementary strands attach to the oligonucleotides and result in a physical or chemical change that
can be detected through some instrument (Illumina Inc., 2020a). In the case of Illumina’s DNA methylation
(Infinium) arrays, which are the source of all array-based data in this thesis, two site-specific fluorescent
probes are produced for each CpG site - one to detect a methylated locus, and the other to detect an un-
methylated locus. Prior to application to the chip, the DNA sample is treated with bisulfite, which converts
unmethylated cytosine to uracil while leaving methylated cytosine unchanged (Clark et al. 2006). After the
bisulfite-treated DNA sample has reacted with the probes on the chip, assessment of the ratio of fluorescent
signals (via a laser-based imaging instrument) between the methylated and unmethylated probes can then
be used to establish a methylation intensity for each CpG site (Illumina Inc., 2020b).
The vast majority of human DNA methylation array data (available on NCBI GEO) has been generated
using one of three platforms produced by Illumina Inc.:
• MethylationEPIC BeadChip (referred to as the EPIC array in this thesis) - the most recent offering,
with 863,904 CpG Sites (Pidsley et al. 2016)
• HumanMethylation450 BeadChip (referred to as 450k) - 482,421 CpG sites (Bibikova et al. 2011)
• HumanMethylation27 BeadChip (referred to as 27k) - 27,578 CpG sites (Bibikova et al. 2009)
An important technical consideration for EPIC and 450k arrays is that two different types of probes are
employed - these are aptly named type I and type II probes. Type I probes are based on the technology used
for the 27k array, and use a single colour with two different probes to generate methylated and unmethy-
lated measurements. Conversely, type II probes use a single probe with two different colours to obtain these
measurements (Wu et al. 2014). This multi-probe design was first used in the 450k array, but was carried
over to the EPIC array (Pidsley et al. 2016). There can be substantial differences in methylation intensities
detected by the different probe chemistries - the type II probes, while being able to be more densely packed
onto the chip surface, tend to be less accurate than the type I probes (Dedeurwaerder et al. 2011).
Another important consideration is that of background fluorescence (Ritchie et al. 2007). This is a source
of error which can be caused by biological phenomena such as non-specific binding of labelled sample to the
surface of the array, technical issues such as optical noise from the sensor, or other factors. Correction of
signal due to background fluorescence is referred to as background correction and is implemented in several
of the methods discussed in section 4.1.
2.1.3 Literature review: Osborne et al. (2020) - Genome-wide DNA methyla-
tion analysis of heavy cannabis exposure in a New Zealand longitudinal
cohort
A study by Osborne et al. (2020) investigated the effects of cannabis exposure on genome-wide DNA
methylation of whole blood samples taken from the Christchurch Health and Development Study (CHDS)
cohort. This study used the EPIC array to assess DNA methylation in a sub-cohort of 120 individuals,
all approximately 28 years of age. While correlations between CpG methylation intensities weren’t investi-
gated specifically, the methods of analysing methylation intensity are applicable to the study being proposed.
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Osborne et al. used beta values derived from the array data in an EWAS, with the intention of identi-
fying the most differentially-methylated CpG sites for cannabis (without tobacco) users vs. controls, and
for cannabis (with tobacco) users vs. controls. Beta values were calculated with the minfi package in R
(Aryee et al. 2014). Techniques used for calculation of these beta values can be used in a similar manner
for studies within this thesis, though some adaptations may have to be made depending on the format of
available datasets.
Prior to conversion to beta values, the raw data was normalised using the NOOB procedure as imple-
mented in minfi. NOOB, or Normal-exponential using out-of-band probes is an approach which accounts
for technical variation in the background fluorescence signal produced during DNA methylation array data
acquisition (Triche et al. 2013). Justification for using NOOB over other normalisation techniques was not
given by the authors, nor were any other normalisation techniques used in the study as a comparison. The
same data was used in another study, where the NOOB method was found to be provide the best results of all
tested methods (Noble, 2021). In both cases, use of this normalisation technique yielded biologically relevant
results so it should be considered as a possible technique of choice for preliminary studies and investigated
further in later analyses.
A number of CpG sites were intentionally excluded from the analysis, including sex chromosomes, failed
probes, sites with adjacent single-nucleotide variations that were deemed “potentially problematic” and all
CpGs that did not map to a unique position on the genome. The result was that only 700,296 CpG sites
were available for analysis, or only about 81% of the total number of CpG sites available on the array. This
was justifiable, considering that the study was looking for individual CpG sites. A study taking a more
statistical approach to the epigenome as a whole, however, would be better off retaining all CpG sites - the
significant reduction in data available for analysis may have weakened potential associations or even removed
them completely.
The study did not justify why whole blood was used and how blood DNA methylation relates to the methy-
lation status of DNA contained within the brain, despite the primary findings of the study involving genes
with reported roles in brain function. Houseman et al. (2015) suggest that there is evidence that whole
blood methylation can be indicative of non-cell-mediated processes in other tissues, so while samples taken
directly from the tissue of interest would provide a greater amount of information specific to cells in that
tissue, whole blood can still provide insights into epigenetic regulation of a number of biochemical pathways
in the body. Justification for taking the same approach in studies in this thesis was given in section 1.5.
In general, the study provides an excellent basis for methods to use for analysis of DNA methylation data
sourced from EPIC arrays (also applicable to other Illumina arrays). The CHDS cohort is a promising
dataset for correlation studies, and has been made available for use in our research.
2.1.4 Interpreting DNA methylation
As alluded to in chapter 1, DNA methylation is an imperfect process requiring a great deal of maintenance.
This clearly leads to some variability in methylation of specific CpG sites within a given tissue type of an
individual. Epigenetic studies use the concept of ‘methylation intensity’, which can be thought of as the
expected level of methylation at a given CpG site. A high methylation intensity suggests that a site tends to
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be more likely to methylated, whereas a low methylation intensity suggests the opposite. Techniques used
in this thesis rely on the premise that technologies can provide a good estimate of methylation intensity for
a given CpG site, based on some quantity of input data.
Two common representations of DNA methylation level are beta value and M-value (Du et al. 2010).
The beta value is described as the proportion of methylated reads at a CpG site and can be calculated from
both WGBS and array datasets. Beta values are always between 0.0 and 1.0, with a higher beta value sug-
gesting a greater methylation intensity. The M-value is the log2 ratio of methylated reads to unmethylated
reads, with an M-value of zero being equivalent to a beta value of 0.5, a positive M-value suggesting a beta
value greater than 0.5 (with M = 2 equal to a beta value of 0.8) and a negative M-value suggesting a beta
value less than 0.5 (with M=-2 equal to a beta value of 0.2).
Studies in this thesis use the beta value representation. This is because they are a linear variable con-
fined to the interval [0.0, 1.0] while M-values are non-linear and do not have defined boundaries. The
linearity of beta values makes statistical comparison easier and calculation of correlations won’t be skewed
immensely by unbounded values, as would be the case if M-values were used. To obtain the required beta
values, Illumina array data will be processed using the minfi R package, available via Bioconductor (Aryee et
al. 2014). Minfi and the means by which we use it is discussed further in sections 2.1.7 and 2.2.1. Selection
of a normalisation method is an option provided by this package - these are discussed in chapter 4.
2.1.5 Analysis of correlation within each chromosome
Correlation is difficult to calculate for large datasets as the size of the correlation matrix scales quadrati-
cally with the number of features (in this case CpG sites) and the amount of computational effort required
increases similarly, dependent on which coefficient of correlation is being calculated. Given that there are
about 28 million CpG sites in total in the human genome and WGBS datasets would see all or most of these
(Frommer et al. 1992), it would take a prohibitive amount of computational effort to calculate correlation
between every CpG site in the human genome as over 784 trillion pairs would need to be calculated, resulting
in about 6.27 petabytes of data (assuming 64-bit floating point representation). Even using all 865000 or so
available from the EPIC array would result in a matrix with about 7.48 × 1011 elements which would use
up almost 6 terabytes under the same assumption. While theoretically possible, this would certainly require
significant high-performance computing resources to achieve in any reasonable period of time.
To simplify the process of computing and comparing correlations, we can consider only the correlation
of CpG sites within individual chromosomes. A study by Ziller et al. (2014) undertook an analysis of 42
whole genome bisulfite sequencing (WGBS) datasets across 30 different human cell and tissue types. Their
results suggested that only a fraction of the methylome ( 21.8%) changed as part of coordinated regulatory
networks, and that 70-80% of the sequencing reads across the datasets provided little or no relevant infor-
mation regarding CpG methylation. The study suggests that the ‘dynamic’ 21.8% of CpG sites tend to be
co-localised with regulatory elements such as enhancers and transcription binding sites, supporting the work
of Thévenin et al. (2014). This supports the idea to limit calculation of correlations to CpGs co-located on
the same chromosome - we would still expect to find some significant correlations, assuming hypothesis 1 was
correct. We must also define a threshold for a ‘strong’ correlation - this, as well as a more-comprehensive
discussion on matters relating to correlation, can be found in section 1.3 and within the studies of chapter 5.
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2.1.6 Use of existing DNA methylation datasets
Online databases such as NCBI GEO (Edgar et al. 2002) and academic institutions can provide DNA methy-
lation data for research use. By using data from previous experiments, there is no need to produce new data
– this vastly simplifies the process of obtaining sufficient data to test hypotheses and mitigates the cost of
WGBS or array profiling.
WGBS and Illumina’s arrays only look at cytosine methylation. The overwhelming majority of mammalian
DNA methylation research limit their scope to this, though recent research suggests that modification of
adenine to N6-methyladenine also occurs to a very limited extent in mammals (Wu et al. 2016). Datasets
for adenine methylation are extremely limited so this study will focus entirely on cytosine methylation.
For the purposes of our research, DNA methylation data will be sourced from existing datasets, includ-
ing those directly available to the University of Canterbury and collaborators, as well as publicly-available
methylation databases which include information on the age of the characterised individual, such as those
described by Komaki et. al (2018) and Li et. al (2018).
Appendix B describes the datasets (cohorts) used for studies in this thesis.
2.1.7 Software tools
The R programming language (Ihaka and Gentleman, 1996) is a common language used for statistical com-
puting. Minfi (Aryee et al. 2014) is a module for R that provides functionality for processing raw data from
Illumina methylation arrays, and has been used in multiple recent EWAS (e.g. Osborne et al. 2020; Noble
2021).
The Python programming language (van Rossum and Drake Jr., 1995) is a common language used for
programming in a multitude of different fields. Python 3 is the most recent major version and is referred
to throughout this thesis more generally as ‘Python’; the specific minor version of Python used for studies
in this thesis is detailed in Appendix A. Subjectively, Python presents a great deal of advantages over R in
terms of ease-of-programming, flexibility and available libraries, so will be used preferentially over R wher-
ever possible. Several open-source Python libraries that provide key functionality for our research have been
identified:
• numpy (van der Walt et al. 2011) - numerical computation
• scipy (Virtanen et al. 2020) - general scientific computing
• scikit-learn (Pedregosa et al. 2011) - general scientific computing
• pandas (McKinney, 2010) - data science library, interoperable with numpy and scipy
• matplotlib (Hunter, 2007) - 2D graphics
• networkx (Hagberg et al. 2018) - network analysis, interoperable with matplotlib
Versions of all software tools used are recorded in appendix A.
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2.2 General methods of calculating correlations in array-derived
DNA methylation data
2.2.1 Array normalisation, preprocessing and beta value extraction
Raw array data, in IDAT format, is processed using the minfi R module (Aryee et al. 2014). This data is
provided as a red/green colour set - the technical aspects of this output were reviewed for the HumanMethy-
lation450 platform (Dedeurwaerder et al. 2014), which was the technological basis for the MethylationEPIC
array used by the CHDS cohort (among others). This is accomplished with several steps:
1. The sample sheet for the raw data is read in. This is only an option for datasets which come with a
sample sheet (or for which one has been generated). For cohorts without a sample sheet, minfi is able
to find all two-colour IDAT files in a specific directory.
2. The set of experimental data, in the form of the two-colour IDAT files, is read in.
3. Preprocessing is performed on the two-colour IDAT files. Depending on the function used for this,
normalisation can be included in this step. The normalisation methods made available by minfi include
all of those discussed in section 4.1. It is also possible to generate a set of preprocessed data that is
not normalised - this is referred to as ‘raw’ preprocessing.
4. Preprocessed data is annotated using the appropriate manifest. At this point, SNP information can
optionally be added if required.
5. Methylation intensity for all CpG sites available on the array is extracted as a beta matrix. It is also
possible to extract other measures of methylation intensity, such as M-values.
Further analysis is conducted using Python, so after producing a set of beta values for any given normalisa-
tion type, they are exported into CSV format for portability.
Unless otherwise stated, research in this thesis always uses System 1 and R configuration 1 (from Appendix
A) for steps described in this subsection.
2.2.2 CpG subset selection and calculation of correlation
Beta values for all CpG sites on the array, for all samples, are referred to as the ‘beta matrix’ and are
contained within a single CSV file. Much of the research presented in this thesis looks at correlations within
specific chromosomes, so a script was written in Python to split this file up based on chromosome. A similar
approach can be taken to arbitrarily subset the overall beta file; for example, all CpG sites on genes associ-
ated with the same pathway can be extracted into its own file, if required. This can also yield a CSV file of
beta values for all autosomal chromosomes (i.e. excluding sex chromosomes). Regardless of which CSV file
is used, correlations are generated by reading it in to Python using the pandas module (McKinney, 2010)
as a dataframe and using the appropriate function, such as the corr method of the dataframe class. The
output of this is referred to as the ‘beta correlation matrix’, abbreviated as BCM. This can be used directly
by other Python functions, but if it is likely to be required for multiple studies, the matrix is serialised using
Python’s inbuilt pickle module (usually via a function in the pandas module) and saved to disk for later use
to reduce future computational load and time requirements.
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When using the corr method to calculate correlations, a measure of correlation coefficient must be specified.
Spearman’s rank correlation is used in this thesis unless specified otherwise. Reasons for this are discussed
in section 1.3.2 and studies within chapter 5.
2.2.3 Identification of a CpG site’s associated gene
The genes associated with CpG sites are included in the array manifest provided by Illumina. This manifest
is available on the Illumina website on their product support page. We can use the manifest directly to
obtain the name of the associated gene and use these as required, though not all CpG sites will necessarily
have an annotated gene, and the manifest may not be regularly updated to make use of the newest research.
In that case, we can consult an external database such as GENCODE (Harrow et al. 2012) or an online tool
such as the UCSC genome browser (Karolchick et al. 2003) may be used to manually identify which gene a
CpG site is associated with.
2.2.4 Statistical analysis of beta values and beta correlation matrices
For the purposes of comparison and evaluation, we can consider the following common metrics for both beta
values and their associated correlation matrices:
• Average/mean: a measure of central tendency of a dataset, generally influenced by all values equally
unless a weighted average is taken
• Median: an alternative measure of central tendency, based on the value of the middle number of the
dataset when ranked in order (or the mean of the middle two, for an even-numbered dataset)
• Standard deviation: a measure of the amount of variation within a set of variables
• Variance: an alternative measure of variation within a set of variables, equal to the standard deviation
squared
• Skew/skewness: a measure of asymmetry of the distribution of a dataset, with a positive skew indicating
that the primary ‘tail’ of a distribution is on the right, and a negative skew indicating that the primary
tail is on the left, for a unimodal distribution. We used the unbiased skew measure in this thesis.
• Excess kurtosis: a measure of the ‘tailedness’ of the distribution of a dataset. An excess kurtosis of
zero generally suggests a normal distribution (e.g. Gaussian). A positive excess kurtosis suggests the
distribution has fatter tails and a more densely-packed centre, and a negative excess kurtosis suggests
the distribution has thinner tails and a less densely packed centre. We use the unbiased excess kurtosis
in this thesis.
Additionally, we define a few more metrics that aren’t in common use:
• Ratio of positive to negative correlations: a measure of the tendency of a method and dataset to
generate positive correlations, rather than negative ones (with a ratio of greater than 1.0 suggesting
more positive correlations, and vice versa). Self-correlations (i.e. the diagonal of the correlation
matrix) are excluded from this calculation. We use this as a basic gauge of the spread of values within
a correlation matrix, with a ratio closer to 1.0 implies a more even distribution of positive and negative
correlation values.
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• Consistent and unique strong correlations for a proportion: a measure of similarity between two or
more subsets of strong correlations, where subsets could be taken from matrices generated from data
produced by a different normalisation type, cohort, etc. Values are sorted and the top and bottom X%
are taken for comparison, where X is the selected proportion. The number of consistent correlations
is the number of pairs that correlate strongly in all subsets. The number of unique correlations, per
subset, is the number of pairs that are only correlate strongly in that subset.
• Offsets in mean and variance/standard deviation within multiple datasets: for a set of n subsets of
data, with an overall mean of µ and overall standard deviation of σ, we take a subset’s offset in mean
as µ subtracted from that subset’s mean, and a subset’s offset in standard deviation as σ subtracted
from that subset’s standard deviation (alternatively, a subset’s offset in variance is σ2 subtracted from
that subset’s variance). These offsets can be compared to determine the relative effects of whatever
the difference is between the subsets, such as comparing effects due to normalisation type.
There are a number of options for evaluating statistical properties. Several Python libraries, such as pandas,
numpy and statsmodels (among others) provide excellent statistical capabilities and integrate nicely into the
larger Python-based data pipeline that we are developing for this research.
2.2.5 Selection of strong correlations
Our two options for selection of strong correlations (both discussed in more detail later in this section) are
threshold-based, where we take all correlations with a magnitude greater than some arbitrary threshold; and
proportion-based, where we take some percentage of the strongest positive and negative correlations. In
either case, we must exclude the following two subsets within the correlation matrix prior to selecting strong
correlations:
1. The correlation matrix diagonal, which are correlation scores of one CpG with itself (trivially 1.0 in
all cases).
2. Either the upper or lower triangle of the matrix, as one is the duplicate of the other.
Either of these exclusions can be performed easily with functions built-in to the Python libraries we are
using for our research, or implemented algorithmically into the selection process.
2.2.5.1 Threshold-based selection
We can define a strong correlation as a correlation coefficient with magnitude greater than or equal to some
number between 0 and 1.0. A script was written to pull out values of at least this strength from a beta
correlation matrix with the two associated CpG sites. These correlations are saved to a file for later use
and/or used immediately by other scripts if required.
As the number of a chromosome’s correlations above this threshold will vary based on factors such as
normalisation type and cohort, it is more difficult to use threshold selection for direct comparison - when
comparing the strongest correlations for a given chromosome (e.g. for comparing normalisation types or
cohorts), a better alternative would be to use a proportion-based method (described in section 2.2.5.2) as
this will ensure the same number of strong correlations are available for comparison.
29
For the purposes of this thesis, the threshold for a strong correlation is defined as 0.7 unless otherwise
stated.
2.2.5.2 Proportion-based selection
An alternative approach to selecting strong correlations is to select a subset of correlations which have values
closest to the extremes; i.e. some number of correlation coefficents which are closest to 1.0 (for positive)
or -1.0 (for negative). This number can be arbitrarily selected, e.g. the 1000 values closest to 1.0, and the
1000 values closest to -1.0, or based on the size of the correlation matrix, e.g. the top and bottom 10% of
correlation coefficients if they were arranged in order from most positive to most negative.
The key advantage of a proportion-based threshold is that we essentially specify how many of the strong
correlations we want. This allows for easier comparison between different methods. The technical cost
of a proportion-based selection is significantly higher, however, as the sorting procedure becomes more
computationally-intensive as the size of the dataset becomes larger - by default, Python’s sorting algo-
rithm is Timsort, which has a worst-case complexity of O(n log(n)) (Auger et al. 20181). Due to this, a
proportional-based threshold might not be computationally-feasible for large datasets. Another concern is
that there may be an insufficient number of total positive or negative correlations for a given proportional
threshold; i.e. if we wanted to take the 10% strongest positive and negative correlations, but the ratio of
positive to negative correlations was such that the 10% most negative correlations includes some values
greater than 0.0, we may run into some difficulty. Therefore, we should also keep in mind this ratio when
using a proportional threshold.
2.2.6 Correlation network analysis
Correlation networks are defined in section 1.3.4.1. To conduct our network analysis, we use the networkx
module for Python (Hagberg et al. 2008). This module allows us to create undirected graphs for network
analysis without having to change programming language.
Networks are constructed by first adding all CpGs with positive correlations as vertices. Where neces-
sary (such as for analysis of genes on specific pathways), genes that these CpG sites are associated with can
be used as vertices instead - they simply inherit the connections of their constituent CpG sites; consequently,
if two correlating CpG sites are associated with the same gene, it is possible for the consolidated gene to be
an orphan vertex. Either way, edges between the positively correlating CpGs/genes are added next. The
overall graph is then updated with negative connections in the same manner, using the positive correlation
graph as a basis.
To aid in visually representing the correlation network, the following colours are defined:
• A positive correlation is represented by a green line
• A negative correlation is represented by a red line
• In the event that two vertices derived from genes share at least one positively-correlating pair of CpGs
and one negatively-correlating pair of CpGs, the line between these genes is a shade of grey or black
1arXiv preprint
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‘Green’ and ‘Red’ are not strictly defined but the differences should be apparent in all graphs shown in
this thesis. Other graph elements remain undefined and are displayed based on how they can best convey
information.
Graph statistics, such as numbers of nodes and edges, can be extracted from graphs using networkx func-
tions such as the number_of_nodes method of the Graph class. Complex operations may be available in the
networkx library but are implemented manually where required.
2.3 Automated acquisition of gene and pathway information
Biological pathways arise from the interplay between different genes; as such, we have a very large and com-
plex set of genes and pathways to work with. Estimates of the number of protein-coding genes within the
human genome have varied greatly over the years, with recent estimates placing the number of protein-coding
genes at about 21,000, non-coding genes at about 22,000, and total number of transcripts to be on the order
of 323,000 (Pertea et al. 2018). Manually going through all of these genes would be quite an endeavour, so
an automated approach is employed.
Several relevant online databases have been identified as having potential use in an automated search context:
• GENCODE (Harrow et al. 2012) - gene features in the human genome
• UCSC genome browser database (Karolchik et al. 2003) - annotated genome sequence information
• Reactome (Fabregat et al. 2018) - biological process information as a network of molecular transfor-
mations
Our knowledge of human metabolism is far from complete, and online databases will reflect not only these
gaps in our knowledge, but also any known genes and pathways that haven’t been added to them (intention-
ally or otherwise). This is something we must keep in mind when discussing results from studies that make
use of automatically-searched data.
2.3.1 Selection of chromosomes based on HPC limitations
As discussed in section 2.1.5, correlation matrices require substantial computational processing power to
generate. Much of the work in this thesis is undertaken on a virtual machine residing in the University
of Canterbury’s Research Compute Cluster. System specifications for this virtual machine are detailed as
System 2 in Appendix A. As HPC resource is not infinite, we have a limited amount of computational ability
for our studies.
Generally, use of the uncorrelated beta matrices will not present an issue as the largest one (comprising
all chromosomes) is a mere 1.8GB for our preferred test cohort (CHDS, described in Appendix B). This
matrix consists of roughly 860,000 beta values for 120 individuals and can easily be manipulated and anal-
ysed with the 128GB of available RAM on our virtual machine. Section 2.1.5 described how this would
result in a correlation matrix about 6TB in size - generating this would not be feasible on our current re-
source. We may run into problems working with larger chromosomes when correlation matrices are involved,
especially if we are performing operations with memory requirements which scale with the size of the dataset.
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Where the analysis of more than one chromosome is required (e.g. the studies in parts II and III), the
best approach is to start with those that generate the smallest correlation matrices and work our way
upwards in size from there. In the context of DNA methylation microarrays, correlation matrix size is
quadratically-proportional to the number of CpG sites probed at each chromosome. The number of probes
for each chromosome, arranged in order of ascending size, is shown in table 2.1.
The computational requirements for a specific task will vary; a simple search of a correlation matrix will not
require much more than what was needed to generate it, but operations involving sorting or large-scale sta-
tistical analysis may be significantly (orders of magnitude) more computationally- and/or memory-intensive.
As such, there is no strict rule around how many chromosomes should be used for a study, other than the
general ‘as long as it fits on the HPC, it’ll be fine’.































A preliminary assessment of
correlations in DNA methylation
3.1 Premise
In this chapter, we use published DNA methylation data to develop a computational pipeline through which
we are able to statistically analyse methylation intensities (in the form of beta values) at different CpG sites,
and correlations between them, using available data for chromosome 21. Specifically, we investigate:
• The statistical distribution of beta values for CpG sites on chromosome 21
• The statistical distribution of beta matrix correlations on chromosome 21
• Analysis of the strongest beta matrix correlations on chromosome 21
• Potential interaction networks that we can infer from beta matrix correlations on chromosome 21
In order to develop the tools, it is necessary to make some assumptions. For example, we assume that
findings from a study of chromosome 21 will also be relevant to other chromosomes and that the choice of
test cohort does not introduce significant sources of error, such as selection bias. This broad approach does
not test any particular hypotheses but rather focuses on development of methods suitable for further studies.
We therefore acknowledge these limitations and take them into consideration when deriving insights from
this preliminary study.
The CHDS cohort (see appendix A) is very well-documented and has been used in other epigenetic studies
(e.g. Osborne et al. 2020), so serves as a suitable test cohort for the purposes of method development and
proof-of-concept.
3.2 Study: Beta values for Chromosome 21
Prior to studying correlations, an initial investigation into the statistical distribution of beta values for CpG
sites on chromosome 21 was undertaken. This chromosome was selected as it was the autosomal chromosome
with the fewest number of CpG probes in the EPIC array (10300) - this would be beneficial for a future
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correlation study (conducted in section 3.3), as would understanding the distribution of beta values so we
can make informed choices on how to approach and interpret the resulting correlation matrix.
Two sets of beta values are looked at - those produced via the NOOB method of normalisation, and those
produced without prior normalisation (‘raw’). NOOB was selected on the basis that it has been shown to
perform better than other normalisation methods in some circumstances (Noble, 2021). Raw betas were
selected for comparison.
3.2.1 Methods
Beta values were computed using the protocol described in section 2.2. Statistical analyses used the Python
pandas library.
This study used System 1 and Python configuration 1 as described in Appendix A.
3.2.2 Results and Discussion
3.2.2.1 Statistical distribution of means
Figure 3.1: Histogram of mean beta values - CHDS
cohort, Chromosome 21, no normalisation (raw)
Figure 3.2: Histogram of mean beta values -
CHDS cohort, Chromosome 21, NOOB normalisa-
tion. Please note that the scale of the y-axis is dif-
ferent between figures 3.1 and 3.2.
Figures 3.1 and 3.2 show that both NOOB-normalised and unnormalised raw beta values from samples
within this cohort tend to be highly-biased towards the extremes of 0.0 and 1.0. The NOOB-normalised
betas seem to follow a J-shaped distribution with a prominent peak at the high-beta end, compared with the
U-shaped distribution in the unnormalised betas which has a much broader and flatter high-beta peak. The
region between the two peaks on both histograms is significantly less-populated, suggesting that samples
tend to be more generally strongly methylated or unmethylated rather than expressing an intermediate level
of methylation at a particular locus. This makes sense biologically as genes would ideally be ‘switched off’ in
places where they are not needed and one mechanism by which this can be accomplished is by methylating
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specific parts of that gene (for reasons discussed in section 1.1). Genes that produce more-commonly required
products would tend to be unmethylated for the same reason. The central ‘flat part’ may represent loci that
are weakly switched on or off depending on the dominant process within their respective tissue type; whole
blood methylation can be indicative of non-cell-mediated processes in other tissues, as described in section
2.1.3.
The overlaps within the two peak regions of each normalisation method were also calculated to observe
how selection of method impacts the beta values in these regions. Rather than defining thresholds, the CpG
sites corresponding to the lowest 2000 and highest 6000 beta values were compared for each normalisation
type. These numbers were chosen based on visual inspection of Figures 3.1 and 3.2, and represent about
20% and 60% of all probed betas for chromosome 21:
• Low beta overlap: 1954/2000 (97.7%)
• High beta overlap: 5871/6000 (97.9%)
The high beta and low beta overlaps are both very high, with only ∼2-3% difference between the raw and
NOOB-normalised beta values. This is good, as it means that normalisation type doesn’t greatly alter which
CpG sites have the highest and lower beta values. It doesn’t tell us if correlations will be consistent, however;
we investigate this in a later study.
3.2.2.2 Statistical distribution of standard deviations
Figure 3.3: Histogram of standard deviations of beta
values - CHDS cohort, Chromosome 21, no normal-
isation (raw)
Figure 3.4: Histogram of standard deviations of beta
values - CHDS cohort, Chromosome 21, NOOB nor-
malisation
Figures 3.3 and 3.4 give an indication of how much the beta values can vary at each CpG site. We see
that the raw betas have a notable cluster of sites with a comparatively-low standard deviation, preceding
a large peak that can also be found in the NOOB-normalised distribution (albeit shifted slightly). Figure
3.4 suggests that NOOB normalisation decreases the standard deviation (and therefore variance) of some
number of CpG sites, based on the peak in Figure 3.4 being shifted to the left. This gives us slightly more
certainty over the accuracy of our measure of methylation intensity at these CpG sites as the true value
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(or population mean) is more likely to sit within a narrower range of values - in statistical terms, a lower
standard deviation equates to a narrower confidence interval in all practical cases, and we can interpret this
as a general increase in certainty of our derived beta value.
3.3 Study: Correlations on Chromosome 21
An initial investigation into the statistical distribution of correlations on chromosome 21 was undertaken
to identify factors that may be relevant to correlation analyses, such as selection of thresholds for strong
correlations.
The same beta values produced for the study in section 3.2 are used for this study, for the same reasons.
3.3.1 Methods
Beta values and correlation matrices were computed using the protocol described in section 2.2. We assess
the distribution of correlation coefficients with a histogram. The statistical analyses in this section use a
dataset comprised of the average for each correlating pair, and were conducted using the Python pandas,
scikit-learn and numpy libraries.
This study used System 1 and Python configuration 1.
3.3.2 Results and Discussion
3.3.2.1 Statistical analysis of correlations
Histograms (Figures 3.5 and 3.6) showing correlation frequency was produced for both beta correlation ma-
trices. Some statistical metrics are presented in Table 3.1.
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Figure 3.5: Histogram of beta correlation (Spear-
man) coefficients - CHDS cohort, Chromosome 21,
no normalisation (raw)
Figure 3.6: Histogram of beta correlation (Spear-
man) coefficients - CHDS cohort, Chromosome 21,
NOOB normalisation. Please note that the scale is




ratio of positive to negative correlations 6.69 1.77
standard deviation 0.183 0.154
skew -0.103 0.344
excess kurtosis -0.195 2.061
Table 3.1: Statistical analysis of all beta matrix correlations calculated for Chromosome 21 (CHDS cohort;
n = 120), for raw (no normalisation) and NOOB normalisation.
While both appear to follow a symmetrical (though offset) distribution, the differences in distribution of
correlation coefficients are very apparent in Figures 3.5 and 3.6. Both distributions have a mean and median
value greater than zero, and the ratio of positive to negative correlations in both cases is greater than one -
this suggests that CpG sites are more likely to correlate positively than negatively as there are more (and
stronger) positive correlations than negative ones. We can see that this is much more the case for the unnor-
malised (raw) data in spite of the negative skew value. This is most likely due to background fluorescence
which has not been accounted for - as the sensor is based on fluorescent signals, background fluorescence
would likely be causing the methylation signal to be stronger than it should be, shifting the distribution
of methylation intensities at each CpG site to the extremes and thus producing stronger correlations for
beta values, as they are constrained to a maximum magnitude of 1.0. An alternative explanation could be
technical bias, such as effects due to CpGs being on the edge of the chip, or batch effects that may only
affect certain CpGs.
The increased excess kurtosis of the NOOB histogram suggests it may be easier to identify strong cor-
relations in NOOB-normalised betas than in those without normalisation as the broader tails provide a
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raw NOOB
Number of strong positive correlations 98644 66137
Number of strong negative correlations 661 16284
Total number of strong correlations 99305 82421
Table 3.2: Number of strong positive and negative correlations derived from beta correlation matrices, per
norm type
greater range from which we can select a cut-off for these strong correlations. Arbitrarily defining a strong
correlation as one of magnitude 0.7 or greater (as in section 1.3.4) is an approach that we could take (e.g.
if we visually selected one based on Figure 3.6), but we may be better off taking an approach based on the
distributions themselves. For example, we could take a subset of the correlations closest to 1.0 and -1.0.
This is explored in section 3.3.2.2.
3.3.2.2 Strongest correlations
Table 3.2 shows the number of strong (magnitude ≥ 0.7) positive and negative correlations taken from
the beta correlation matrices calculated from the unnormalised (raw) betas and normalised (NOOB) betas.
About 0.09% of all correlations were classified as strong. We saw in section 3.3.2.1 that the unnormalised
beta values were biased towards producing positive correlations, and by counting the number of strong cor-
relations, we can see that it is rare for values within the unnormalised beta correlation matrix to be less than
or equal to -0.7. Though not nearly as severe, a similar effect can be seen for the NOOB-normalised data,
with about 80% of the strong correlations being positive. This is something that will need to be considered
when selecting thresholds for later correlation studies.
Table 3.3 shows the number of overlapping strong (magnitude ≥ 0.7) positive and negative correlations
taken from the beta correlation matrices calculated from the unnormalised (raw) betas and normalised
(NOOB) betas.
raw NOOB
Overlapping positive correlations 41493/98644 (42.1%) 41493/66137 (62.7%)
Overlapping negative correlations 658/661 (99.5%) 658/16284 (4.04%)
Table 3.3: Overlap of strong positive and negative correlations derived from beta correlation matrices, per
norm type (magnitude threshold for strong correlation = 0.7)
Overlap of positive correlations is inconsistent, as is the overlap in negative correlations. The percentage of
overlapping negative correlations is being skewed significantly due to the difference in number of negative
correlations of each method (661 versus 16284) as there simply are not enough strong negative correlations
within the raw betas to make for a viable comparison. As an alternative, we can consider some number
of strong positive and negative correlations rather than setting an arbitrary threshold, as this will ensure
that the numbers of strong positive and negative correlations are consistent between different normalisation
types. This approach is described in section 2.2.5.2. Table 3.4 shows the results if we look at the strongest
1% of positive and negative correlations, for a total of 1060900 of each.
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raw NOOB
Positive overlap 303824 (28.6%)
Negative overlap 341113 (32.2%)
Positive range [0.56937, 0.98472] [0.42089, 0.98858]
Negative range [-0.15896, -0.882033] [-0.24806, -0.919633]
Table 3.4: Overlap of strong positive and negative correlations derived from beta correlation matrices, per
norm type (1% strongest positive and negative correlations)
We can see a ∼ 30% overlap in 1% of the data, but taking the top 1% lowers the equivalent threshold of a
strong negative correlation to -0.15896 for the raw beta values. This has a much lower magnitude than the
threshold for a strong correlation defined as 0.7 in section 2.2.5. Further research is required to work out if
we can find biologically-relevant correlations with such a low effective threshold.
3.3.2.3 Network analysis of strong correlations
To determine the value of correlation analyses in identifying biologically relevant correlations between CpG
sites, a network analysis was conducted using correlations with an absolute strength of 0.7 or greater.
Methods for conducting this analysis are described in section 2.2.6. For this analysis, each CpG site was
represented as a node on a graph, with edges representing a strong correlation (coloured red for negative,
and green for positive correlation). The overall graph for both methods is hard to resolve in a way that
works in a written format, so CpG labels were removed for the purposes of visualisation in this subsection.
These can be seen in Figures 3.7 and 3.8. Notably, these graphs consist of a primary core network and a
large number of very small ’satellite’ networks.
Figure 3.7: Unlabelled graph of strong beta correla-
tions on chromosome 21 (unnormalised betas)
Figure 3.8: Unlabelled graph of strong beta correla-
tions on chromosome 21 (NOOB-normalised betas)
As per section 2.2.3, we can convert the CpG vertices to their annotated gene. Using methods discussed
in section 2.2.6 we can focus on a specific gene and only look at other genes connected (via correlation)
within a certain number of edges, i.e. sub-networks centered on a gene of interest and looking at a defined
’neighbourhood’ of correlating genes and CpG sites. As an example, Figure 3.9 shows a subnetwork of the
NOOB-normalised network, focused on the KRTAP6-1 gene and its immediate neighbours. This gene was
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first characterised by Rogers et al. in 2002 and is one of a number of keratin-associated proteins found on
chromosome 21.
Figure 3.9: Subnetwork of keratin-associated protein 6-1 (KRTAP6-1) and its immediate highly-correlating
neighbours, taken from the network derived from highly-correlating pairs within the NOOB-normalised beta
correlation matrix.
From Figure 3.9 we can see that several keratin-associated proteins have CpG sites which tend to correlate
positively in methylation intensity; based on this, the methylation intensity of KRTAP6-1 would appear to
correlate with both KRTAP10-11 and KRTAP24-1. Additionally, the negative correlation between methy-
lation intensity of BTG3 and both KRTAP10-11 and KRTAP6-1 is link which is not particularly intuitive,
given that BTG3 (B-cell translocation gene 3) is known more for its alleged anti-proliferative properties
(Winkler, 2010) rather than its action with keratin-associated proteins. The relationship between BTG3
and keratin-associated proteins has not yet been studied. However, data in this study suggests that our
understanding of these genes may benefit from further research.
3.4 Concluding remarks
This preliminary assessment has investigated the potential methods and implications for DNA methylation
intensity correlation analysis. The approaches described in section 2.2 have indicated that this methodology
is able to detect correlations among CpG sites that may be useful for identifying biologically-relevant corre-
lations between sites, and will serve as a basis for other studies discussed in this thesis.
Using the NOOB method of normalisation produce results that were more-easily delineated than those
produced using unnormalised data when it came to assessing correlations, though a more robust comparison
is required - chapter 4 investigates this further. Further research into how to determine strong correlations
is also required as arbitrary setting a threshold resulted in a very imbalanced spread of negative and positive
values. An alternative to this is taking some percentage of the strongest and weakest correlations. We
investigated this initially in section 3.3.2.2 and take this investigation further in chapter 5.
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We have shown that we can build networks from CpG sites that correlate in methylation intensity. Network
analysis yielded graphs that suggested there may be some large and complex networks between correlating
CpG sites, but this is something that requires significantly more research effort to investigate - chapter 7
goes into correlation network analysis in more depth. Our work is not done, however. To fully take ad-
vantage of the research potential of these networks, we will need to undertake further studies to aid in our
selection of methods used for array normalisation and calculation of strong correlations. These in particular
are investigated in chapters 4 and 5.
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Chapter 4
An assessment of array normalisation
method choice
4.1 Selected array normalisation methods
The general ideas behind DNA methylation microarrays and array normalisation were discussed in section
2.1.2. Further to that, this study has investigated five methods of array normalisation, as well as a sixth
approach which used raw data, referred to in this thesis as ‘raw normalisation’, ‘unnormalised’, etc. as
appropriate. A detailed description and explanation of each of the individual methods is beyond the scope of
this thesis, however each of the five normalisation types is briefly described in the following subsections. The
sixth ‘raw’ normalisation method simply uses data as presented by the array and does not require further
explanation.
4.1.1 Normal-exponential using out-of-band probes (NOOB)
This method was described by Triche et al. (2013) as an extension of an earlier approach to correcting for
background fluorescence (Ritchie et al. 2007). The general idea is that the background effects are estimated
using a set of control probes, taken from a set of known negative controls and out-of-band type I probes.
A probabilistic approach is taken to determine the expected (exponentially-transformed) signal parameter,
given an observed foreground intensity. An enhancement to NOOB was described that removed the need
for a reference sample (Fortin et al. 2017) - this is referred to as ssNOOB and was incorporated into minfi’s
implementation of NOOB.
4.1.2 Stratified quantile normalisation (Quant)
Stratified quantile normalisation was initially proposed by Touleimat and Tost (2012) to overcome the issues
presented by the two different probe chemistries present on the HumanMethylation450 microarray. Quantile
normalisation is a statistical technique which has been used in genomics studies for some time (Amaratunga
and Cabrera, 2001) which, in short, alters statistical distributions so that they have the same statistical
properties. The premise of this method involves using the signals from type I probes as ‘anchors’ to normalise
type II probes, producing results that were considered significantly better than those generated using other
normalisation methods in use at the time (Touleimat and Tost, 2012).
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4.1.3 Functional normalisation (FunNorm)
Functional normalisation was proposed as an extension to Stratified Quantile normalisation. Where quantile
normalisation forces the empirical marginal distributions of the samples to be same, removing all variation
in the statistic, functional normalisation makes use of reference covariates (recommended as the first m=2
principal components of the control summary matrix by the method’s author) when removing variation, thus
reducing some of the technical effects present in quantile normalisation (Fortin et al. 2014).
4.1.4 Subset-quantile within array normalisation (SWAN)
The SWAN method was described by Maksimovic et al. (2012). Similar to the Quant method, it is a
between-array normalisation technique, though it uses a random subset of probes to do the between-array
normalisation. Maksimovic suggests that SWAN provides an advantage for modern Illumina arrays, as the
technique accounts for differences between type I and type II probes on a single array, allowing them to be
normalised together with fewer consequences that other methods.
4.1.5 Illumina’s method
The minfi library has a reverse-engineered implementation of the normalisation method used in their Genome
Studio tool. The original algorithm is described in the GenomeStudio Methylation Module v1.8 User Guide
(Illumina Inc. 2010). This method requires a reference array to be selected manually. The documentation
in minfi doesn’t specify what to do in the absence of a defined reference. In the context of this thesis, this
method will be used for comparative purposes but won’t be considered for any serious biological study owing
to its lack of documentation.
4.2 Research trends
It would be difficult to directly assess the relative popularity of the normalisation methods investigated in
this study, so we’ve opted for a näıve comparison of citations for each method’s original publication, based on
PubMed and Google Scholar. The source for Illumina’s method is not available on either of these platforms
so is not considered here. This data was taken on 16 December 2020.






Table 4.2.0: Comparison of PubMed and Google Scholar citations for papers first describing selected
normalisation methods
As we can see, Maksimovic’s paper for SWAN is the most cited of these, even if we combine the number of
citations for NOOB and ssNOOB. We interpret this as SWAN being the most popular method, though this
doesn’t necessarily imply that it is the best method.
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4.3 Computational considerations
To compare the time taken for each of the five methods (and raw preprocessing), they were subjected to
computational profiling. For testing, the six methods of preprocessing (five different normalisation methods
and the sixth method of ’no normalisation’) described in section 4.1 were conducted sequentially, each using
unprocessed array data from the CHDS cohort (see appendix B), and the computational time for each
method was profiled. This was run twice, with the second time running the methods in a different order,
to ensure there were no ‘under the hood’ effects due to order. This analysis was conducted using System 1
using R Configuration 1, both described in appendix A, and all functions used default arguments except for
the input RGChannelSet which was derived from the raw IDAT data.
Method Runtime 1 (s) Runtime 2 (s) Average Runtime (s)
preprocessRaw 3.24 2.37 2.81
preprocessNoob 99.03 100.30 99.67
preprocessSWAN 74.40 75.67 75.04
preprocessFunnorm 210.51 212.01 211.26
preprocessQuantile 69.05 68.62 68.84
preprocessIllumina 14.24 13.74 13.99
Table 4.3.0: Computational profiling of selected normalisation methods: time taken (in seconds) to
generate normalised data for Chromosome 21.
Ignoring the trivial case of no preprocessing (preprocessRaw), the fastest results are achieved with the
Illumina-based algorithm. Conversely, functional normalisation has the highest runtime by a significant
margin, at over twice the runtime for the next-slowest method and about 15x that of the Illumina method.
The most popular method as determined in section 4.2 (SWAN) is somewhere in the middle.
Preprocessing is something that only has to be performed once per cohort and the time taken for the
procedure scales linearly with the number of probes in a chromosome, and individuals in the cohort. As
such, computational time is less important for normalisation in comparison with other processing activities
(such as calculating correlation matrices, which scales quadratically with the number of probes). This study
has profiled the time taken to perform the normalisation procedure on the entire chromosome for a cohort
of 120 individuals. Unless we are dealing with cohorts with several orders of magnitude more participants,
or significantly more cohorts overall, the linear computational complexity and relative similarity of runtime
(within one order of magnitude) between methods means that selection of normalisation type should not be
particularly concerned with how long each method takes to run, and instead be primarily focused on results.
4.4 Study: Statistical differences in beta values due to selection
of normalisation type
4.4.1 Rationale
Before investigating the differences between beta correlation matrices caused by normalisation type selection,
we undertook an investigation of the effects it has on the beta values themselves. This study observes the
effects of normalisation type on the statistical properties of beta values.
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4.4.2 Methods
Beta matrices for each chromosome and normalisation method, as well as one containing CpG sites on all
autosomal chromosomes, were computed for each normalisation method using the relevant steps of section
2.2. For all matrices, the mean and standard deviation for beta values at each CpG site were calculated
using the pandas and numpy Python modules. The average mean and average standard deviation was then
calculated for each matrix. A pair of ‘offset’ parameters (explained in section 2.2.4) were calculated as a
difference between the calculated averages and:
• Autosome-wide averages for each normalisation method, so that relative differences between chromo-
somes can be assessed
• Chromosomal averages for each normalisation method, so that relative differences between normalisa-
tion methods can be assessed
The procedure was run using System 1 running Python configuration 1 as defined in Appendix A.
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4.4.3 Results
Figure 4.1: Differences between chromosome-average mean and all-autosome-average mean, and
chromosome-average standard deviation and all-autosome-average standard deviation, for CpG methylation
intensity (beta) values in each autosome. Source data: CHDS dataset
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Figure 4.2: Differences between chromosome-average mean for a given normalisation type and chromosome-
average mean of all normalisation types, and chromosome-average standard deviation for the given normal-
isation type and chromosome-average standard deviation of all normalisation types, for CpG methylation
intensity (beta) values in each autosome. The average for each normalisation type is also included (marked
with +); this average is unweighted so smaller chromosomes have a proportionally-greater effect. Source
data: CHDS dataset
48
Figure 4.3: Differences between chromosome-average mean and all-autosome-average mean, and
chromosome-average standard deviation and all-autosome-average standard deviation, for CpG methylation
intensity (beta) values in each autosome. Source data: MTAB-7069 dataset
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Figure 4.4: Differences between chromosome-average mean for a given normalisation type and chromosome-
average mean of all normalisation types, and chromosome-average standard deviation for the given normal-
isation type and chromosome-average standard deviation of all normalisation types, for CpG methylation
intensity (beta) values in each autosome. The average for each normalisation type is also included (marked
with +); this average is unweighted so smaller chromosomes have a proportionally-greater effect. Source
data: MTAB-7069 dataset
We can see that both cohorts present notable chromosome-based clustering for the plots of average standard
deviation offset versus overall mean offset per normalisation type (figures 4.1 and 4.3). This particularly
evident from chromosomes 6, 16, 17 and 19. General visual trends, such as a ’arrow’-shape are present (more
visible in figure 4.3), and relative positions of the centres of these clusters are positioned similarly.
The same offsets per chromosome also show a distinct pattern of clustering (4.2 and 4.4), though the cluster
placement does not appear to be as consistent.
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4.4.3.1 Allosomes for comparison
Figure 4.5: Differences between chromosome-average mean and all-autosome-average mean, and
chromosome-average standard deviation and all-autosome-average standard deviation, for CpG methyla-
tion intensity (beta) values in each chromosome, including sex chromosomes (which are not included in the
all-autosome averages). Source data: CHDS dataset
The sex chromosomes were excluded from the analysis in section 4.4.3 as most individuals will either have a
Y chromosome or experience X-inactivation, and this complicates epigenetic studies. We plot the offsets of
the X and Y chromosome for the CHDS dataset in figure 4.5. We can see that chromosomes X and Y have
significantly higher average standard deviation for all normalisation methods.
4.5 Study: Statistical differences in beta correlation matrices due
to selection of normalisation type
4.5.1 Rationale
Beta values themselves can vary significantly in statistical properties due to selection of array normalisation
method, as shown in section 4.4 and discussed in section 4.6. To investigate whether underlying epigenetic
trends may still be extractable from the data, we can compare their correlation matrices. It is hypothesised
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that those trends will still be present (at least partially) and that this will manifest as an overlap in ‘strong’
correlations between beta correlation matrices produced with different normalisation methods.
4.5.2 Methods
Beta correlation matrices for all six normalisation types (including raw) were calculated for the CHDS dataset
using methods described in section 2.2. Statistical analysis of these correlation matrices was conducted using
the pandas and numpy Python libraries where possible. It was only possible to analyse correlation matrices
up to a certain size, owing to technical limitations of the HPC resource used for the study (discussed in
section 2.3.1). Nonetheless, we were able to use available HPC resources to analyse a subset of chromosome
beta correlation matrices and compare their mean and standard deviation. This procedure was repeated
with the MTAB-7069 dataset (described in appendix B) to confirm that normalisation methods have similar
effects on beta correlation matrices for other cohorts (the caveats regarding use of this cohort are described
in section 4.6). Chromosomes available for this study include: 4, 8, 9, 13, 14, 15, 16, 18, 20, 21, 22, X and
Y. This subset of chromosomes provides coverage of half of the autosomes in the human genome, as well
as both allosomes. It should be noted that this subset does not provide coverage of half of all probed CpG
sites, but as we are focused on chromosomes specifically, this is accepted as a limitation for this study.
Similar to methods described in section 4.4.2, we calculate an overall mean and variance for each corre-
lation matrix (of which there is one for every combination of chromosome and normalisation type). To
compare normalisation types, offset parameters for mean and variance are calculated as the difference be-
tween the actual values for a correlation matrix and the average of values across all normalisation types for a
given chromosome. From this, we can identify the relative ‘shift’ in mean and variance occurring as a result
of normalisation method choice.
Additionally, the beta correlation matrices (abbreviated as BCMs) for several chromosomes are analysed
in depth. Chromosomes for these matrices include 21, 22, X and Y. The following metrics were ascertained
for each matrix:
• Overall average, variance, skew and excess kurtosis
• Average positive correlation
• Average negative correlation
• Ratio of positive to negative correlations
We also determined the strongest 10% positive and negative correlations for each beta correlation matrix.
From this, we identified which pairs are considered strong (per chromosome) across all six methods, and
which pairs are considered strong in only one method. This information is used later to compare the
different methods of normalisation.
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4.5.3 Results
4.5.3.1 Beta correlation matrix offsets in mean and variance
Figure 4.6: Differences between beta correlation matrix (BCM) mean and average of BCM means for all
norm types, and BCM variance and average of BCM variances for all norm types, for selected chromosomes.
Source data: CHDS dataset
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Figure 4.7: Differences between beta correlation matrix (BCM) mean and average of BCM means for all
norm types, and BCM variance and average of BCM variances for all norm types, for selected chromosomes.
Source data: MTAB7069 dataset
Strikingly, both separate datasets produce a similar clustering based on normalisation-type, as shown in
figures 4.6 and 4.7. In both cases, quantile normalisation tends to have the lowest offset in average mean,
followed by NOOB, functional normalisation and Illumina normalisation (in the same cluster), then SWAN,
then the unnormalised set. In terms of variance, there is significantly more overlap in the range of values for
each normalisation type.
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4.5.3.2 Statistical analyses of beta correlation matrices for chromosome 21
raw noob swan quant funnorm illumina
Overall average 0.214 0.0531 0.0739 0.00194 0.0526 0.0482
Overall variance 0.0336 0.0237 0.0193 0.0164 0.0252 0.0199
Overall skew -0.103 0.344 0.157 0.158 0.427 0.121
Overall excess kurtosis -0.195 2.06 1.73 2.66 1.88 1.89
Average positive correlation 0.249 0.134 0.136 0.0986 0.137 0.124
Average negative correlation -0.0833 -0.0919 -0.0789 -0.0951 -0.0937 -0.0897
Ratio of positive to negative correlations 6.69 1.77 2.48 1.01 1.71 1.79
Table 4.1: Statistical comparison of beta correlation matrices of Chromosome 21 for different normalisation
methods (CHDS cohort)
Overall averages and variances are highest for the BCM produced from unnormalised data, and lowest for
that produced from data normalised using Quantile normalisation. A negative skew for the raw data BCM
suggests the centre of mass is shifted to the right, while positive skews for all other normalisation types
suggests the opposite. Similarly, the raw data BCM is platykurtic (negative excess kurtosis), implying a
broader distribution with thinner tails; the other normalisation types are all leptokurtic (positive excess
kurtosis) which suggests fatter tails and a denser centre. In all cases, the average positive correlation has a
greater magnitude than the average negative correlation. There also tend to be more positive correlations
than negative correlations; all normalisation types have a positive ratio of positive to negative correlations,
though the quantile-normalised BCM is very close to one. The quantile-normalised BCM also has the lowest
average variance within each CpG site.
4.5.3.3 Statistical analyses of beta correlation matrices for chromosome 22
raw noob swan quant funnorm illumina
Overall average 0.243 0.0508 0.0839 0.00438 0.0481 0.0513
Overall variance 0.0381 0.0212 0.0202 0.0179 0.0218 0.0208
Overall skew -0.172 0.267 0.202 0.165 0.268 0.205
Overall excess kurtosis -0.407 2.24 1.57 2.3 1.87 1.67
Average positive correlation 0.277 0.127 0.143 0.104 0.128 0.128
Average negative correlation -0.0836 -0.0891 -0.0778 -0.0982 -0.0916 -0.0898
Ratio of positive to negative correlations 7.37 1.81 2.75 1.04 1.73 1.8
Table 4.2: Statistical comparison of beta correlation matrices of Chromosome 22 for different normalisation
methods (CHDS cohort)
The relative statistical properties of beta correlation matrices for chromosome 22 are very similar so the
commentary in section 4.5.3.2 is applicable here as well. In short:
• Overall average and variance is highest for the BCM of the unnormalised data
55
• Skew and kurtosis are both negative for the unnormalised BCM, and positive for all other normalisation
types
• The magnitude of average positive correlation is greater than that of the average negative correlation
in all cases
• The ratio of positive to negative correlations is greater than one in all cases, but only marginally-so
for Quantile-normalised data
4.5.3.4 Statistical analyses of beta correlation matrices for chromosome X
raw noob swan quant funnorm illumina
Overall average 0.0972 0.0362 0.0452 0.000295 0.0476 0.0155
Overall variance 0.152 0.176 0.157 0.157 0.177 0.167
Overall skew -0.0326 -0.0762 0.0226 0.000889 -0.104 -0.0257
Overall excess kurtosis -1.22 -1.41 -1.23 -1.39 -1.41 -1.36
Average positive correlation 0.395 0.391 0.369 0.35 0.394 0.367
Average negative correlation -0.276 -0.355 -0.312 -0.35 -0.354 -0.351
Ratio of positive to negative correlations 1.4 1.15 1.16 1.0 1.19 1.07
Table 4.3: Statistical comparison of beta correlation matrices of Chromosome X for different normalisation
methods (CHDS cohort)
The beta correlation matrices for chromosome X have different statistical tendencies than those for the
autosomal chromosomes we tested. While the trend of the raw BCMs having a higher overall average is
maintained, we see significant differences in most other metrics. Overall variance does not differ much
between normalisation types, and we can see that in all cases, the variance is in the next order of magnitude
compared with the autosomal chromosomes. Skew is no longer negative for only the raw BCMs, and excess
kurtosis is negative for all normalisation types. As in the autosomes, the ratio of positive to negative
correlations tends to be above 1.0 (except for Quantile normalisation which is very close to one) and the
magnitude of average positive correlations tends to be higher than that of the average negative correlation
(again, with the exception of Quantile normalisation).
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4.5.3.5 Statistical analyses of beta correlation matrices for chromosome Y
raw noob swan quant funnorm illumina
Overall average 0.14 0.103 0.0993 0.0564 0.102 0.0604
Overall variance 0.195 0.231 0.194 0.196 0.214 0.12
Overall skew -0.261 -0.226 -0.224 -0.189 -0.354 -0.172
Overall excess kurtosis -1.46 -1.54 -1.52 -1.59 -1.54 -1.19
Average positive correlation 0.462 0.464 0.439 0.414 0.443 0.316
Average negative correlation -0.337 -0.4 -0.363 -0.397 -0.418 -0.286
Ratio of positive to negative correlations 1.54 1.34 1.38 1.25 1.47 1.35
Table 4.4: Statistical comparison of beta correlation matrices of Chromosome Y for different normalisation
methods (CHDS cohort)
As with chromosome X, BCMs for chromosome Y generally show different statistical than those for the
autosomes that we tested. Overall average is once again higher for the unnormalised BCMs than for any of
those using normalised data, but variance does not show the same behaviour. As with chromosome X, our
measure of kurtosis is consistently negative, though only in the case of chromosome Y is skew consistently
negative for all normalisation methods. Like what we’ve mostly seen for the other chromosomes, the average
positive correlation has a higher magnitude than the average negative correlation, and the ratios of positive
to negative correlations are higher, for all normalisation methods.
4.5.4 Overlapping strong correlations
Chromosome 21 22 X Y
Observed positive correlations 5,304,006 16,866,512 18,220,536 14,393
Consistently-correlating pairs 1,222,948 4,233,544 6,821,248 2,190
Unique positive correlations - raw 1,821,513 5,181,375 1,608,290 2,457
Unique positive correlations - NOOB 212,119 786,984 1,053,037 3,054
Unique positive correlations - SWAN 967,257 3,803,112 1,246,056 681
Unique positive correlations - quant 1,518,447 4,426,411 2,194,822 2,028
Unique positive correlations - FunNorm 435,388 848,841 2,246,787 2,741
Unique positive correlations - Illumina 531,024 1,086,739 783,833 3,142
Table 4.5: Overlapping positive correlations between selected normalisation methods, for chromosomes 21,
22, X and y (CHDS cohort)
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Chromosome 21 22 X Y
Observed negative correlations 5,304,006 16,866,512 18,220,536 14,393
Consistently-correlating pairs 814,694 2,274,764 6,098,384 8,975
Unique negative correlations - raw 1,712,001 6,023,526 1,840,373 816
Unique negative correlations - NOOB 262,143 825,236 591,885 930
Unique negative correlations - SWAN 659,721 2,434,576 644,893 355
Unique negative correlations - quant 1,794,978 5,932,545 2,722,840 2,524
Unique negative correlations - FunNorm 397,326 1,216,331 1,071,097 1,963
Unique negative correlations - Illumina 500,854 1,499,322 481,850 2,387
Table 4.6: Overlapping negative correlations between selected normalisation methods, for chromosomes 21,
22, X and y (CHDS cohort)
Tables 4.5 and 4.6 both show that there is a low degree (∼ 10−20%) of overlap in strong correlations between
all six methods. The raw and quantile methods produce the highest number of unique strong correlations for
the autosomes, within 50% of an order of magnitude of each other. The quantile method produces the highest
number of unique strong correlations for the allosomes, though functional normalisation also produces a lot
of unique strong correlations. Conversely, we see that NOOB produces the fewest unique strong correlations
for both autosomes. For allosomes, SWAN produces the fewest unique strong correlations in both cases.
4.6 Discussion
4.6.1 The effect of normalisation type on beta values for autosomes
Figure 4.1 shows some prominent chromosome-based clusters in this dataset. For example, chromosome 19
has a notably lower average mean and standard deviation for its associated beta values, which form their
own ‘island’ on the graph. Other notable islands exist for chromosomes 5, 6, 16 and 17, and results for
the six normalisation methods tend to be relatively co-located for most of the chromosomes. This suggests
that the choice of normalisation method doesn’t drastically alter the statistical distribution of beta values,
relative to other methods; the difference is driven largely by the chromosomes themselves.
Figure 4.2 shows statistical difference based on normalisation type. An intuitive way of thinking about
it would be considering one of the clusters in figure 4.1, and taking the difference between each point and
the mean of the cluster. The clusters in figure 4.2 are very well-distinguished and show a clear demarcation
between the different normalisation types. Of particular note is that the case of no normalisation (‘raw’ in
the figure) tends to produce data with a higher standard deviation than any of the other methods. This is
possibly due to other methods removing some of the ‘noise’ in the data, whether intentionally or not.
For comparison, the same procedure was run for the MTAB-7069 dataset (also in appendix B). The re-
sults can be seen in figures 4.3 and 4.4. It must be noted that the MTAB-7069 dataset is rarely-used in this
thesis owing to the small size of its cohort and the presence of confounding factors due to taking multiple
samples from the same individuals. The MTAB-7069 has 11 participants and takes three blood samples from
each (one from the umbilical cord at birth, one at 5 years and one at 10 years) for a total of 33 samples.
Influences from both genetic factors and age, discussed in section 1.1, are likely to be significant confounding
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factors in this dataset. Nonetheless, we felt it would be appropriate to test the performance of our six
normalisation methods on this dataset as well.
Figures 4.1 and 4.3 show a very similar trend in offsets per chromosome. Many of the clusters present
in the MTAB-7096 chromosome offsets have a similar position relative to each other as the clusters in the
CHDS chromosome offsets. This suggests that the overall mean DNA methylation and average standard
deviation of this at each CpG site tends to be chromosome-specific.
Figures 4.2 and 4.4 do not show any concordant relationship. Clusters are present in both but their relative
positions do not appear to follow a specific trend. A potential explanation for this is inconsistent selection
of reference probes by normalisation algorithms (for methods that use reference probes). Unfortunately, the
previously-observed high relative standard deviation offset of the non-normalised betas is not reproduced in
this dataset.
This study suggests that the statistical properties of beta values can vary greatly depending on which
normalisation type is selected, and the effects of a particular normalisation type are not necessarily consis-
tent between cohorts. This poses a problem for meta-analyses or new research that combines beta values
from past studies, and use these beta values directly - additional care must be taken to ensure normalisation
type is consistent between cohorts when combining pre-processed data, or researchers must obtain unpro-
cessed data from which they can generate beta values with consistent normalisation. Studies in this thesis
do not combine cohorts, so we do not face this problem; however, we discuss some theory regarding cohort
combination in section 8.5.9.
4.6.2 The effect of normalisation type on beta values for allosomes
CpG sites on the X and Y chromosomes have a significantly higher average standard deviation than any
of the autosomal chromosomes, as per their very high offsets of average standard deviation shown in figure
4.5. It is proposed that this is due to X-inactivation in the case of the X chromosome (described in section
1.2.3), as this process is associated with gains in methylation at a number of silenced genes (Sharp et al.
2011) so sites that would typically experience lower levels of methylation on the active X chromosome would
be significantly more-methylated on the inactive chromosome. For the Y chromosome, it is suggested that
this may be due to calculation of beta values of this chromosome for individuals who do not have one, as
the cohort consists of males and females (by gender) and the beta matrix for the Y chromosome does not
exclude samples from anyone. This is perhaps something that should be considered for later analyses; given
the difficulty of interpreting data derived from allosomes, then maybe they should be considered separately
or omitted from analyses where appropriate. The major factors that play into X- and Y- chromosome
regulation are biological sex, and if we intend to obtain results applicable to people regardless of this, then
we will need to devise methodologies specific to these chromosomes. We approach later studies in this thesis
with this fact in mind, opting to separate out allosomal data from autosomal data as required.
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4.6.3 The effect of normalisation type on beta correlation matrices
4.6.3.1 Statistical properties
Figures 4.6 and 4.7 show the effects of normalisation type on the mean and variance of the beta correlation
matrix, for CHDS and MTAB7069 cohorts respectively. Both figures show four primary clusters, positioned
similarly (relative to other clusters) for both cohorts. From left to right (or smaller to larger mean):
• The Quant (stratified quantile normalisation) cluster
• The NOOB-FunNorm-Illumina cluster
• The SWAN cluster
• The raw cluster
The raw cluster has the greatest positive offset in mean; tables 4.1 to 4.4 also show this as the overall av-
erage for the raw method is more positive that of all other methods for the four chromosomes analysed in
detail. It is proposed that this is due to the background fluorescence signal which remains unaccounted for
in this method. This increase in average correlation may make it harder to delineate strong correlations with
threshold-selection and may introduce noise which makes it more difficult to find them with proportional
selection.
The Quant cluster has the the greatest negative offset in mean. Tables 4.1 to 4.4 show that the overall
average for the Quant method is closer to zero than those of other methods for the four chromosomes anal-
ysed in detail. We also see that the ratio of positive to negative correlations is the closest to 1.0 in all of these
chromosomes. This suggests that the method produces a very balanced correlation matrix. Beta correlation
matrix variance was lowest for the Quant method for the autosomes, though this wasn’t the case for the
allosomes. We also see that the magnitude of excess kurtosis for the Quant beta correlation values tends
to be high for autosomal chromosomes, relative to the other normalisation types. This suggests that the
distribution is ‘squished’ inwards, making the tails of the distribution more prominent. This would make
it easier to select a threshold for strong correlations, as there is a broader ‘surface’ along which we can set
the threshold without dramatically increasing the number of correlations we need to consider. We could
therefore use the high relative kurtosis in beta correlation matrices produced by the Quant method to our
advantage. This is something we should keep in mind if we have issues with threshold selection.
The NOOB-FunNorm-Illumina cluster, in conjunction with tables 4.1 to 4.4, shows that these three meth-
ods had a similar overall mean. Indeed, the aforementioned tables also show that they are similar in other
statistical properties, particularly for the autosomes - in particular, their ratio of positive to negative corre-
lations was very similar in both cases (within 0.1) whereas the other methods produced ratios with a greater
difference than this. It is assumed that these three methods produced similar beta correlation matrix means
due to having a similar effect on the beta values themselves - figure 4.1 shows that these three methods had
a comparable mean offset clustering for the beta values prior to correlation.
It is difficult to suggest a normalisation method on the basis of the statistical properties of its correla-
tion matrix. In the absence of past studies suggesting the contrary, we assume that the NOOB, FunNorm
and Illumina methods are the best options when evaluating beta correlation matrices, as their most basic
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statistical properties are the most similar - we can take this as suggesting that other methods have ramifi-
cations which alter correlation matrices in a negative way. This is not necessarily the case, as it is just as
likely that these three methods are equally bad, rather than good, so further information must be considered
when selecting a normalisation method to use in future studies. To that end, we will need to make a decision
based on other information - in this case, overlapping strong correlations. The outcome of our discussion on
strong correlation overlaps (section 4.6.3.2) applies to correlation studies in general as we will typically be
interested in these strong correlations more than anything else.
4.6.3.2 Strong correlation overlaps
Tables 4.5 and 4.6 both show that there is a low degree (∼ 10 − 20%) of overlap between strong corre-
lations of all six methods. Though it may be small, this overlap could be indicative of genuinely strong
and biologically-meaningful relationships, as they’re present regardless of what we do to the data prior to
correlating. In future studies, we could consider using multiple methods when assessing the strength of cor-
relations to improve the robustness of results. An approach to this, which we refer to as metaN, is described
later in this discussion (section 4.6.4.1).
We see that the raw and Quant methods produce the highest number of unique strong correlations for
the autosomes. A high number of unique correlations could suggest one of two things:
1. the method is well-suited to finding biologically-meaningful correlations, and all other methods are not
2. the method is finding correlations that are occuring only due to the method, and this is not biologically-
meaningful
If the first of these is correct, then we would see one method with a high number of unique strong correlations,
and all of the others would have a low number. This is not the case, and as the second of the above can
apply to multiple methods, it is more likely to be what is happening in this instance; by this logic, the raw
and Quant methods are ill-suited to finding biologically-meaningful correlations for these chromosomes in
the CHDS dataset. We can expand upon the above logic to identify the best-performing method for strong
correlation identification under the conditions in this study. In the absence of any evidence to the contrary,
we have to initially assume that all methods are generally equivalent. If there is not a single ‘stand-out’
method with a high number of unique strong correlations, then we should instead consider the method with
the fewest unique strong correlations. This is because this method will produce the highest number of cor-
relations that are backed up by at least one other method.
For autosomes, we see that NOOB produces the fewest unique strong correlations in both cases. For allo-
somes, SWAN produces the fewest unique strong correlations in both cases. Based on this, we should consider
using both NOOB and SWAN in correlation studies where identification of strong correlations using a single
normalisation method is important, with NOOB being used preferentially for autosomes and SWAN being
used for allosomes.
4.6.4 Development of combination methods
Each of the methods described in section 4.1 have their advantages and disadvantages, and all have been
used individually in studies by other research. In the context of finding correlating CpG sites - if we’re not
61
too concerned about the relative strength of correlations, just whether or not we consider them to be above
some arbitrary threshold, then we can take the approach of using multiple sets of betas as calculated with
different normalisation methods (from the same source data). For example, if several different normalisation
methods all suggest that a specific pair of CpG sites tend to correlate strongly, then the likelihood that there
is an underlying association is higher. To that end, we can consider ‘meta’ methods to make use of results
from multiple different normalisation methods.
4.6.4.1 metaN
The most straightforward meta method would be to require that a correlation is present in some number of
normalised datasets. We refer to this as metaN, where N is the minimum number of methods that yield a
strong correlation for the meta method to consider a correlation to be genuinely strong. For example, we
can define meta5 as the following:
• meta5: a strong correlation only exists between the methylation intensities of two CpG sites if all
five of the selected methods of normalisation (NOOB, Quant, FunNorm, SWAN, Illumina) produce a
strong correlation between the two sites
We can also define meta6 as having the same criteria as meta5, except with the additional criterion that
a strong correlation must also exist in the unnormalised data. meta1 is the trivial case where we consider
a correlation to be genuinely strong if it is present following any method of normalisation (including not
normalising).
We can also define a ‘metaN score’ for a given pair of CpG sites, which is the number of methods that
yield a strong correlation between these sites. In this case, a score of six suggests that it was found in all
methods, and conversely, a score of zero suggests that no method identified a strong correlation between
these CpG sites. A higher score increases the likelihood that a biologically-meaningful association is present.
These methods do not provide a derived correlation coefficient, but rather are a means of suggesting a
more significant association. If a coefficient is required, then it can be (for example) taken as an average
of each of the individual N correlations, or the lowest correlation can be taken, etc. This will be defined as
required on a per-study basis.
4.7 Concluding remarks
In this chapter, we have investigated the effects of normalisation method choice on the resulting Spearman
beta correlation matrices, derived from several chromosomes, using the CHDS and MTAB7069 cohorts. Our
findings suggest that there are certainly differences in the outputs of each method, and this needs to be
taken into account when deciding which normalisation method to apply to a dataset.
Both NOOB normalisation and no normalisation (raw) were used in the preliminary study of chapter 3,
for reasons described in section 3.2. The results of studies in this chapter have supported continued use of
NOOB normalisation prior to calculation of correlation matrices, but only for autosomes. SWAN should be
considered for allosomes owing to its better performance in this study. In both cases, their use is recom-
mended on the basis that their strong correlations are more likely to be backed up by at least one other
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method; in the absence of a single method that picks up the majority of unique strong correlations, we instead
assume that all methods have some merit, and that the method with the fewest unique strong correlations is
best at capturing biologically-meaningful correlations. In the instance where a single method is insufficient,
we can instead use the metaN method to identify strong correlations using a scoring system, where the score
of a correlating pair is equal to the number of methods in which it is identified a as strong, given a consistent
threshold or proportion for strength identification.
Further studies could validate results in this section using more chromosomes, different test cohorts, etc.
For the time being, we consider there to be sufficient evidence to continue to use the NOOB and SWAN
normalisation methods when evaluating correlations in methylation intensity where use of a single method is
required. When we are not constrained to a single method, use of the metaN approach should be considered
as it may provide better results.
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Chapter 5
A comparison of different correlation
methods
5.1 Premise
A correlation is a statistical relationship between two variables. The overarching theme of research in this
thesis involves identifying CpG sites on the genome that correlate in methylation intensity. It is therefore
important that we evaluate our different options for calculating correlation coefficients. As discussed in
section 1.3.2, we have three common measures:
• Pearson correlation
• Spearman rank correlation
• Kendall rank correlation
The preliminary study in chapter 3 used the Spearman method and we were able to generate a basic correla-
tion network from the results. However, we should also quantify the performance of all three of our possible
measures of correlation, so we can make better-informed decisions for future studies.
In this chapter, we compare the different methods of calculating correlation and some considerations re-
garding their use. Two studies were undertaken as part of an effort to assess correlation method. The first
was computational profiling to characterise the performance of the three correlation coefficients, and the
second was a statistical analysis comparing the results.
5.2 Study: Computational considerations
To compare the time taken to generate beta correlation matrices, the three methods were subjected to
computational profiling. Correlation matrices consist of an n-by-n matrix for a set of n variables. The total
number of unique values that need to be calculated for these matrices is n(n−1)2 , so the number of correlation
coefficients that have to be calculated grows quadratically with the size of the dataset. This poses a problem
for DNA methylation data, as the more CpG sites we look at (and thus more values of methylation intensity
from which we have to calculate correlations), the more computationally-intensive the procedure becomes.
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To ensure that correlation matrices can be calculated in an acceptable time frame, we need to investigate
how long they take to generate on an appropriate dataset.
5.2.1 Methods
Raw data was processed and correlations generated as per the methods discussed in section 2.2, for the
CHDS cohort. The serialisation step was included as it is a key component of the pipeline and should take
the same period of time regardless of method. Chromosome 21 was selected for profiling as it is the smallest
autosomal chromosome, with 10300 probes on the EPIC array.
Profiling was undertaken by measuring the runtime of a Python function (using the standard datetime
library) containing the following processing steps:
1. Reading the CSV file containing beta values for a specific normalisation method and chromosome
2. Calculating the beta correlation matrix for a specific correlation type
3. Serialising the correlation matrix
This was repeated separately for each correlation type so profiling measured the same high-level operations
for each method. Profiling was undertaken using System 2 and Python configuration 2 as described in
Appendix A. Correlations are generated via the implementation in the Python pandas library as this is the
main data processing library we use in this thesis.
5.2.2 Results
Spearman Pearson Kendall
Run 1 (s) 195.04 27.87 20652.82
Run 2 (s) 202.24 35.97 19923.58
Run 3 (s) 203.63 34.77 19907.44
Average 200.30 32.87 20161.28
Table 5.1: Computational profiling of selected correlation methods: time taken (in seconds) to generate beta
correlation matrices for Chromosome 21.
All three of our trials show the same results - the Spearman method is roughly an order of magnitude slower
than the Pearson method, and the Kendall method is roughly two orders of magnitude slower than the
Spearman method. These results include all steps as described in section 5.2.1.
5.3 Study: Comparison of coefficients calculated between methy-
lation intensities of CpG sites, for selected chromosomes
To compare results for each of the three correlation methods, they were also subjected to a statistical analysis.
While no literature exists on the topic of correlations in DNA methylation intensity (and consequently, we
have no benchmark to compare against) we may be able to gain some understanding of the benefits and
downsides of each method by statistically comparing the resulting correlation matrices. As the precursor
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data for each chromosome (in terms of the beta values) used for each different correlation method is the
same, any variation in statistical quantities such as mean, variance etc. is entirely due to the correlation
method, as opposed to the data. As such, intensive statistical tests are not required and we can simply use a
direct comparison. Given the comparatively-extreme length of time required to generate Kendall correlation
matrices, only a small selection of chromosomes will be used in this analysis.
5.3.1 Methods
Raw data was processed with NOOB preprocessing and correlations generated as per the methods discussed
in section 2.2, for the CHDS cohort. Chromosomes 21, X and Y were selected for comparison, on the
following bases:
• Chromosome 21 is the smallest autosomal chromosome (10300 probes)
• Chromosomes X (19090 probes) and Y (537 probes) were shown to have a significantly higher standard
deviation than autosomal chromosomes in section 4.4.3.1, and the possibility that this increase in
standard deviation may be dependent on correlation method is something that should be investigated.
The pandas and scipy modules were used for statistical analysis.
For overlap comparison, a proportional threshold (described in section 2.2.5.2) was used - the strongest
10% positive and negative correlations were taken from each correlation matrix. We compare the number of
strong positive and negative correlations that are found throughout all three methods (‘consistent correla-
tions’), and the number found only by one method (‘unique correlations’), with the total number of strong
positive and negative correlations.
This study used system 2 and Python configuration 2 (as described in Appendix A).
5.3.2 Results
5.3.2.1 Statistical comparisons
Correlation type Spearman Pearson Kendall
Mean correlation 0.05314 0.05319 0.03622
Mean variance of correlation 0.02183 0.02274 0.01031
Mean positive correlation 0.13389 0.13503 0.09093
Mean negative correlation -0.09187 -0.09239 -0.0622
Ratio of positive to negative correlations 1.772 1.751 1.776
Table 5.2: Statistical comparison of different correlation methods, applied to the NOOB-normalised betas
for Chromosome 21 (10300 sites)
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Correlation type Spearman Pearson Kendall
Mean correlation 0.03625 0.10465 0.04710
Mean variance of correlation 0.17609 0.42183 0.08872
Mean positive correlation 0.39069 0.58791 0.27996
Mean negative correlation -0.35499 -0.53070 -0.25123
Ratio of positive to negative correlations 1.146 1.128 1.154
Table 5.3: Statistical comparison of different correlation methods, applied to the NOOB-normalised betas
for Chromosome X (19090 sites)
Correlation type Spearman Pearson Kendall
Mean correlation 0.10272 0.1364 0.07669
Mean variance of correlation 0.19755 0.51011 0.09372
Mean positive correlation 0.46421 0.71292 0.32278
Mean negative correlation -0.40037 -0.64829 -0.26800
Ratio of positive to negative correlations 1.342 1.298 1.345
Table 5.4: Statistical comparison of different correlation methods, applied to the NOOB-normalised betas
for Chromosome Y (537 sites)
The Spearman rank correlation matrix and the Pearson correlation matrix had similar properties for chromo-
some 21 (mean correlation, mean variance of correlation, mean positive correlation, mean negative correlation
and ratio of positive to negative correlations all within 5%), compared with the Kendall matrix which was
notably different for all of our metrics except ratio of positive to negative correlations.
The same degree of similarity was not found for either of the sex chromosomes; while the ratio of posi-
tive to negative correlations was within 10% in all cases, other statistical properties varied substantially
compared to the patterns we saw in chromosome 21.
The only consistent trend we see across all chromosomes and correlation methods is that the ratio of positive
to negative correlations is always greater than one, and the magnitude of the mean positive correlation is
always greater than the magnitude of the mean negative correlation.
5.3.3 Overlaps and uniqueness of strong correlations
The displayed number of positive correlations for each chromosome does not include the trivial values of 1.0
(for self-correlation).
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Chromosome 21 x y
Observed positive correlations 5,303,985 18,220,451 14,392
Consistent positive correlations 4,385,976 8,570,169 6,081
Unique positive correlations - Pearson 808,822 8,935,654 7,931
Unique positive correlations - Spearman 81,425 326,712 503
Unique positive correlations - Kendall 81,771 621,339 424
Observed negative correlations 5,303,985 18,220,451 14,392
Consistent negative correlations 4,142,041 10,724,161 7,114
Unique negative correlations - Pearson 1,040,737 6,718,785 6,716
Unique negative correlations - Spearman 89,223 268,841 379
Unique negative correlations - Kendall 101,581 685,135 465
Table 5.5: Statistical comparison of different correlation methods, applied to the NOOB-normalised betas
for Chromosome 21 (10300 sites)
For chromosome 21, we can see that there are a lot of consistent correlations ( 80% of the total), and
that the Pearson correlation method produces the highest number of unique strong correlations. A similar
trend can be seen with the sex chromosomes - the Pearson method consistently produces the highest number
of unique strong correlations. There is a higher proportion of consistent strong correlations for chromosome
21 than the sex chromosomes.
5.4 Discussion
5.4.1 Computational considerations
The results in table 5.1 suggest that generation of the Pearson correlation method is the fastest, followed
by the Spearman rank correlation matrix, then finally the Kendall rank correlation matrix which took a
significantly longer time (orders of magnitude longer than the comparable Spearman method). From a
performance point of view, calculating the Pearson correlation is fastest, though the Spearman method is
typically only slower by less than an order of magnitude. Given the preference for a rank-correlation metric
owing to the presumed non-linearity in the data (as discussed in section 1.3.2) the Spearman rank correlation
appears to be the best choice.
It must be considered that profiling results can be significantly influenced by the efficiency of the imple-
mentation of whatever is being profiled. In our case, we are using the same Python library for all three
methods; future studies may make use of a different software implementation which may improve perfor-
mance for any of our tested methods so profiling results may vary.
5.4.2 Statistical considerations
The percentage of positive correlations was similar (within 1%) and mean correlation is within 0.1 for each
method, for all tested chromosomes. This suggests that the underlying statistical distribution may be similar.
This is supported by the high proportion of consistent correlations (>80% for all except positive correlations
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on the Y chromosome) of the strongest 10% between each method for the tested chromosomes, shown in
table 5.5.
In all cases, the mean correlation coefficient was significantly closer to zero for the Kendall matrices than
those for the Spearman or Pearson methods. On its own, this would suggest a more ‘centred’ distribution
(and thus a more even split between positive and negative correlations) but we can also see that the positive-
to-negative ratio actually tends to be slightly greater than those of the other methods, so this doesn’t appear
to be the case. The main concern regarding distribution of correlation values and positive-to-negative ratio
would be that a sufficiently-skewed distribution would make it difficult to identify a threshold (or propor-
tion) for selecting strong correlations. All three methods produce a similar ratio of positive to negative
correlations, though table 5.5 shows that there were some significant differences in which correlations were
identified. The number of strong correlations that were found consistently regardless of correlation matrix
was substantially higher than the number of strong correlations unique to each method, but there were still a
large number of strong correlations unique to a particular method - we can use the numbers of unique strong
correlations to identify the (likely) best method, following a similar logic to that discussed for normalisation
types in section 4.6.3.2.
The Spearman approach produced the fewest unique strong correlations, which suggests that it performs
better at capturing more ‘legitimate’ strong correlations, as more often not, its strongest correlations were
backed up by at least one of the other methods - in other words, having fewer unique values means that it was
less likely to pick up strong correlations that are only produced by the Spearman method. In the absence of
evidence to the contrary, we must assume that a proportion of strong correlations aren’t grounded in biology
and only occur due to the mathematical nuances of the method used to generate them (if this weren’t the
case, there would be no correlations unique to each method). Assuming that this proportion is the same for
all methods (a näıve approach, but we have no evidence to say otherwise) then the method that produces
the fewest unique correlations is also the method that produces the highest number of legitimate correlations.
The Pearson method’s strong correlations tended to have less overlap with either of the other methods.
This is potentially due to the fact that Pearson correlation is less-suited to non-linear relationships, and we
would expect underlying epigenetic phenomena to be highly non-linear in nature owing to the complexity
of interactions happening at a molecular level. In this case, the high number of unique Pearson correlations
show that there is certainly a difference in strong correlations detected via rank and non-rank methods, and
we should err on the side of using rank methods as they are more suited for non-linear relationships.
Kendall’s method generated correlation matrices with a lower overall variance than either of the other
methods. Variance is a measure of spread that is particularly sensitive to outliers - in this case, the low
variance suggests that there are fewer correlations at the extremes of the distribution than in other methods.
This may make it difficult to select a threshold for a strong correlation if using the Kendall rank correlation
coefficient. Conversely, Pearson’s method had the highest overall variance in beta correlation matrix for all
chromosomes tested, which would make it easier to find a threshold; however the assumption of linearity
made for the Pearson coefficient means it is unlikely to be suitable for DNA methylation data.
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5.5 Concluding remarks
In this chapter, we have investigated the effects of correlation method choice on the resulting correlation
matrices produced from NOOB-normalised beta values, derived from several chromosomes, using the CHDS
cohort. Our findings suggest that there are certainly differences in the outputs of each method, and this
needs to be taken into account.
The Spearman rank correlation was the method of choice in the preliminary study of chapter 3, for reasons
described in section 2.2.2. The results of studies in this chapter have supported the use of the Spearman
method, for multiple reasons:
• Out of the options for a rank correlation coefficient (desired as the underlying data is assumed to
be non-linear), the Spearman coefficient is orders of magnitude faster to compute than the Kendall
coefficient, for the data that we tested, so we are able to assess correlations much faster.
• There are significant differences between rank and non-rank correlation methods, and given the pre-
sumed non-linearity of the underlying epigenetic associations, a rank correlation method would be
preferable.
Further studies could validate results in this section using more chromosomes, different test cohorts, etc. For
the time being, we consider there to be sufficient evidence to continue to use the Spearman rank correlation






Distance between correlating loci
within a chromosome
6.1 Premise
One of our hypotheses is that CpG sites that are located closer together will tend to correlate more strongly
in methylation intensity. In this chapter, we look at the distance between strongly-correlating loci on the
same chromosome, and also how the typical strength of correlations change as this distance increases.
Studies have shown that functional gene groups are often co-located on the same chromosome (Thévenin
et al. 2014). The physical ‘architecture’ of the genome is thought to play a role in gene interaction and
regulation and recent techniques have begun to assess the functional implications of topologically-associating
domains (Pombo and Dillon, 2015). Given the interplay between various different epigenetic mechanisms,
it would be interesting to see if spatial associations in DNA methylation were also present. We would also
expect to see some (relatively short-distance) associations owing to the presence of CpG islands (discussed
in section 1.2) which would be likely to have a similar methylation state for many of its constituent CpG
sites if it were associated with a promoter.
To test our hypothesis, four studies are undertaken:
• A comparison of correlation strength versus overall distance between sites located on the same chro-
mosome
• A comparison of correlation strength versus overall distance between sites associated with the same
gene (and chromosome)
• An analysis of where strongly-correlating loci are situated physically (within the same chromosome)
• An analysis of correlation within CpG islands
Discussion for the studies in this chapter is included in the general discussion (chapter 8).
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6.2 Study: Correlation strength versus distance - per chromosome
In this study, we attempt to identify a relationship between correlation strength and distance between cor-
relating loci. In the absence of any past studies suggesting the contrary, we assume that such a relationship
would have a detectable linear component. A complete model for correlation strength probability versus
distance between the correlating pair is beyond the scope of this thesis, though we may be able to identify
linear components of a relationship via regression analysis.
Topologically-associating domains are extremely complex, reflecting the complexity of genome architecture
as a whole, but the general idea is that there are regions in which compartments of the genome interact
with each other more frequently than with regions outside that compartment (Pombo and Dillon, 2015). As
chemical and physical properties arise for a given region of the genome due to the sequence of bases in that
region, it follows that many of the self-interacting sequences would have to be at least partially contiguous;
i.e. co-located within some relatively short stretch of the genome. The complexity of that interaction would
certainly result in non-linear effects, but our simplified linear model may be capable of detecting some aspects
of the overall trend.
6.2.1 Methods
Using the protocol specified in section 2.2, beta correlation matrices were calculated for a selection of chro-
mosomes using data for the CHDS cohort (see appendix B) for the normalisation types selected on the basis
of chapter 5:
• NOOB, for autosomes
• SWAN, for allosomes
Due to the computational intensity of this study, a selection of chromosomes were used, as per the rationale
in 2.3.1. These chromosomes include: 9, 13, 15, 18, 20, 21, 22, X and Y.
The physical distance between each correlating pair was derived from Illumina’s manifest by taking the
difference between the position (on the chromosome) for each member of the pair. Linear regression analysis
was performed between the correlation coefficient and the physical distance between the associated loci (us-
ing the statsmodels Python library), as this would indicate a relationship. Rather than taking the absolute
magnitude of the correlation and generating a single regression model, positive and negative correlations
were regressed separately as studies in chapter 4 suggested that they have different statistical properties, so
combining them may result in less-accurate models.
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6.2.2 Results
Positive Correlations Negative Correlations
Number of observations 210811274 131531587
R-Squared 0.0 0.0
F-score 7880.0 52.8
F-score P-value 0.0 3.72e-13
Gradient -1.78e-11 1.36e-12
Gradient standard error 2e-13 1.87e-13
Gradient T-score -88.7 7.26
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-1.82e-11, -1.74e-11) (9.92e-13, 1.72e-12)
Intercept 0.134 -0.0954
Intercept standard error 1.24e-05 1.16e-05
Intercept T-score 10800.0 -8210.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.134, 0.134) (-0.095, -0.095)
Table 6.1: Linear regression results for strength of correlation versus distance between correlating pair, for
chromosome 9, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 136109854 85220426
R-Squared 0.0 0.0
F-score 60700.0 11400.0
F-score P-value 0.0 0.0
Gradient -9.15e-11 3.63e-11
Gradient standard error 3.71e-13 3.4e-13
Gradient T-score -246.0 107.0
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-9.22e-11, -9.08e-11) (3.57e-11, 3.7e-11)
Intercept 0.146 -0.101
Intercept standard error 1.8e-05 1.64e-05
Intercept T-score 8090.0 -6150.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.146, 0.146) (-0.101, -0.101)
Table 6.2: Linear regression results for strength of correlation versus distance between correlating pair, for
chromosome 13, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 254297067 158711103
R-Squared 0.0 0.0
F-score 91100.0 27000.0
F-score P-value 0.0 0.0
Gradient -1.18e-10 6.13e-11
Gradient standard error 3.92e-13 3.73e-13
Gradient T-score -302.0 164.0
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-1.19e-10, -1.18e-10) (6.05e-11, 6.2e-11)
Intercept 0.138 -0.0987
Intercept standard error 1.26e-05 1.19e-05
Intercept T-score 10900.0 -8290.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.138, 0.138) (-0.099, -0.099)
Table 6.3: Linear regression results for strength of correlation versus distance between correlating pair, for
chromosome 15, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 68742921 42239730
R-Squared 0.0 0.0
F-score 17200.0 1850.0
F-score P-value 0.0 0.0
Gradient -9.78e-11 2.9e-11
Gradient standard error 7.46e-13 6.74e-13
Gradient T-score -131.0 43.0
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-9.93e-11, -9.64e-11) (2.77e-11, 3.03e-11)
Intercept 0.146 -0.1
Intercept standard error 2.59e-05 2.35e-05
Intercept T-score 5630.0 -4270.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.146, 0.146) (-0.1, -0.1)
Table 6.4: Linear regression results for strength of correlation versus distance between correlating pair, for
chromosome 18, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 165890096 97679224
R-Squared 0.0 0.0
F-score 1620.0 1420.0
F-score P-value 0.0 4.87e-310
Gradient -2.15e-11 -1.97e-11
Gradient standard error 5.33e-13 5.23e-13
Gradient T-score -40.3 -37.6
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-2.25e-11, -2.04e-11) (-2.07e-11, -1.87e-11)
Intercept 0.131 -0.0931
Intercept standard error 1.45e-05 1.44e-05
Intercept T-score 9040.0 -6470.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.131, 0.131) (-0.093, -0.093)
Table 6.5: Linear regression results for strength of correlation versus distance between correlating pair, for
chromosome 20, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 33906857 19132993
R-Squared 0.0 0.0
F-score 2180.0 1560.0
F-score P-value 0.0 0.0
Gradient 1.12e-10 9.76e-11
Gradient standard error 2.39e-12 2.47e-12
Gradient T-score 46.7 39.4
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (1.07e-10, 1.16e-10) (9.27e-11, 1.02e-10)
Intercept 0.136 -0.0961
Intercept standard error 3.05e-05 3.11e-05
Intercept T-score 4450.0 -3090.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.136, 0.136) (-0.096, -0.096)
Table 6.6: Linear regression results for strength of correlation versus distance between correlating pair, for
chromosome 21, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 108741296 59922865
R-Squared 0.0 0.0
F-score 9480.0 3780.0
F-score P-value 0.0 0.0
Gradient -1.19e-10 8.04e-11
Gradient standard error 1.22e-12 1.31e-12
Gradient T-score -97.3 61.5
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-1.21e-10, -1.16e-10) (7.78e-11, 8.29e-11)
Intercept 0.131 -0.0931
Intercept standard error 1.77e-05 1.89e-05
Intercept T-score 7420.0 -4920.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.131, 0.131) (-0.093, -0.093)
Table 6.7: Linear regression results for strength of correlation versus distance between correlating pair, for
chromosome 22, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 97951388 84253117
R-Squared 0.001 0.001
F-score 142000.0 65000.0
F-score P-value 0.0 0.0
Gradient -2.09e-10 1.3e-10
Gradient standard error 5.56e-13 5.08e-13
Gradient T-score -376.0 255.0
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-2.1e-10, -2.08e-10) (1.29e-10, 1.31e-10)
Intercept 0.372 -0.329
Intercept standard error 3.76e-05 3.42e-05
Intercept T-score 9910.0 -9610.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.372, 0.373) (-0.329, -0.329)
Table 6.8: Linear regression results for strength of correlation versus distance between correlating pair, for
chromosome x, using swan-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 83330 60586
R-Squared 0.01 0.001
F-score 826.0 82.8
F-score P-value 1.15e-180 9.41e-20
Gradient -2.89e-09 9.71e-10
Gradient standard error 1e-10 1.07e-10
Gradient T-score -28.7 9.1
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-3.08e-09, -2.69e-09) (7.62e-10, 1.18e-09)
Intercept 0.465 -0.379
Intercept standard error 0.001 0.001
Intercept T-score 448.0 -338.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.463, 0.467) (-0.382, -0.377)
Table 6.9: Linear regression results for strength of correlation versus distance between correlating pair, for
chromosome y, using swan-normalised data (CHDS dataset).
The results show that the R-squared values for our linear models is at or near zero in all cases. R-squared
can be thought of as a measure of the predictive capability of a model - as all of our models have such a low
R-squared, the predictive capability of our linear regression model for all tested chromosomes is practically
negligible; in other words, the vast majority of the variation in the data cannot be explained by our regression
line. Nonetheless, details for each of the models are retained in this section for posterity.
6.3 Study: Correlation strength versus distance - within genes
In section 6.2, we investigated the general trend of correlation strength versus distance with chromosomes.
In this study, we use a similar approach and justification to investigate the association between correlation
strength and distance for CpG sites within the same genes. One of our overarching hypotheses is that CpG
sites located close to each other will tend to correlate strongly in methylation intensity; we can take this
further and postulate that CpG sites in the same functional group will tend to demonstrate similar effects.
6.3.1 Methods
For this study, the methods described in section 6.2.1 were adapted such that they only looked at correlations
that were on the same gene. The majority of the process is the same, with the main difference being that
correlations were only included in the regression analysis if their constituent CpG sites are on the same
gene. This difference also significantly reduces the computational intensity of the study, so we can look
at all chromosomes rather than a subset. An additional linear regression was performed on all same-gene
correlating pairs from all autosomal chromosomes.
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6.3.2 Results
Positive Correlations Negative Correlations
Number of observations 1128773 579331
R-Squared 0.0 0.0
F-score 3.18 0.00033
F-score P-value 0.0744 0.986
Gradient -6.79e-11 -5.71e-13
Gradient standard error 3.81e-11 3.14e-11
Gradient T-score -1.78 -0.018
Gradient P > |T | 0.074 0.986
Gradient 95% confidence interval (-1.43e-10, 6.69e-12) (-6.22e-11, 6.1e-11)
Intercept 0.161 -0.102
Intercept standard error 0.0 0.0
Intercept T-score 1220.0 -821.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.161, 0.161) (-0.102, -0.101)
Table 6.10: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 1, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 790649 424188
R-Squared 0.002 0.0
F-score 1660.0 23.8
F-score P-value 0.0 1.05e-06
Gradient -4.86e-08 4.93e-09
Gradient standard error 1.19e-09 1.01e-09
Gradient T-score -40.7 4.88
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-5.09e-08, -4.62e-08) (2.95e-09, 6.91e-09)
Intercept 0.171 -0.104
Intercept standard error 0.0 0.0
Intercept T-score 837.0 -572.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.17, 0.171) (-0.104, -0.104)
Table 6.11: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 2, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 554420 322046
R-Squared 0.0 0.002
F-score 25.7 580.0
F-score P-value 4.05e-07 4.68e-128
Gradient -6.8e-09 -2.56e-08
Gradient standard error 1.34e-09 1.06e-09
Gradient T-score -5.07 -24.1
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-9.43e-09, -4.17e-09) (-2.77e-08, -2.35e-08)
Intercept 0.177 -0.108
Intercept standard error 0.0 0.0
Intercept T-score 691.0 -485.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.176, 0.177) (-0.108, -0.108)
Table 6.12: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 3, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 461036 248332
R-Squared 0.002 0.0
F-score 1040.0 32.4
F-score P-value 1.74e-228 1.24e-08
Gradient -5.47e-08 -7.64e-09
Gradient standard error 1.69e-09 1.34e-09
Gradient T-score -32.3 -5.69
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-5.8e-08, -5.14e-08) (-1.03e-08, -5.01e-09)
Intercept 0.17 -0.102
Intercept standard error 0.0 0.0
Intercept T-score 642.0 -445.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.17, 0.171) (-0.102, -0.101)
Table 6.13: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 4, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 538688 284307
R-Squared 0.0 0.001
F-score 1.61 212.0
F-score P-value 0.204 5.52e-48
Gradient -1.63e-09 -1.52e-08
Gradient standard error 1.28e-09 1.04e-09
Gradient T-score -1.27 -14.6
Gradient P > |T | 0.204 0.0
Gradient 95% confidence interval (-4.14e-09, 8.84e-10) (-1.72e-08, -1.31e-08)
Intercept 0.18 -0.106
Intercept standard error 0.0 0.0
Intercept T-score 732.0 -487.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.18, 0.181) (-0.106, -0.106)
Table 6.14: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 5, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 795144 435094
R-Squared 0.0 0.0
F-score 0.163 21.8
F-score P-value 0.686 2.97e-06
Gradient -1.13e-10 -1.23e-09
Gradient standard error 2.79e-10 2.63e-10
Gradient T-score -0.404 -4.67
Gradient P > |T | 0.686 0.0
Gradient 95% confidence interval (-6.59e-10, 4.34e-10) (-1.74e-09, -7.13e-10)
Intercept 0.166 -0.104
Intercept standard error 0.0 0.0
Intercept T-score 994.0 -708.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.165, 0.166) (-0.104, -0.104)
Table 6.15: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 6, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 1669987 809132
R-Squared 0.006 0.002
F-score 10400.0 1550.0
F-score P-value 0.0 0.0
Gradient -3.74e-08 1.37e-08
Gradient standard error 3.67e-10 3.48e-10
Gradient T-score -102.0 39.4
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-3.81e-08, -3.67e-08) (1.3e-08, 1.44e-08)
Intercept 0.151 -0.0933
Intercept standard error 0.0 0.0
Intercept T-score 1200.0 -754.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.15, 0.151) (-0.094, -0.093)
Table 6.16: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 7, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 504443 274149
R-Squared 0.0 0.0
F-score 241.0 7.13
F-score P-value 2.42e-54 0.00757
Gradient -9.61e-09 1.64e-09
Gradient standard error 6.19e-10 6.13e-10
Gradient T-score -15.5 2.67
Gradient P > |T | 0.0 0.008
Gradient 95% confidence interval (-1.08e-08, -8.4e-09) (4.36e-10, 2.84e-09)
Intercept 0.163 -0.102
Intercept standard error 0.0 0.0
Intercept T-score 764.0 -528.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.163, 0.164) (-0.103, -0.102)
Table 6.17: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 8, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 256050 134440
R-Squared 0.001 0.0
F-score 153.0 43.3
F-score P-value 3.16e-35 4.75e-11
Gradient -2.46e-08 -1.18e-08
Gradient standard error 1.99e-09 1.8e-09
Gradient T-score -12.4 -6.58
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-2.85e-08, -2.07e-08) (-1.53e-08, -8.29e-09)
Intercept 0.165 -0.1
Intercept standard error 0.0 0.0
Intercept T-score 518.0 -343.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.164, 0.166) (-0.101, -0.099)
Table 6.18: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 9, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 829795 419801
R-Squared 0.002 0.0
F-score 1600.0 68.1
F-score P-value 0.0 1.54e-16
Gradient -4.42e-08 8.24e-09
Gradient standard error 1.1e-09 9.98e-10
Gradient T-score -40.0 8.25
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-4.63e-08, -4.2e-08) (6.28e-09, 1.02e-08)
Intercept 0.163 -0.101
Intercept standard error 0.0 0.0
Intercept T-score 836.0 -538.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.163, 0.164) (-0.101, -0.1)
Table 6.19: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 10, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 731467 364664
R-Squared 0.002 0.0
F-score 1470.0 133.0
F-score P-value 4.6e-321 1.05e-30
Gradient -3.3e-08 9.79e-09
Gradient standard error 8.61e-10 8.5e-10
Gradient T-score -38.3 11.5
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-3.47e-08, -3.13e-08) (8.13e-09, 1.15e-08)
Intercept 0.163 -0.102
Intercept standard error 0.0 0.0
Intercept T-score 861.0 -558.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.162, 0.163) (-0.102, -0.101)
Table 6.20: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 11, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 533400 281389
R-Squared 0.0 0.0
F-score 24.1 3.52
F-score P-value 9.35e-07 0.0606
Gradient -4.05e-09 -2.59e-09
Gradient standard error 8.25e-10 1.38e-09
Gradient T-score -4.91 -1.88
Gradient P > |T | 0.0 0.061
Gradient 95% confidence interval (-5.67e-09, -2.43e-09) (-5.29e-09, 1.15e-10)
Intercept 0.165 -0.101
Intercept standard error 0.0 0.0
Intercept T-score 777.0 -485.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.165, 0.166) (-0.102, -0.101)
Table 6.21: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 12, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 359881 176484
R-Squared 0.0 0.001
F-score 3.41 130.0
F-score P-value 0.0648 3.64e-30
Gradient -3.27e-09 -1.84e-08
Gradient standard error 1.77e-09 1.61e-09
Gradient T-score -1.85 -11.4
Gradient P > |T | 0.065 0.0
Gradient 95% confidence interval (-6.73e-09, 2.01e-10) (-2.16e-08, -1.52e-08)
Intercept 0.161 -0.0988
Intercept standard error 0.0 0.0
Intercept T-score 579.0 -358.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.16, 0.161) (-0.099, -0.098)
Table 6.22: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 13, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 313867 168714
R-Squared 0.0 0.0
F-score 76.3 18.6
F-score P-value 2.47e-18 1.6e-05
Gradient -1.07e-08 -4.49e-09
Gradient standard error 1.22e-09 1.04e-09
Gradient T-score -8.73 -4.31
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-1.31e-08, -8.3e-09) (-6.54e-09, -2.45e-09)
Intercept 0.168 -0.105
Intercept standard error 0.0 0.0
Intercept T-score 586.0 -400.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.168, 0.169) (-0.106, -0.105)
Table 6.23: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 14, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 341288 179510
R-Squared 0.002 0.0
F-score 809.0 42.2
F-score P-value 1.02e-177 8.3e-11
Gradient -6.67e-08 -1.32e-08
Gradient standard error 2.35e-09 2.03e-09
Gradient T-score -28.4 -6.5
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-7.13e-08, -6.21e-08) (-1.72e-08, -9.2e-09)
Intercept 0.169 -0.101
Intercept standard error 0.0 0.0
Intercept T-score 555.0 -362.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.168, 0.169) (-0.102, -0.1)
Table 6.24: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 15, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 562970 275649
R-Squared 0.001 0.0
F-score 399.0 17.0
F-score P-value 1.14e-88 3.66e-05
Gradient -2.27e-08 -4.55e-09
Gradient standard error 1.13e-09 1.1e-09
Gradient T-score -20.0 -4.13
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-2.49e-08, -2.04e-08) (-6.71e-09, -2.39e-09)
Intercept 0.154 -0.0978
Intercept standard error 0.0 0.0
Intercept T-score 788.0 -492.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.154, 0.155) (-0.098, -0.097)
Table 6.25: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 16, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 750461 371595
R-Squared 0.005 0.0
F-score 3770.0 67.8
F-score P-value 0.0 1.83e-16
Gradient -1.09e-07 -1.38e-08
Gradient standard error 1.77e-09 1.67e-09
Gradient T-score -61.4 -8.23
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-1.12e-07, -1.05e-07) (-1.7e-08, -1.05e-08)
Intercept 0.16 -0.0978
Intercept standard error 0.0 0.0
Intercept T-score 821.0 -491.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.16, 0.161) (-0.098, -0.097)
Table 6.26: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 17, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 183691 96735
R-Squared 0.0 0.001
F-score 40.2 106.0
F-score P-value 2.24e-10 7.43e-25
Gradient -1.97e-08 -2.7e-08
Gradient standard error 3.11e-09 2.62e-09
Gradient T-score -6.34 -10.3
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-2.58e-08, -1.36e-08) (-3.21e-08, -2.18e-08)
Intercept 0.174 -0.103
Intercept standard error 0.0 0.0
Intercept T-score 380.0 -249.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.173, 0.175) (-0.104, -0.102)
Table 6.27: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 18, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 332414 169477
R-Squared 0.009 0.0
F-score 3150.0 44.4
F-score P-value 0.0 2.63e-11
Gradient -4.03e-07 -4.17e-08
Gradient standard error 7.18e-09 6.26e-09
Gradient T-score -56.1 -6.67
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-4.17e-07, -3.89e-07) (-5.4e-08, -2.95e-08)
Intercept 0.161 -0.0962
Intercept standard error 0.0 0.0
Intercept T-score 555.0 -355.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.16, 0.161) (-0.097, -0.096)
Table 6.28: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 19, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 269591 124097
R-Squared 0.002 0.001
F-score 659.0 126.0
F-score P-value 2.97e-145 3.59e-29
Gradient -4.13e-08 -1.37e-08
Gradient standard error 1.61e-09 1.22e-09
Gradient T-score -25.7 -11.2
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-4.44e-08, -3.81e-08) (-1.61e-08, -1.13e-08)
Intercept 0.167 -0.0945
Intercept standard error 0.0 0.0
Intercept T-score 530.0 -338.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.166, 0.167) (-0.095, -0.094)
Table 6.29: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 20, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 114552 58678
R-Squared 0.001 0.002
F-score 93.8 94.4
F-score P-value 3.62e-22 2.73e-22
Gradient -5.08e-08 -4.42e-08
Gradient standard error 5.25e-09 4.55e-09
Gradient T-score -9.68 -9.71
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-6.11e-08, -4.05e-08) (-5.32e-08, -3.53e-08)
Intercept 0.168 -0.1
Intercept standard error 0.001 0.0
Intercept T-score 325.0 -207.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.167, 0.169) (-0.101, -0.099)
Table 6.30: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 21, using noob-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 223608 103282
R-Squared 0.004 0.0
F-score 884.0 23.6
F-score P-value 8.33e-194 1.17e-06
Gradient -9.85e-08 -1.53e-08
Gradient standard error 3.31e-09 3.15e-09
Gradient T-score -29.7 -4.86
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-1.05e-07, -9.2e-08) (-2.15e-08, -9.14e-09)
Intercept 0.166 -0.0971
Intercept standard error 0.0 0.0
Intercept T-score 457.0 -271.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.165, 0.166) (-0.098, -0.096)
Table 6.31: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome 22, using noob-normalised data (CHDS dataset).
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Positive Correlations Negative Correlations
Number of observations 114812 72079
R-Squared 0.021 0.002
F-score 2440.0 165.0
F-score P-value 0.0 1.06e-37
Gradient -1.26e-07 3.57e-08
Gradient standard error 2.55e-09 2.78e-09
Gradient T-score -49.3 12.8
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-1.31e-07, -1.21e-07) (3.02e-08, 4.11e-08)
Intercept 0.422 -0.324
Intercept standard error 0.001 0.001
Intercept T-score 602.0 -428.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.42, 0.423) (-0.326, -0.323)
Table 6.32: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome x, using swan-normalised data (CHDS dataset).
Positive Correlations Negative Correlations
Number of observations 1124 622
R-Squared 0.022 0.089
F-score 25.4 60.4
F-score P-value 5.45e-07 3.2e-14
Gradient -2.48e-07 4.65e-07
Gradient standard error 4.91e-08 5.98e-08
Gradient T-score -5.04 7.77
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-3.44e-07, -1.51e-07) (3.47e-07, 5.82e-07)
Intercept 0.543 -0.429
Intercept standard error 0.006 0.008
Intercept T-score 86.0 -53.3
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.531, 0.556) (-0.445, -0.413)
Table 6.33: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, for chromosome y, using swan-normalised data (CHDS dataset).
90
Positive Correlations Negative Correlations
Number of observations 12246175 6301094
R-Squared 0.0 0.0
F-score 727.0 14.0
F-score P-value 4.65e-160 0.000182
Gradient -1.01e-09 1.15e-10
Gradient standard error 3.74e-11 3.08e-11
Gradient T-score -27.0 3.74
Gradient P > |T | 0.0 0.0
Gradient 95% confidence interval (-1.08e-09, -9.35e-10) (5.48e-11, 1.75e-10)
Intercept 0.16 -0.101
Intercept standard error 4.06e-05 3.75e-05
Intercept T-score 3950.0 -2680.0
Intercept P > |T | 0.0 0.0
Intercept 95% confidence interval (0.16, 0.16) (-0.101, -0.101)
Table 6.34: Linear regression results for strength of correlation versus distance between correlating pairs
within the same gene, across all chromosomes, using noob-normalised data (CHDS dataset).
We saw in section 6.2.1 that our linear models had very limited predictive capability, owing to their low
R-squared values. The same can be seen in our results here, for the most part. The sex chromosomes are
the notable exceptions, with a substantially-higher R-squared than all autosomal models. With models for
positive correlations having an R-squared of around 0.02 in both cases, and the negative correlation model
for chromosome Y having an R-squared of almost 0.09, predictive power is still extremely low, though we
can see some semblance of a trend emerging here. As we’ve done previously, details for each of the models
are retained for posterity.
6.4 Study: Distance between strongly-correlating loci
Previously in this chapter, we have used linear regression to test our hypothesis that CpG sites located
closer together will tend to correlate more strongly in methylation intensity. In this study, we take a
different approach - rather than attempt to generate a model relating distance to correlation for some subset
of CpG sites within the genome, we instead compare the distance graphically. Through this method, we can
identify notable clusters of highly-correlating pairs in close proximity, which may help us identify parts of
the genome that tend to associate epigenetically.
6.4.1 Methods
Raw data was processed and correlations generated as per the methods discussed in section 2.2, for the CHDS
cohort. We took a proportional threshold approach (section 2.2.5.2), selecting the strongest 10% positive
and weakest correlations as the strongest. Due to proportional thresholds requiring significant computational
resource for large chromosomes, we only use this method to look at a subset of chromosomes, as per section
2.3.1. The subset of chromosomes used for this study includes: 4, 8, 9, 13, 14, 15, 16, 18, 20, 21, 22, X and Y.
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One of the key difficulties is that a strong correlation may only be present if a specific normalisation type
is used prior to correlation calculation. As a solution to this, we apply the metaN method as described in
section 4.6.4.1 - that is, we consider a correlation to be more meaningful if it can be identified in datasets
produced by multiple normalisation methods (including no normalisation).
To display the distances between these correlations, we plot the chromosomal positions of the two CpG
sites on the X and Y axis respectively. This allows us to get a general idea of where the strong correlations
are occuring, and identify areas that are particularly dense in strong correlations. Correlations are plotted
in green if they are positive, and red if they are negative. If for some reason they are present in both (i.e.
a pair is simultaneously strong and positive for one method, but strong and negative for another), they are
plotted in black, though this is not considered to be a likely occurrence. Transparency of a given point on
the graph is dependent on the number of times it was identified as a strong correlation in a dataset produced
by one of the six methods of normalisation. Strongly-correlating pairs consistent across all six datasets are
plotted with a darker shade of red or green.
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6.4.2 Results
Figure 6.1: Location of strong correlations in CpG methylation intensity (beta) for chromosome 4, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.2: Location of strong correlations in CpG methylation intensity (beta) for chromosome 8, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.3: Location of strong correlations in CpG methylation intensity (beta) for chromosome 9, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.4: Location of strong correlations in CpG methylation intensity (beta) for chromosome 13, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.5: Location of strong correlations in CpG methylation intensity (beta) for chromosome 14, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.6: Location of strong correlations in CpG methylation intensity (beta) for chromosome 15, with
intensity based on score for the metaN method. Source data: CHDS dataset
98
Figure 6.7: Location of strong correlations in CpG methylation intensity (beta) for chromosome 16, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.8: Location of strong correlations in CpG methylation intensity (beta) for chromosome 18, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.9: Location of strong correlations in CpG methylation intensity (beta) for chromosome 20, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.10: Location of strong correlations in CpG methylation intensity (beta) for chromosome 21, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.11: Location of strong correlations in CpG methylation intensity (beta) for chromosome 22, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.12: Location of strong correlations in CpG methylation intensity (beta) for chromosome X, with
intensity based on score for the metaN method. Source data: CHDS dataset
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Figure 6.13: Location of strong correlations in CpG methylation intensity (beta) for chromosome Y, with
intensity based on score for the metaN method. Source data: CHDS dataset
In all tested chromosomes, we see a distinct banding pattern across both axes. This is accompanied by
notable clusters in the data where we see an abundance of strong correlations (either positive or negative) in
a localised area. We also see a positively-correlating diagonal for all chromosomes. This indicates a tendency
for strong positive correlations to occur in ‘data-adjacent’ CpGs, though we must keep in mind that there
may be unprobed CpGs between CpG sites in our data as the EPIC array only observes 3% of the CpG sites
in the human genome.
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6.5 Study: Correlation trends within CpG islands
CpG islands, discussed in section 1.2, are loosely-defined regions of the genome that contain a high frequency
of CpG sites. This results in increased proximity between sites; though spatial effects throughout the genome
are assessed more generally in other studies in this thesis, this study focuses specifically on regions that have
been annotated as CpG islands. Results from section 6.4 show that CpG islands may contain strong positive
correlations, and these are visible as a diagonal in the location plot of CpG pairs for each chromosome. In
this study, we quantify these findings using statistical methods.
6.5.1 Methods
Methods from section 2.2 are used to obtain correlation matrices for a selection of chromosomes. The com-
putational intensity of this procedure is a limiting factor (discussed in section 2.3.1) so only the following
chromosomes are investigated: 4, 8, 9, 13, 14, 15, 16, 18, 20, 21, 22, X and Y.
CpG sites are associated with islands based on the Illumina manifest, which contains information on CpG
islands defined by UCSC. We extract a list of all annotated islands and their associated CpG sites for each
chromosome. CpG sites from islands that have more than one associated CpG site are used to produce two
sets:
• A set of all possible pairs within each island, with n!2!(n−2)! pairs possible for n CpG sites within an
island
• A set of all data-adjacent pairs within each island, i.e. the CpG sites are sorted by distance and pairs
taken from adjacent elements in this sorted set, with n − 1 pairs possible for n CpG sites within an
island
Both of these sets are divided into positive and negative subsets then subjected to one-way ANOVA against
all correlations within a chromosome to test for the statistical significance of their differences. Python’s scipy
module is used for ANOVA functionality.
6.5.2 Results
Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 403073784 74658 10554
Number of negative correlations 272961051 37451 2595
Mean positive correlation 0.146 0.17 0.243
Mean negative correlation -0.103 -0.0992 -0.0838
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 2670.0 5810.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 67.5 116.0
Negatives ANOVA p-value 2.1e-16 3.7e-27
Table 6.35: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 4, and
all correlations within chromosome 4 in general, fromcorrelation matrices derived from noob-normalised beta
values. Number of islands with more than one CpG site: 1010 (cohort: chds)
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Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 449077532 77084 10727
Number of negative correlations 290181394 39323 2569
Mean positive correlation 0.139 0.17 0.245
Mean negative correlation -0.0986 -0.0948 -0.0851
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 4820.0 7960.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 72.9 60.8
Negatives ANOVA p-value 1.35e-17 6.29e-15
Table 6.36: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 8, and
all correlations within chromosome 8 in general, fromcorrelation matrices derived from noob-normalised beta
values. Number of islands with more than one CpG site: 1001 (cohort: chds)
Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 210811274 45242 8246
Number of negative correlations 131531587 24096 2151
Mean positive correlation 0.133 0.162 0.227
Mean negative correlation -0.0953 -0.0941 -0.0827
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 2900.0 5510.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 5.21 47.5
Negatives ANOVA p-value 0.0224 5.58e-12
Table 6.37: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 9, and
all correlations within chromosome 9 in general, fromcorrelation matrices derived from noob-normalised beta
values. Number of islands with more than one CpG site: 1145 (cohort: chds)
Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 136109854 45383 6114
Number of negative correlations 85220426 19952 1389
Mean positive correlation 0.142 0.172 0.246
Mean negative correlation -0.0997 -0.0933 -0.0866
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 2540.0 4180.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 103.0 29.2
Negatives ANOVA p-value 3.85e-24 6.57e-08
Table 6.38: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 13, and
all correlations within chromosome 13 in general, fromcorrelation matrices derived from noob-normalised
beta values. Number of islands with more than one CpG site: 573 (cohort: chds)
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Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 266185214 71333 9113
Number of negative correlations 170401261 35364 2110
Mean positive correlation 0.135 0.165 0.24
Mean negative correlation -0.0992 -0.0939 -0.0826
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 4630.0 7240.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 124.0 71.8
Negatives ANOVA p-value 8.15e-29 2.41e-17
Table 6.39: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 14, and
all correlations within chromosome 14 in general, fromcorrelation matrices derived from noob-normalised
beta values. Number of islands with more than one CpG site: 779 (cohort: chds)
Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 254297067 64196 8491
Number of negative correlations 158711103 33240 2026
Mean positive correlation 0.135 0.164 0.239
Mean negative correlation -0.0971 -0.095 -0.0839
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 3970.0 6830.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 19.5 47.0
Negatives ANOVA p-value 9.95e-06 7.02e-12
Table 6.40: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 15, and
all correlations within chromosome 15 in general, fromcorrelation matrices derived from noob-normalised
beta values. Number of islands with more than one CpG site: 759 (cohort: chds)
Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 449528374 106536 14661
Number of negative correlations 270136517 50734 3256
Mean positive correlation 0.125 0.165 0.24
Mean negative correlation -0.0928 -0.0922 -0.0804
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 15600.0 17900.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 2.15 69.9
Negatives ANOVA p-value 0.143 6.14e-17
Table 6.41: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 16, and
all correlations within chromosome 16 in general, fromcorrelation matrices derived from noob-normalised
beta values. Number of islands with more than one CpG site: 1433 (cohort: chds)
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Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 68742921 31732 4557
Number of negative correlations 42239730 14625 1060
Mean positive correlation 0.143 0.173 0.252
Mean negative correlation -0.0995 -0.0921 -0.082
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 1860.0 3480.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 101.0 41.5
Negatives ANOVA p-value 1.13e-23 1.2e-10
Table 6.42: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 18, and
all correlations within chromosome 18 in general, fromcorrelation matrices derived from noob-normalised
beta values. Number of islands with more than one CpG site: 504 (cohort: chds)
Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 165890096 59054 8096
Number of negative correlations 97679224 27088 1723
Mean positive correlation 0.131 0.187 0.262
Mean negative correlation -0.0936 -0.0921 -0.081
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 15200.0 11200.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 9.05 38.9
Negatives ANOVA p-value 0.00263 4.49e-10
Table 6.43: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 20, and
all correlations within chromosome 20 in general, fromcorrelation matrices derived from noob-normalised
beta values. Number of islands with more than one CpG site: 800 (cohort: chds)
Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 33906857 22451 3368
Number of negative correlations 19132993 9861 691
Mean positive correlation 0.137 0.177 0.252
Mean negative correlation -0.0951 -0.0913 -0.0795
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 2640.0 3320.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 18.5 21.9
Negatives ANOVA p-value 1.71e-05 2.89e-06
Table 6.44: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 21, and
all correlations within chromosome 21 in general, fromcorrelation matrices derived from noob-normalised
beta values. Number of islands with more than one CpG site: 352 (cohort: chds)
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Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 108741296 46751 6899
Number of negative correlations 59922865 21570 1488
Mean positive correlation 0.13 0.177 0.252
Mean negative correlation -0.0921 -0.0919 -0.079
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 9010.0 9010.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 0.192 35.6
Negatives ANOVA p-value 0.661 2.48e-09
Table 6.45: Statistical comparison of correlations between CpG sites on CpG islands on chromosome 22, and
all correlations within chromosome 22 in general, fromcorrelation matrices derived from noob-normalised
beta values. Number of islands with more than one CpG site: 710 (cohort: chds)
Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 97951388 47234 7468
Number of negative correlations 84253117 18763 1187
Mean positive correlation 0.361 0.508 0.544
Mean negative correlation -0.322 -0.334 -0.258
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 21700.0 5280.0
Positives ANOVA p-value 0.0 0.0
Negatives ANOVA F-score 84.7 142.0
Negatives ANOVA p-value 3.48e-20 9.58e-33
Table 6.46: Statistical comparison of correlations between CpG sites on CpG islands on chromosome x, and
all correlations within chromosome x in general, fromcorrelation matrices derived from swan-normalised beta
values. Number of islands with more than one CpG site: 754 (cohort: chds)
Whole chromosome All CpG island pairs Adjacent CpG island pairs
Number of positive correlations 83330 852 245
Number of negative correlations 60586 369 36
Mean positive correlation 0.442 0.55 0.577
Mean negative correlation -0.371 -0.386 -0.3
All islands vs. chromosome Adjacent vs. chromosome
Positives ANOVA F-score 277.0 126.0
Positives ANOVA p-value 4.63e-62 4.02e-29
Negatives ANOVA F-score 2.66 6.23
Negatives ANOVA p-value 0.103 0.0126
Table 6.47: Statistical comparison of correlations between CpG sites on CpG islands on chromosome y, and
all correlations within chromosome y in general, fromcorrelation matrices derived from swan-normalised beta
values. Number of islands with more than one CpG site: 59 (cohort: chds)
Our results showed that all of our tested chromosomes have a higher average positive correlation within CpG
islands than the baseline level of the entire chromosome. Similarly, data-adjacent CpG pairs have a higher
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average positive correlation than the already-elevated average of the CpG island subset. In both cases, results
are generally statistically significant as per ANOVA (p << 0.001), but this trend of statistical significance
is only consistent for strong positive correlations within the autosomes. Mean negative correlation tends to
become more positive in most cases with the notable exception of the sex chromosomes - for chromosomes X
and Y, the mean negative correlation across all CpG island pairs was more negative than the chromosomal
average, but more positive for adjacent CpG island pairs.
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Chapter 7
Correlations within genes and
pathways
7.1 Premise
CpG sites may strongly correlate (either positively or negatively) in methylation intensity with multiple
other CpG sites. A key hypothesis that we must test is the methylation intensity of CpG sites within genes
and biological pathways will tend to correlate more-strongly than those not on these similar functional groups.
In this chapter, we undertake two studies:
• An analysis of the statistical distribution of correlations within the same genes, versus that of correla-
tions across the chromosome in general
• An analysis of the difference in distribution of correlations within the same pathways, versus that of
correlations across the chromosome in general
The results in this chapter are best considered in conjunction with the results from chapter 6. Both chapters
are discussed in a combined general discussion in chapter 8.
7.2 Study: Correlation trends within genes
In this study, we aim to find evidence of significant correlation in methylation intensity between different
CpG sites within the same gene. To achieve, this, we estimate a probability distribution function (in the
form of a histogram) of correlation coefficients for correlations within genes, versus that of the overall beta
correlation matrix.
7.2.1 Methods
Methods from section 2.2 are used to obtain correlation matrices for a selection of chromosomes. The com-
putational intensity of this procedure is a limiting factor (discussed in section 2.3.1) so only the following
chromosomes are investigated: 4, 8, 9, 13, 14, 15, 16, 18, 20, 21, 22, X and Y. As per section 2.2.3, CpG
sites are related to genes using the Illumina manifest. Two overlapping histograms are generated using the
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Python matplotlib module - one for the distribution of correlation coefficients across the entire chromosome,
and one for the distribution of correlation coefficients between CpG pairs located on the same annotated
gene. Distributions are approximated by scaling the total number of items in each histogram bin by the
total number of items in that histogram.
A second set of results is produced using the same methods as above, except we exclude CpG islands
(as annotated in the Illumina manifest).
7.2.2 Results
7.2.2.1 Distributions with CpG islands
Figure 7.1: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 4. Source data: CHDS dataset
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Figure 7.2: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 8. Source data: CHDS dataset
Figure 7.3: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 9. Source data: CHDS dataset
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Figure 7.4: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 13. Source data: CHDS dataset
Figure 7.5: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 14. Source data: CHDS dataset
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Figure 7.6: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 15. Source data: CHDS dataset
Figure 7.7: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 16. Source data: CHDS dataset
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Figure 7.8: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 18. Source data: CHDS dataset
Figure 7.9: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 20. Source data: CHDS dataset
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Figure 7.10: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 21. Source data: CHDS dataset
Figure 7.11: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 22. Source data: CHDS dataset
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Figure 7.12: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome X. Source data: CHDS dataset
Figure 7.13: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome Y. Source data: CHDS dataset
For all autosomes, we can see a notable section of the estimated distribution function for correlation within
the same gene lies to the right of that for the entire chromosome. The right tail is also significantly longer and
fatter in these cases, and their peak is also slightly to the right of that of the entire chromosome distribution;
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all of this suggests that same-gene correlations tend to have stronger correlations for autosomes. Though
hard to see, the left tail of the same-gene distribution is also thicker in some cases, suggesting that there’s
an increased tendency for stronger negative correlations than the average for these chromosomes.
The same trend is much harder to see in the sex chromosomes (owing to their multimodal, as opposed
to unimodal distributions), but as with the autosomes, the distribution of same-gene correlations has a
notable component to the right of the whole-chromosome curve.
7.2.2.2 Distributions without CpG islands
Figure 7.14: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 4, excluding all CpG sites on annotated CpG islands.
Source data: CHDS dataset
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Figure 7.15: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 8, excluding all CpG sites on annotated CpG islands.
Source data: CHDS dataset
Figure 7.16: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 9, excluding all CpG sites on annotated CpG islands.
Source data: CHDS dataset
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Figure 7.17: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 13, excluding all CpG sites on annotated CpG
islands. Source data: CHDS dataset
Figure 7.18: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 14, excluding all CpG sites on annotated CpG
islands. Source data: CHDS dataset
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Figure 7.19: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 15, excluding all CpG sites on annotated CpG
islands. Source data: CHDS dataset
Figure 7.20: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 16, excluding all CpG sites on annotated CpG
islands. Source data: CHDS dataset
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Figure 7.21: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 18, excluding all CpG sites on annotated CpG
islands. Source data: CHDS dataset
Figure 7.22: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 20, excluding all CpG sites on annotated CpG
islands. Source data: CHDS dataset
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Figure 7.23: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 21, excluding all CpG sites on annotated CpG
islands. Source data: CHDS dataset
Figure 7.24: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome 22, excluding all CpG sites on annotated CpG
islands. Source data: CHDS dataset
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Figure 7.25: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome X, excluding all CpG sites on annotated CpG
islands. Source data: CHDS dataset
Figure 7.26: Frequency of correlation coefficients for whole genome (orange) and subset of correlating pairs
from CpGs within the same gene (blue) for chromosome Y, excluding all CpG sites on annotated CpG
islands. Source data: CHDS dataset
In this section, we see similar results to what we saw in section 7.2.2.1. Visual comparison suggests that
the distribution of same-gene-excluding-island correlations is biased more to the right (positive correlations)
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than same-gene correlations that include CpG islands. Otherwise, much of the commentary is the same.
7.3 Study: Correlation trends within pathways
This study aims to find evidence of strong correlation in methylation intensity between CpG sites on different
genes on the same biological pathway.
7.3.1 Methods
We used the same methods from section 7.2.1 to select chromosomes, obtain correlation matrices and convert
CpG sites to genes. We search the reactome database for biological pathway information, using techniques
described in section 2.3.
The mean positive and negative correlations are calculated for the following subsets of each chromosome:
• CpG pairs on genes that share a pathway as detected by our automated search tool, except for those
that are on the same gene
• All CpG pairs within that chromosome
Correlations within the same gene are investigated in section 7.2. To remove the effects due to correlations
within the same gene, all correlations within the same gene would be removed from the subset based on
genes with common pathways; this leaves only correlating pairs with CpG sites on separate genes, within the
same pathway. The other subset represents the chromosome as a whole - it will include genes and pathways
that were not correctly identified by our automated search tool as well as anything that has yet to been
added to the database that we used.
To investigate the significance of the difference between the two subsets, we use a one-way ANOVA test




Whole chromosome Shared pathways
Number of CpG sites 36771 2426
Number of known genes assessed 440 440
Identified overlapping pathways 189 189
Number of positive correlating pairs 403073784 1532486
Number of negative correlating pairs 272961051 1179790
Mean positive correlation 0.146 0.152
Mean negative correlation -0.103 -0.111
Positive correlations Negative correlations
One-way ANOVA F-score 3630.0 9060.0
One-way ANOVA p-value 0.0 0.0
Table 7.1: Statistical comparison of correlations between genes on shared pathways on chromosome 4, and
all correlations within chromosome 4 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
Whole chromosome Shared pathways
Number of CpG sites 38452 2248
Number of known genes assessed 391 391
Identified overlapping pathways 183 183
Number of positive correlating pairs 449077532 1545450
Number of negative correlating pairs 290181394 1115880
Mean positive correlation 0.139 0.136
Mean negative correlation -0.0986 -0.103
Positive correlations Negative correlations
One-way ANOVA F-score 1330.0 2470.0
One-way ANOVA p-value 1.44e-291 0.0
Table 7.2: Statistical comparison of correlations between genes on shared pathways on chromosome 8, and
all correlations within chromosome 8 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
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Whole chromosome Shared pathways
Number of CpG sites 26167 2407
Number of known genes assessed 428 428
Identified overlapping pathways 189 189
Number of positive correlating pairs 210811274 1475228
Number of negative correlating pairs 131531587 973470
Mean positive correlation 0.133 0.135
Mean negative correlation -0.0953 -0.0979
Positive correlations Negative correlations
One-way ANOVA F-score 711.0 918.0
One-way ANOVA p-value 1.19e-156 1.44e-201
Table 7.3: Statistical comparison of correlations between genes on shared pathways on chromosome 9, and
all correlations within chromosome 9 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
Whole chromosome Shared pathways
Number of CpG sites 21040 1236
Number of known genes assessed 196 196
Identified overlapping pathways 81 81
Number of positive correlating pairs 136109854 794354
Number of negative correlating pairs 85220426 518162
Mean positive correlation 0.142 0.139
Mean negative correlation -0.0997 -0.1
Positive correlations Negative correlations
One-way ANOVA F-score 358.0 28.0
One-way ANOVA p-value 6.91e-80 1.21e-07
Table 7.4: Statistical comparison of correlations between genes on shared pathways on chromosome 13, and
all correlations within chromosome 13 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
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Whole chromosome Shared pathways
Number of CpG sites 29550 2033
Number of known genes assessed 343 343
Identified overlapping pathways 165 165
Number of positive correlating pairs 266185214 2723202
Number of negative correlating pairs 170401261 1892004
Mean positive correlation 0.135 0.135
Mean negative correlation -0.0992 -0.105
Positive correlations Negative correlations
One-way ANOVA F-score 0.000914 7450.0
One-way ANOVA p-value 0.976 0.0
Table 7.5: Statistical comparison of correlations between genes on shared pathways on chromosome 14, and
all correlations within chromosome 14 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
Whole chromosome Shared pathways
Number of CpG sites 28741 2357
Number of known genes assessed 364 364
Identified overlapping pathways 150 150
Number of positive correlating pairs 254297067 1492116
Number of negative correlating pairs 158711103 968528
Mean positive correlation 0.135 0.138
Mean negative correlation -0.0971 -0.1
Positive correlations Negative correlations
One-way ANOVA F-score 1200.0 1350.0
One-way ANOVA p-value 5.12e-263 4.75e-295
Table 7.6: Statistical comparison of correlations between genes on shared pathways on chromosome 15, and
all correlations within chromosome 15 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
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Whole chromosome Shared pathways
Number of CpG sites 37939 2415
Number of known genes assessed 450 450
Identified overlapping pathways 190 190
Number of positive correlating pairs 449528374 2844484
Number of negative correlating pairs 270136517 1848404
Mean positive correlation 0.125 0.126
Mean negative correlation -0.0928 -0.0963
Positive correlations Negative correlations
One-way ANOVA F-score 167.0 3270.0
One-way ANOVA p-value 3.41e-38 0.0
Table 7.7: Statistical comparison of correlations between genes on shared pathways on chromosome 16, and
all correlations within chromosome 16 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
Whole chromosome Shared pathways
Number of CpG sites 14899 810
Number of known genes assessed 134 134
Identified overlapping pathways 73 73
Number of positive correlating pairs 68742921 280860
Number of negative correlating pairs 42239730 190970
Mean positive correlation 0.143 0.14
Mean negative correlation -0.0995 -0.103
Positive correlations Negative correlations
One-way ANOVA F-score 136.0 263.0
One-way ANOVA p-value 2.29e-31 3.8e-59
Table 7.8: Statistical comparison of correlations between genes on shared pathways on chromosome 18, and
all correlations within chromosome 18 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
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Whole chromosome Shared pathways
Number of CpG sites 22960 1734
Number of known genes assessed 294 294
Identified overlapping pathways 152 152
Number of positive correlating pairs 165890096 1043752
Number of negative correlating pairs 97679224 664018
Mean positive correlation 0.131 0.131
Mean negative correlation -0.0936 -0.0964
Positive correlations Negative correlations
One-way ANOVA F-score 4.88 768.0
One-way ANOVA p-value 0.0272 3.85e-169
Table 7.9: Statistical comparison of correlations between genes on shared pathways on chromosome 20, and
all correlations within chromosome 20 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
Whole chromosome Shared pathways
Number of CpG sites 10300 931
Number of known genes assessed 127 127
Identified overlapping pathways 38 38
Number of positive correlating pairs 33906857 183758
Number of negative correlating pairs 19132993 91590
Mean positive correlation 0.137 0.144
Mean negative correlation -0.0951 -0.0946
Positive correlations Negative correlations
One-way ANOVA F-score 797.0 2.74
One-way ANOVA p-value 2e-175 0.0978
Table 7.10: Statistical comparison of correlations between genes on shared pathways on chromosome 21, and
all correlations within chromosome 21 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
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Whole chromosome Shared pathways
Number of CpG sites 18367 1367
Number of known genes assessed 235 235
Identified overlapping pathways 126 126
Number of positive correlating pairs 108741296 740188
Number of negative correlating pairs 59922865 463874
Mean positive correlation 0.13 0.129
Mean negative correlation -0.0921 -0.101
Positive correlations Negative correlations
One-way ANOVA F-score 10.5 4790.0
One-way ANOVA p-value 0.00121 0.0
Table 7.11: Statistical comparison of correlations between genes on shared pathways on chromosome 22, and
all correlations within chromosome 22 in general, from correlation matrices derived from noob-normalised
beta values (cohort: chds)
Whole chromosome Shared pathways
Number of CpG sites 19090 1895
Number of known genes assessed 343 343
Identified overlapping pathways 140 140
Number of positive correlating pairs 97951388 609790
Number of negative correlating pairs 84253117 480862
Mean positive correlation 0.361 0.389
Mean negative correlation -0.322 -0.327
Positive correlations Negative correlations
One-way ANOVA F-score 9680.0 312.0
One-way ANOVA p-value 0.0 8.29e-70
Table 7.12: Statistical comparison of correlations between genes on shared pathways on chromosome x, and
all correlations within chromosome x in general, from correlation matrices derived from swan-normalised
beta values (cohort: chds)
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Whole chromosome Shared pathways
Number of CpG sites 537 36
Number of known genes assessed 6 6
Identified overlapping pathways 3 3
Number of positive correlating pairs 83330 238
Number of negative correlating pairs 60586 186
Mean positive correlation 0.442 0.557
Mean negative correlation -0.371 -0.511
Positive correlations Negative correlations
One-way ANOVA F-score 89.5 121.0
One-way ANOVA p-value 3.12e-21 3.27e-28
Table 7.13: Statistical comparison of correlations between genes on shared pathways on chromosome y, and
all correlations within chromosome y in general, from correlation matrices derived from swan-normalised
beta values (cohort: chds)
For all autosomes, there is no regular difference in mean positive and negative correlation. ANOVA scores
generally had quite low P-values, so differences were likely present; but this lack of consistency means we
can not make assertions on the relationship between correlation strength and presence of a common pathway
between CpG sites for autosomes. For allosomes however, the average magnitude of positive and negative
correlations is higher in both cases. This was validated by ANOVA, with p << 0.001 in all cases. It should
be considered that the number of overlapping pathways on the Y chromosome is very small compared to
most other chromosomes (typically two orders of magnitude fewer) so the dataset we are working with here





In this thesis, we sought to find epigenetic trends by looking at the correlation between DNA methylation
intensities of CpG sites within the human genome, from data derived from microarray analysis of whole
blood samples. Our studies have found evidence to support several of our hypotheses. Some key findings
include:
• Choice of array normalisation method has a significant impact on the ability to detect underlying
associations in DNA methylation data
• Methylation intensities of CpG sites within CpG islands tend to correlate more positively than the
average for a chromosome
• Correlations tend to be stronger between CpG sites associated with the same gene, and this effect isn’t
entirely due to CpG islands
These findings have made use of largely-ignored or unconsidered opportunities in DNA methylation correla-
tion analysis, and are elaborated upon in later sections of this chapter.
More generally, the success we’ve had with our novel approach is encouraging. Throughout this thesis,
we have discussed some of the implications of DNA methylation and why the study thereof is a valuable
and medically-important endeavour. Our correlation studies have been, in the grand scheme of things, very
limited in scope; can we make use of similar methods in future studies? As more data becomes available
and our processing capabilities improve, we will have an abundance of opportunity for further studies in this
area. Some potential avenues for future research are touched upon in section 8.5, though the purview of
what we can do with DNA methylation studies is significantly more broad.
8.2 Technical discussions
Several studies earlier in this thesis had outcomes that influenced how the studies in part III. Rather than
include them in this discussion, they have been incorporated into their corresponding chapters as the context
of each study greatly improves readability for the discussion. The reader is reminded of the following
discussions:
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• Section 3.2.2: A preliminary study of the statistical properties of beta values for chromosome 21
• Section 3.3.2: A preliminary study of the statistical properties of beta correlation matrices for chro-
mosome 21
• Section 3.3.2.3: A preliminary network analysis of a beta correlation matrix for chromosome 21
• Section 4.6: A discussion of the impact of normalisation type on beta correlation matrices
• Section 5.4: A discussion of the impact of correlation method on beta correlation matrices
8.3 Implications of results from biological studies
8.3.1 The methylation intensities of CpG sites within CpG islands tend to cor-
relate more positively than the average for a chromosome
The results of section 6.4 showed that a number of the strongest 10% of positive correlations were present
along the diagonal of the beta correlation matrix. These are not self-correlations; section 2.2.5 explains that
these are removed. Rather, they are correlations between the methylation intensity of two CpG sites in
relative proximity to each other. It was hypothesised that these strong correlations were on CpG islands
(which are discussed in section 1.2), and that these islands may contain evident and biologically-relevant
correlations owing to their role in gene regulation. This study was followed up by another study (in section
6.5) that explicitly investigated correlations within CpG islands.
The results in section 6.5 showed that, without exception, all chromosomes tested had a higher average
positive correlation within CpG islands than the baseline level of the entire chromosome. Similarly, it
showed that adjacent (in the available data) CpG pairs had a higher average positive correlation than the
already-elevated average of the CpG island subset. In both cases, the ANOVA results suggested that these
results were statistically significant (p << 0.001).
A potential explanation for this phenomenon is that CpG islands, being regulatory elements, tend to be
consistently hypo- or hyper-methylated (Bird 1986; Esteller 2002) and this would manifest as a higher cor-
relation score between CpG sites within the same island.
CpG islands are only loosely defined and their definition has always been somewhat objective. UCSC
use the following algorithm for prediction of CpG islands (University of California Santa Cruz, 2020):
• Each dinucleotide within the genome is scored (+17 for CG and -1 for others) and maximally-scoring
segments are identified (it is not explained how). Each segment is evaluated for the following criteria:
– GC content of 50% or greater
– length greater than 200 bp
– ratio greater than 0.6 of observed number of CG dinucleotides to the expected number on the
basis of the number of Gs and Cs in the segment
• The CpG count is the number of CG dinucleotides in the island. The Percentage CpG is the ratio of
CpG nucleotide bases (twice the CpG count) to the length. The ratio of observed to expected CpG is
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calculated according to the formula Obs CpGExp CpG =
Number of CpG×N
Number of C×Number of G where N is the length of the
sequence (as per the formula cited in Gardiner-Garden and Frommer, 1987).
Our findings suggest that it may be possible to use strong correlations to identify new CpG islands or confirm
existing ones. This is discussed further in section 8.5.1.
Average negative correlations tended to be more positive for both tested subsets, for most chromosomes,
but the relatively high p-values in several cases as well as the inconsistency of trend means that we have
insufficient evidence to suggest anything regarding this.
8.3.2 There is insufficient evidence to suggest a significant linear relationship
between distance and correlation strength
Section 6.2 used linear regression to investigate the relationship between the distance between two CpG sites
on the same chromosome, and their degree of correlation. A similar investigation into the same relationship
between CpG sites on the same genes was undertaken in section 6.3 and similar results were obtained. For
all chromosomes, the R-squared value of the regression is at or near zero. R-squared can be thought of as
the proportion of variation explained by the model, with an R-squared close to one meaning that more of
the variation in the data is explained by the model, and vice versa. Across the entire chromosome, all of
our linear regression models all have an extremely low R-squared, never exceeding 0.01 (which occurred in
the Y chromosome) - this suggests that their predictive capability is practically negligible. The same was
largely shown for correlations within the same gene, though the sex chromosomes possessed an R-squared
of roughly 0.02 for positive correlations, and the relationship between same-gene negative correlations and
distance on the Y chromosome was roughly 0.09. We deem these R-squared values too low for their models
to provide any meaningful insights, and therefore we do not consider there to be sufficient evidence to suggest
a relationship between distance and correlation strength.
Another factor that suggests no significant linear relationship between distance and correlation strength
is the tenuousness of the gradients of each linear regression as shown in the tables of the relevant results
sections. We would expect a general trend to hold in terms of direction of gradient for positive and negative
correlations; e.g. assuming correlation strength was proportional to distance, all regressions of positive cor-
relations would have a negative gradient, and all regressions of negative correlations would have a positive
gradient. This is not the case. We can see multiple examples of both positive and negative linear regressions
having gradients in the same direction, and this direction is not consistent within these examples.
A key limitation to our methods could be the use of linear models, rather than taking a more flexible
approach to modelling. Rather than try out a number of different models, it was decided that the best
course of action was taking a different approach and looking and correlations within functional gene groups,
which tend to be co-located on the same chromosome (Thévenin et al. 2014). Studies investigating this
include those in sections 6.5, 7.2 and 7.3, discussions of which are included in this chapter.
8.3.3 Correlations tend to be stronger within genes
Despite the apparent lack of relationship between distance and strength described in section 8.3.2, our his-
tograms in section 7.2.2.1 suggest that the statistical distribution of correlation strengths is weighted more
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towards the strong positive side for all tested chromosomes.
This was initially hypothesised to be caused by CpG islands. The presence of CpG islands within genes
has long been studied (Larsen et al. 1992) and we discussed in section 8.3.1 that CpG islands tend to
correlate more strongly; consequently, inclusion of correlations between sites on CpG islands would shift the
histogram to the right. To test this hypothesis, we generated another set of histograms that did not include
correlations involving CpG sites associated with CpG islands. These are shown in section 7.2.2.2. Assuming
that our hypothesis was correct, the distribution should have shifted back towards the mean (perhaps even
following the distribution of the overall chromosome if the islands were the only factor), but what we saw (in
autosomes) was the opposite - rather than shift towards the mean, the distribution of correlations actually
became more skewed to the right, suggesting they tended to become stronger when we didn’t consider the
CpG islands. This suggests that correlations in methylation intensity between CpGs within the same genes
are stronger on average, in comparison to CpGs across the chromosome as a whole, and this effect occurs
outside CpG islands, at least in autosomes. We did not see the same trend in allosomes, though it is difficult
to draw conclusions from their histograms as they follow more-complex distributions.
One possible explanation could be that the regulatory effect of CpG islands is dispersed throughout the
gene, so even if a CpG site is not considered part of an existing CpG island (or a functional but unannotated
island) it could still have similar correlations between the methylation intensities of its CpG sites. More
generally, given that we know that gene regulation is highly complex and involves more than methylation at
CpG islands, other regulatory mechanisms could well be acting upon the gene to ensure that transcription
is activated/repressed consistently.
8.3.4 There is insufficient evidence to suggest a significant relationship between
correlation strength and presence of a common pathway, for autosomes
Section 7.3 compared the average positive and negative correlation between all chromosomes, with results
available in section 7.3.2. It must be acknowledged that we are limited in what pathways we are able to
assess with our data. There are multiple limiting factors here (described more generally in section 8.4):
• We only data for CpG sites probed in the EPIC array
• The database we used for pathway information doesn’t yet contain data for all pathways across the
human genome
• The automated search tool, being an unsupervised algorithm, may erroneously detect pathways or gene
products where it shouldn’t, or miss those that it should
With the above in mind, we still had a substantial subset of data to work with, with generally 5-10% of
all CpG sites within a chromosome situated on shared pathways. Results were generally not in agreement
with hypotheses. For all autosomes, there is no regular difference in mean positive and negative correlation.
ANOVA scores generally had quite low P-values, so differences were likely present; but this lack of consis-
tency means we can not make assertions on the relationship between correlation strength and presence of a
common pathway between CpG sites for autosomes. We discuss allosomal results in section 8.3.5.
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It should be pointed out that in table 7.5 we can see a p-value of 0.976 for the one-way ANOVA test
for positive correlations, which is high relative to that of other chromosomes. This will most likely be due
to the fact that both tested subsets have the same mean.
8.3.5 Correlations to be stronger between genes on shared pathways within the
sex chromosomes
As discussed in section 8.3.4, there was no evidence to suggest a significant relationship between correlation
strength and the presence of a common pathway for non-sex chromosomes. The same study showed that
for the X and Y chromosomes, the average magnitude of positive and negative correlations is higher in both
cases. This was validated by ANOVA, with p << 0.001 in all cases.
For the X chromosome, it is proposed that many of the strong correlations arise due to co-methylation
occurring as part of X-inactivation (discussed in section 1.2.3). This phenomenon ‘switches off’ an entire
chromosome, and as we are looking at pathways on the same chromosome, they will all be switched on or off
together, manifesting as a notably stronger positive correlation - though this ‘signal’ will apply to all CpG
sites on the chromosome, so it is not pathway-specific. A potential explanation to why correlations between
pathways tends to be stronger on the X chromosome is dosage compensation, an epigenetic phenomenon
wherein the level of transcription is altered in some X-linked genes (Lucchesi et al. 2005). It should be
pointed out that Lucchesi et al. explain that X-inactivation is one mechanism of dosage compensation, but
others exist.
For the Y chromosome, it is possible that statistical effects due to small numbers of genes on the same
pathway may make these results significant, despite no underlying biological phenomenon. Future studies
could make use of new information regarding genes and pathways on the Y chromosome to validate the
results of this study.
8.3.6 There are regions within chromosomes wherein CpG sites appear to have
a significantly increased tendency to strongly correlate in methylation
intensity with other CpG sites
In section 6.4, we show the locations of pairs CpG sites which correlate strongly in methylation intensity.
Our plots show a distinct banded pattern in all cases.
One possibility is that these bands are biologically-relevant and are subjected to epigenetic regulatory pres-
sures. They could be regulatory regions that all tend to be ‘switched on or off’ in response to a common
environmental influence - this possibility was described in section 1.3.3. An alternative explanation could
be that homology between these regions results in similar activity at these regions by active methylation or
demethylation enzymes. This was not explored in studies in this thesis, but is a potential avenue for future
research.
It should be pointed out that we can also see regions where no strong correlations occur in our data.
These could be regions of relatively low methylation activity; it could be that their regulation is dominated
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by mechanisms other than DNA methylation, such as histone modification. Studies have shown that DNA
methylation and histone modification in particular are linked (e.g. reviewed in Cedar and Bergman, 2009)
though further research would be required to determine if altered correlations in methylation intensity occur
due to other epigenetic mechanisms.
A more mundane explanation for the described findings could be technical bias in the underlying array.
While we attempt to account for background fluorescence, our methods can never truly eliminate it; this is
simply a limitation of the technology we use to capture DNA methylation information. It could be that some
probes (or clusters of them on the array) are more prone to background fluorescence than others. Perhaps
another issue could be ‘crosstalk’ between probes during data acquisition - this may be too faint or difficult
to identify in beta values, but if it were consistent between samples, it would manifest as an increased cor-
relation coefficient. Further technical studies into the phenomena affecting the EPIC array would be needed
to confirm either of these explanations.
8.4 General limitations
8.4.1 Microarray data is limited in scope
Our analyses have a number of limitations. The first (which we consider to be most significant) is that we
used data from the EPIC array for our analysis, which only looks at a small fraction of CpG sites across
the genome. This severely limits the our visibility of the general methylome. Selection bias may also be a
significant factor as probes for the EPIC array were likely chosen based on some technical criteria rather than
being randomly selected from the genome as a whole. The EPIC array can be used to investigate roughly
3% of the human genome, as discussed in section 2.1.1. We would need to use other techniques, such as
whole-genome bisulfite sequencing, to increase the number of CpGs we have available for analysis.
8.4.2 Cohort size
Most of our analyses only used a single cohort of 120 individuals. We do not know if this is a sufficient
number for calculation of ‘stable’ correlations, in the context of DNA methylation studies. A 2013 study
by Schönbrodt and Perugini (corrected in 2018) suggest that the point of stability for correlations is in the
vicinity of n = 161; the CHDS cohort has about 75% of this. The Monte Carlo simulation used by Schönbrodt
and Perugini for their study used bootstrapped samples from a bivariate Gaussian distribution; this may not
translate particularly well to the distribution of methylation intensities at a CpG site for a given cohort due
as the presence of SNPs and other confounding factors. The future potential for research into a minimum
cohort size for stable correlation calculation is discussed in section 8.5.7.
8.4.3 Incomplete annotation of genes
As of early 2021, we are still facing a number of unresolved gaps and issues with our most modern and well-
studied human genome assemblies (Genome Reference Consortium, 2021). This, combined with the fact
that researchers are still at odds over the number of genes in the human genome, means that our existing
set of gene annotations are likely to remain incomplete for some time. Our research can only make use the
existing subset of annotations so our studies related to correlations within or pertaining to genes do not use
all of them in the entire human genome.
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8.4.4 Incomplete pathway databases
Researchers around the world have been contributing to our knowledge of biological pathways, but given
the relative infancy of bioinformatics in the grand scheme of things, we are a long way off being able to say
with certainty that we have a complete database of every pathway in the human genome. The Reactome
database that we used in studies for this thesis is particularly well-used, with publications detailing the
database being released every few years, and thousands of other papers citing these. Reactome has provided
a great amount of information for this thesis but is ultimately a long way from being a comprehensive source
of every pathway that we could consider in our research. Additionally, further studies across a number of
fields may result in us revising our understanding on pathways that had been supported by previous research;
future updates to the database may edit or remove existing ones, so our results come with the caveat that
they’re based off information that is currently accurate, but may not be in future.
8.5 Future opportunities
8.5.1 Using correlations to identify CpG islands
We discussed in section 8.3.1 how the methylation intensity of CpG sites within CpG islands (as arbitrated
by UCSC) tend to correlate more positively with each other, compared with correlations across the chro-
mosome as a whole. We discussed how the regulatory nature of CpG islands may be the cause of these
higher-than-average correlations. Assuming this is the case, correlation could be used as an alternative mea-
sure to either confirm existing islands or possibly extend/shorten/subdivide them based on functional CpG
groups. Currently, CpG islands are identified using genomic methods, such as using the frequency of CpG
dinucleotides in a subsequence as an indicator (Gardiner-Garden and Frommer, 1987). I propose that we
make use of epigenetic data to delineate CpG islands, as much of their biological relevance appears to be
in the context of epigenetic regulation. Improving our understanding and demarcation of these regulatory
areas may have applications for the design of DNA methylation microarrays (for example), as we would be
able to make more-informed selections of which CpG sites to add to these arrays.
8.5.2 Improving our ability to identify strong correlations in DNA methylation
data
One of the limitations discussed in section 1.3.1.3 was that many of our strong correlations could be due to
random chance. Further research could examine methods of accounting for randomness or identify different
approaches which could be used when looking for biologically-relevant correlations. This would greatly
enhance the potential to extract meaningful insights from correlation studies as our findings would come
with fewer caveats.
8.5.3 Correlation analysis using whole-genome data
As discussed in section 8.4, use of the EPIC array limits our analyses to a small proportion of the methylome.
DNA methylation datasets obtained via whole-genome bisulfite sequencing have been produced for years and
the recent advent of techniques to measure DNA methylation with nanopore technologies will improve the
ability for more full-methylome datasets to be made. Both of these techniques are described in section 2.1.1.
There will certainly be trends in the ∼ 97% of the methylome that we were not able to access in studies in
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this thesis, so analysis of data obtained by more comprehensive techniques is a significant future opportunity.
In particular, a full-methylome method would provide much greater resolution when used to identify CpG
islands with correlations.
8.5.4 Investigating the effects of aging on correlations
An epigenetic phenomenon associated with aging is dysregulation of DNA methylation, as discussed in sec-
tion 1.2.6. The primary dataset used in this thesis, CHDS, consisted of 120 individuals whose age was within
a year of 28 at time of data collection. A comparable dataset of 120 individuals at later ages was not available
for this study; while several informal investigations undertaken alongside several studies in this thesis looked
at the differences that may have been caused by age, there was insufficient data to make robust scientific
claims. A future study could look into the effects of age on correlation in more detail, provided the dataset
was sufficient. An example of a sufficient dataset would be a future assessment of the CHDS cohort, so the
methylomes of individuals can be tracked at a range of different ages. This would also ensure that genetic
and environmental effects were relatively consistent.
One observation I would hypothesise is that the average correlation between methylation intensities would
decrease as one ages. There are several reasons for this:
• A decrease in epigenetic regulation weakens the ‘epigenetic signal’, which would result in weaker asso-
ciations in DNA methylation and consequently lower correlation coefficients
• We have seen that there is generally a bi-modal distribution in DNA methylation values across the
genome (e.g. in section 3.2.2) - the global decrease in methylation associated with age (Bollati et al.
2009; Heyn et al. 2012) would flatten and shift the right-most peak of the distribution to the left,
increasing variance and therefore ‘noise’ within that peak which may obscure the monotonic changes
that we hope to find using the Spearman rank correlation method
Another hypothesis is that different CpG sites correlate at different life stages. For example, a cell from an
embryo undergoing early development may have different epigenetic associations than an individual who is
in later stages of life.
Research into both of these hypotheses could yield benefits for the study of aging, such as identifying which
pathways remain consistent into old age, which ones are the first to deteriorate, etc. This research could
have applications in treatment of the diseases associated with aging, which will only grow more frequent as
the average age of our population increases.
8.5.5 Investigating the effects of tissue type on correlations
The influence of tissue type on DNA methylation was discussed briefly in section 1.2.5. For the purposes of
this study, we have only have whole blood samples available from the CHDS cohort. This has been acceptable
for a proof of concept, but there is significant potential for research into correlations in DNA methylation
in different tissue types. I hypothesise that there will be some strong correlations that are present in most
tissue types (perhaps even all of them) as they are simply required for continued survival of the cell. I
suggest that the overlap of strong correlations is higher for similar cell types (e.g. in skin and alveoli, both
squamous epithelial cells) than for those in different cell types (e.g. skin and brain tissues).
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8.5.6 Investigating correlations using multiple samples from a single individual
All studies in this thesis used a single sample with multiple individuals. Something that may provide scientific
value would be a study of multiple samples from the same individual. It is proposed that correlations
within the methylome are influenced by epigenetic phenomena. A dysregulation of epigenetically-grounded
regulatory systems could lead to a substantially different correlation profile for specific CpG sites, between
different samples. In general terms, a given set of CpG sites may be expected to correlate with a certain
strength, and deviation from this could suggest a disease phenotype or epigenetic dysfunction. This could
occur spatially or temporally:
• Different correlation profiles between samples from the same tissue type could indicate disease, e.g.
there may be a set of CpGs which correlate less in methylation intensity in cancerous or pre-cancerous
conditions in the skin, compared with healthy skin
• Different correlation profiles between repeated samples from the same tissue type over time could also
indicate disease progression, e.g. if a consistent pattern of correlation in some set of CpGs is observed
for a long period of time (on the scale of years or decades), a sudden change may suggest the onset of
a disease phenotype.
Genetic factors would obviously dominate any epigenetic signal if correlations were calculated from tissue
samples within a single individual, so a significant amount of research would be required to identify which
genetic variants can alter epigenetic associations.
8.5.7 Identification of a minimum cohort size for stable calculation of correla-
tions
We discussed briefly in section 8.4.2 that there exists a minimum size for calculation of stable correlation
coefficients. One of the general issues with correlations (and indeed quantitative statistics as a whole) is
that cohorts only represent a small sample of the available population and many factors contribute to ‘noise’
in the data which adversely affects the similarity of a metric calculated for a sample (correlation in this
case) to that overall metric for the population. Correlation coefficients in particular are prone to this noise
as they rely on two noisy data points, so sample-based effects can be quite pronounced in the data. The
primary cohort used in this thesis had about 75% of the value recommended in a past Monte Carlo sim-
ulation (Schönbrodt and Perugini, 2013) - this was the largest and best-curated cohort available for these
studies, so was the best option despite having a smaller sample size that this recommendation. That said,
the recommended value was based on normally-distributed pairs, and the preliminary study in chapter 3
suggested that the distribution of average beta values is more complex than that - the effects on minimum
cohort size due to this distribution, as well as biological phenomena such as SNPs and technical aspects such
as normalisation type, are yet to be seen.
Regardless, there will be a minimum cohort size required for stable calculation of correlations. With more
data on the distribution of methylation intensity across each CpG site, it may be possible to conduct a Monte
Carlo simulation similar to that undertaken by Schönbrodt and Perugini, from which we can determine the
minimum number of individual samples needed for future correlation studies.
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8.5.8 Correlation analysis of non-5mC methylation
Our research, and indeed much of the worldwide research into DNA methylation, has focused specifically
on 5-methylcytosine as the primary mark of methylation. Other bases are known to undergo methylation
as well - for example, N6-methyladenine conversion was described briefly in section 1.2. As part of the
ongoing efforts to understand epigenetic tags other than 5mC, we could conduct correlation analyses of
m6A. This could involve reassessment of hypotheses of earlier studies in the context of adenine methylation
or investigation of some of the potential future avenues of research described in this section.
8.5.9 Development of combined cohorts
Researchers develop their own cohorts based on the requirements of their own research and these are often
suitable for further analysis in other studies. This is not always the case, however. Smaller research cohorts
may have insufficient subjects to derive statistically-significant information (perhaps having as few as a single
subject) and if they are to be used in a larger EWAS, they must be combined with other cohorts. This poses
a number of challenges owing to the impact of factors discussed in 1.2). Nonetheless, we can still make efforts
to combine cohorts for use in broader studies, provided we are aware of the caveats.
We expect the state of DNA methylation to be highly variable between different individuals. A very sim-
plified model for the methylation intensity of each CpG site in the genome for a specific tissue type in any
arbitrary individual could be defined as:
x(t) = x̄(t) + g(t) + e(t) + i (8.1)
where x(t) is a vector of methylation intensities of each CpG site (as a function of time/chronological age),
x̄(t) is the ‘baseline’ methylome for any arbitrary human at a given age, g(t) is the genetic influence, e(t)
is the environmental impact specific to that individual, and i is the one-off impact of inheritance (with
long-term inherited factors considered as part of g(t) and e(t)). Of these quantities, only x̄(t) is not specific
to the individual - rather, this is something that we can estimate. The other factors are all specific to the
individual. Both g(t) and e(t) would be dependent on the individual’s genome and epigenetic landscape for
that tissue type; both of these dependencies change over time (albeit less so in case of the genome), and
the epigenetic landscape also has genomic dependencies, so there’s a great deal of complexity if we consider
them separately. Instead, if we combine the individual-specific factors into a single drift factor d(t), we can
define our estimate for the average methylation intensity for a given tissue type within an individual as:
x̂(t) = x̄(t) + d(t) (8.2)
Further to this, if we assume the drift factor to be stochastic with a mean of zero, then for a sufficiently
large cohort, the average drift factor will tend towards zero and the average of all individual methylation
intensities will be approximately equal to the baseline epigenetic landscape.
x̂cohort(t) ≈ x̄(t) for a sufficiently large cohort (8.3)
The larger the cohort, the better the cohort will be at representing of the human species in general. Selection
bias is an unavoidable issue but we can still get a pretty good idea of the epigenetic characteristics of a large
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number of CpG sites and their associated genes, especially if their pathways tend to be conserved between
people of different genetic heritage.
A key practical difficulty of combining cohorts for EWAS is that we do not yet have the ability to per-
fectly assess the methylation intensity of any particular CpG site within the human body. Any measurement
of this is going to be prone to some level of error, causing results to be less accurate than we’d like. This
error is caused by factors specific to the technologies being used. We can define the estimate of methylation
intensity x̂(t), taken at a specific time ts for a tissue type in a given individual as:
x̂(ts) = x(ts) + εf (8.4)
Where x(ts) is the actual methylation intensity. The error term εf comprises technology-specific issues such
as background fluorescence (in the case of arrays) and sequencing issues (e.g. for WGBS). We can make
the assumption that εf is stochastic and can be modelled as a normal distribution with a mean of µf and
standard deviation of σf . In practice, εf is unlikely to follow a perfect normal distribution, but for the sake
of discussion, we can model εf as:
εf ∼ N (µf , σf 2) (8.5)
Each normalisation type will have a different µf and σf . For example, a set of unnormalised values for
methylation intensity would be influenced by background fluorescence much more than values that were
normalised, and this may lead to increased variance within a CpG site. This is studied in more depth in
section 4.4. There may also be some dependency on CpG type as probe chemistry and presence of SNPs
would have an effect on εf as well, and the effects of these may vary between the different normalisation
types. Consequently, combining two datasets produced with different normalisation methods will result in a
more complicated and thus less predictable error term which would adversely affect our ability to obtain a
decent estimate of x̂(t).
A study where in cohorts are combined is beyond the scope of this thesis, though would certainly allow
us to make better-informed choices when combining cohorts for new studies and meta-analyses. This discus-
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CHDS: Christchurch Health and Development Study
The Christchurch Health and Development Study is an ongoing longitudinal study of a cohort consisting
of 1,265 individuals born in the Christchurch urban region in mid-1977. In this thesis, we use a subset of
120 individuals from this cohort, from which whole blood samples were collected at approximately age 28.
These samples were subjected to methylation analysis using the Illumina Infinium MethylationEPIC array,
providing data for over 850,000 CpG sites.
As of time of submission, further information regarding this cohort can be found at:
https://www.otago.ac.nz/christchurch/research/healthdevelopment/.
The manifest used for this dataset was the Infinium MethylationEPIC v1.0 B5, provided by Illumina.
MTAB-7069: Methylation arrays (MethylationEPIC) of longitudi-
nal cord and peripheral blood from children aged 0, 5 and 10 years
old
E-MTAB-7069 is a dataset made available by the European Bioinformatics Institute, containing data col-
lected for a longitudinal study of epigenetic changes which occur over the first 10 years of life. There are 11
subjects in this study, with three blood samples from each subject, taken at 5 years of age, 10 years of age,
and from the umbilical cord after birth.
As of time of submission, further information regarding this cohort can be found at:
https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7069/?array=A-GEOD-21145.
The original publication for this cohort is included in the bibliography (Pérez et al. 2019).
The manifest used to divide the dataset based on chromosome was the Infinium MethylationEPIC v1.0




This appendix is included in case someone wants to re-use the scripts written for this thesis. They can cur-
rently (as of time of submission, March 26 2021) be found at https://gitlab.com/kjalaric/correlation methylome boreilly2021.
Relevant commit hashes (ordered by timestamp) are:
• 12b50799391df9596b8304d56d3612838d3289a2 for the scripts and pipeline
• 17296aa3250ecb46abc38075b3d75464be6de94a for gene and pathway information scraped from the re-
actome database
• 6264faf32a4aea1ab5a4d816586315ec92fb0d20 for a very sparse readme
• 80b214eabed14f11ce4fc1cf4ddd9986bf21bbec for licensing information (this is also the final commit for
the thesis)
Contact me if the repo is not available and I may be able to send you the files.
The repo also includes the full set of gene and pathway information scraped from the reactome database.
As of time of submission, these can be found in pathway jsons/ directory in the main repo. Those used for
the project were added in the commit with hash 17296aa3250ecb46abc38075b3d75464be6de94a.
General workflow
An overview of methods can be found in section 2.2. This section covers how the main ones are implemented
in practice.
File locations and directory structure are specified in common/file_format.py. A script to set up directo-
ries for a given cohort was written but has not been maintained in the later stages of the project. It can still
provide a decent skeleton from which to work with though - scripts/set_up_directories_for_new_cohort.py.
Generating beta matrices
• Required: .idat files
• Produces: beta .csv file for a given normalisation type and cohort; chromosomal beta csv files for a
given normalisation type, cohort and all chromosomes
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I used minfi in R to process raw .idat files into beta matrices. The following R script shows an example of





GRset = read.metharray.exp(targets = samplesheet) # force=TRUE as an argument if it doesn’t work
GRset = preprocessNoob(GRset)
GRset = mapToGenome(GRset)
GRset = addSnpInfo(GRset) # possibly not needed
# get beta and write it as a csv file
beta = getBeta(GRset)
write.table(beta, "beta_noob.csv", sep=",", row.names=TRUE, col.names=NA)
These large files need to be split based on chromosome unless you have 6TB+ of RAM and an abundance
of time. The script pipeline/split_beta_into_chromosome.py can split the file for you.
Generating and serialising a beta correlation matrix
• Required: chromosome beta .csv file for a given normalisation type and cohort
• Produces: correlation .pkl file for a given normalisation type, cohort, chromosome and correlation
method
Beta correlation matrices are generated using pandas in Python. I serialise all of these into .pkl files as
they’re used frequently and generating them from scratch every time takes too long. An implementation
using multiprocessing to speed thing up is in pipeline/mp_correlation.py. This needs to be configured
based on how much RAM you want to use. Alternatively, pipeline/correlation.py can run one correlation
procedure at a time.
By default, Spearman correlation matrices are generated. This is changed via an argument in the script.
Finding strong correlations
• Required: correlation .pkl file for a given normalisation type, cohort, chromosome and correlation
method
• Produces: .txt file containing strong correlations (either proportional or thresholded)
Generating a list of strong correlations, using either the proportional or threshold method, can be done using
the aptly-named pipeline/find_strong_correlations.py. This generates a .txt file (technically its a CSV
with a different file extension, I might update this at some point but doing so during my thesis would break
everything) containing the following information on each line:
• cpg1, cpg2, correlation coefficient
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Generating beta matrix statistics
• Required: chromosome beta .csv file for a given normalisation type and cohort
• Produces: .json file of statistics for the supplied betas
scripts/mean_versus_standard_deviation_betas.py was used to generate statistical information and plots
used in chapter 4.
scripts/ratio_positive_to_negative_correlations.py can be used to obtain the ratio of positive (>= 0)
or negative (< 0) correlations in a given correlation .pkl.
Generating beta correlation matrix statistics
• Required: correlation .pkl file for a given normalisation type, cohort, chromosome and correlation
method
• Produces: statistics .txt file for the supplied .pkl file, and (optionally) a .csv file containing statistics
for each CpG site
Beta correlation matrix statistics can be generated using pipeline/stats_for_correlation_df.py. This out-
puts a general report with global statistics of the correlation matrix, as well as a .csv file with statistics for
each individual CpG site within that chromosome.
An alternative implementation is pipeline/stats_for_correlation_df_basic.py. This version does not gen-
erate the .csv file or any statistics particular to a given CpG site (e.g. kurtosis within that site). In this thesis,
it has been preferable to use this version for larger chromosomes as it is significantly more lightweight and
the larger chromosomes generally are not used for the detailed studies that require CpG-specific information.
Finding all correlations within all genes on a chromosome
• Required: correlation .pkl file for a given normalisation type, cohort, chromosome and correlation
method
• Produces: .csv file containing a list of all correlating CpG pairs that are on a same gene, where these
CpGs are located, the strength of the correlation and an identifier for the database used to obtain the
annotation
pipeline/find_all_correlations_within_genes.py provides a .csv file with the following scheme:
• gene, annotation source, cpg1, cpg1 mapinfo, cpg2, cpg2 mapinfo, distance between sites, correlation
coefficient
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